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The principal aim of this study was to discover, through virtual screening, new non-
immunosuppressive inhibitors for the human immunophilin FKBP12, a target of the 
immunosuppressant drugs rapamycin and FK506. The enzyme acts as peptidyl-prolyl 
isomerase catalysing protein folding in the cell. Structurally similar isomerase domains are 
important for molecular recognition in multi-domain chaperone proteins. FKBP inhibitors 
have been shown to have protective effects against nerve damage and are therefore 
interesting targets for the treatment of neurodegenerative diseases.  
 
Virtual screening has been used to discover novel inhibitors for protein drug targets. Recent 
advances in computational power and the availability of large virtual libraries, such as the 
EDULISS database at Edinburgh University, have enhanced the appeal of this approach.  
X-ray structures of known protein-ligand complexes were examined to obtain an 
understanding of the key non-covalent interactions in the FKBP12 binding pocket. Virtual 
screening hits were selected using macromolecular docking and programs that employed a 
ligand-based approach. The bulk of the virtual screening in this study used Edinburgh 
University’s in-house program LIDAEUS. In the course of this study nearly three hundred 
compounds were screened in the laboratory using biophysical and biochemical binding 
assays. Thirty four compounds were found to have an affinity for FKBP12 of less than one 
hundred micromolar. 
 
To test virtual hits, it was necessary to select the most appropriate medium-throughput 
biophysical assay. The aim was to employ methods with sufficient sensitivity to detect 
compounds with affinity in the order of one hundred micromolar, coupled with the capacity 
to screen hundreds of compounds in a week. This study used a wide variety of biophysical 
techniques, these including: electrospray ionisation mass spectrometry, surface plasmon 
resonance and isothermal titration calorimetry. There was a particular emphasis on the 
quality of data from electrospray ionisation mass spectrometry. A correlation was found 
between the cone voltages that gave 50 % dissociation of the complex with the enthalpic 
contribution to the free energy of binding. From the careful examination of the differences in 
charge-state distributions between a pure protein and a protein-ligand mixture, it was 
possible to determine if a protein-ligand complex had been present in solution prior to 
dissociation during the electrospray process. This observation provides the basis for an assay 
that could be of general utility in detecting very weak inhibitors. 
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1 Chapter 1  Introduction  
1.1 Scope of the project 
This study focuses on discovering new small molecule inhibitors for the human 
immunophilin FKBP12 using virtual screening and biophysical techniques.  High resolution 
x-ray structures of FKBP12-ligand complexes were used to predict key protein-ligand 
interactions and as templates for docking experiments.  Hits from virtual screening programs 
were purchased and tested in the laboratory on recombinant protein using biophysical 
methods. The most active compounds were confirmed in a biochemical assay in which the 
inhibitor competed with a substrate for the active site of the protein. There was a particular 
emphasis on extending the sensitivity of biophysical methods to detect low affinity ligands 
of FKBP12.  
1.2 Drug discovery 
1.2.1 Exploring chemical space 
Chemical space is vast; it has been estimated that there are 10
60
 drug-like compounds with 
up to 30 heavy atoms (Congreve et al., 2008). All experimental screening methods rely on 
some rationale to provide a suitable number of compounds for testing in the laboratory. An 
experimental medicinal chemist might approach the problem from two directions. They may 
select a diverse range of compounds from a “real” compound library, or focus on the target 
protein by selecting or synthesising compounds chemically similar to known 
inhibitors/substrates (Snowden and Green, 2008; Diller, 2008). In the pharmaceutical 
industry the first stage in experimental compound testing often takes the form of a high-
throughput screen (HTS) where many hundred thousand compounds are tested in a 
robotically assisted assay. As an alternative approach, virtual screening has the potential to 
sample a much larger portion of chemical space than any in-house “real” compound 
collection (Oprea and Matter, 2004). This is particularly true in a University setting where 
large compound libraries are not commonly held. Virtual screening aims to increase the 
probability of a test compound hitting the target protein when compared to a random 
selection; this process is known as enrichment (Halgren et al., 2004; Verdonk et al., 2004). 
In this study virtual screening took the place of HTS which was not possible for reasons of 
equipment and cost. It is of course possible to combine virtual methods in series with HTS to 
focus the screening library (Bajorath, 2002; Schnecke and Bostrom, 2006). 
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1.2.2 Structure-based drug discovery and virtual screening 
Virtual screening methods are all based on some form of structural information. The 
observation that the arrangement of atoms of specific properties is important in drug design 
is not a new one. Alexander Crum-Brown wrote in 1869, “There can be no reasonable doubt 
that a relation exists between the physiological action of a substance and its chemical 
constitution, understanding by the latter the mutual relations of the atoms in the substance.” 
(Crum Brown and Fraser, 1869).  The difficulty lies in how completely we describe the 
geometric arrangement, the properties and the interactions between the atoms in the virtual 
model. Structure–based drug discovery using virtual screening may be split up into a series 
of stages; these are illustrated in Figure 1-1.  
 
 
Figure 1-1 Structure-based drug discovery 
 
In the first stage it is necessary to select a protein target or cellular receptor of therapeutic 
interest that can be produced in a stable form for experimental screening. Structures of the 
target and/or ligands are then assembled as input for the virtual screening program. The 
available structures influence the choice of virtual screening method. Virtual screening can 
be broadly divided into two classes; these are summarised in Figure 1-2 (together with the 
programs used in this study). The first class molecular docking uses a high-resolution 
structure of the target, these are usually x-ray or NMR structures of proteins or protein 
assemblies. Homology models have been used but are not considered optimum (Kitchen et 
al., 2004). Structures of the target in complex with a ligand usually perform better than apo 
structures (Thomas et al., 2006). In the second class, the ligand-similarity methods, it is not 
essential to know the target structure but structures of  biologically active ligands are 
necessary (Willett, 2006; Eckert and Bajorath, 2007).  
 
 There is inevitably a trade off between complexity of the model and the speed of 
computational prediction. The preference in this project was to use high-throughput (HT) 
virtual screening programs. HT programs aim to encode the key features of a molecule and 
inter-molecular interactions to make fast but useful predictions; choice of these key 
parameters is not a trivial problem. The goal of HTS programs is to screen from thousands to 

















Figure 1-2 Virtual screening methods used in this project 
 
Four different programs were used for virtual screening in this project, two protein-based 
and two ligand-based. Docking experiments were performed using the programs LIDAEUS 
(Wu et al., 2003) and FlexX (Rarey et al., 1996). Here the aim of experiments was to match 
a 3D description of the test ligand to a 3D description of the target protein, score the 
potential interaction and rank ligands by score. UFSRAT, a ligand similarity based method, 
was used to compare the shape and polarity of known inhibitor of FKBP12 to molecules in a 
virtual library (Steven Shave, Edinburgh University). This method was not dependent on 
knowing the structure of the target protein. Finally, a Bayesian machine learning method was 
used to assign a relative activity probability to a compound in a library (Angelopoulos et al., 
2009). Pre-calculated physicochemical/structural descriptors and experimental activity data 
from a set of known actives and inactives of FKBP12 were used to train the algorithm. Like 
UFSRAT, the Baysian method did not rely on knowledge of the structure of the protein 
target. The method can be distinguished from UFSRAT in that the model includes 
experimental affinity data for many rather than one known inhibitor of FKBP12.  
 
In the final stage, ligands selected by a virtual screening program are purchased and tested in 
an experimental assay. This project used a wide variety of biophysical techniques, these 
included: electrospray ionisation mass spectrometry, surface plasmon resonance and 
isothermal titration calorimetry. Biochemical and biophysical assays are discussed in 
Chapters 3, 4, 5 and 6. The experimental results for compound collections are discussed in 











 Bayesian method 
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1.3 Virtual screening databases – EDULISS 2 
EDULISS 2 (EDinburgh University Ligand Selection System) was the principle database of 
virtual small molecules used in this study. EDULISS (Hinton, 2005; Hsin, 2009) is a 
relational database comprising over 6 million compounds from commercial and academic 
compound collections (http://eduliss.bch.ed.ac.uk/eduliss/, Jan 2009). The aim of the 
database was to store 3D structures for virtual screening experiments with a very wide 
variety of associated molecular descriptors that are thought likely to correlate with biological 
activity. The energy minimised 3D coordinates for each molecule were calculated from the 
2D coordinates provided by the compound supplier using the program CONCORD 
(TRIPOS). 1665 topological, geometric, physicochemical and toxicological descriptors were 
calculated from 2D structure for each molecule in the database using the programs 
DRAGON 5.4 (Todeschini R. and Consonni V., 2005) and DEREK (Sanderson and 
Earnshaw, 1991). Of the 6 million compounds, some 4.3 million fit the Lipinski “Rule of 5s” 
criteria (Lipinski et al., 1997); 3.2 million the Oprea lead-like criteria (Hann and Oprea, 
2004) and 230,000 the Astex “Rule of 3” (Carr et al., 2005). Drug-like criteria are discussed 
in 1.4. 
 
A novel method for identifying unique compounds in the database was developed by Kun-Yi 
Hsin (PhD Thesis, Edinburgh University, 2009). This method relies on distinguishing 
compounds using a small number of particularly discriminatory descriptors. These include a 
3D-Wiener index, an electronegativity descriptor and a polarisability descriptor. Of the 6 
million compounds in the database, 3.8 million are unique.  
 
Hsin has developed a web-based interface for EDULISS 2 that provides a convenient way of 
extracting families of compounds with a user-defined set of properties. It was 
straightforward to apply a filter for drug-likeness when selecting compounds from EDULISS 
2. The virtual compound sub-library was extracted in the form of a concatenated SDF file 
that was then piped into the virtual screening program. It was possible to append the SDF file 
to include a field for any descriptor of interest. 
1.4 Screening compounds for drug-likeness 
Towards the end of the last century it became apparent that many drugs were failing at a 
relatively late stage in the drug development pipeline due to unfavourable ADMET 
properties (absorption, distribution, metabolism, excretion and toxicity). This is obviously 
inefficient in terms of time and money. Much effort has gone into predicting ADMET 
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properties using in-silico methods (Norinder and Bergstrom, 2006). Experimentally 
measured physicochemical properties and toxicity data are not available for many 
compounds in HTS screens and virtual databases. A simple solution to the ADMET problem 
is to use a selection of these physicochemical parameters to determine whether a molecule is 
“drug-like” or not.   
 
Christopher Lipinski undertook survey of physicochemical properties of known orally 
delivered drugs (Lipinski et al., 1997). He defined “drug-like” molecules  as those that met 3 
out of 4 of the following rules: a molecular weight ≤ 500 Da, ≤ 5 hydrogen bond donors, ≤ 
10 hydrogen bond acceptors, the sum of N’s and O’s ≤10 and a ClogP ≤ 5 (MlogP ≤ 4.15). 
These criteria are known as Lipinski’s “Rule of 5s” (Ro5), poor absorption and permeation 
are more likely if they are not met. ClogP is a calculated log of the octanol/water partition 
coefficient (P) from structure. MlogP is a commercial algorithm performing this function 
(Moriguchi I. et al., 1992). LogP reflects the relative hydrophobicity of the molecule. 
Hydrophobicity is a factor in the oral bioavailability and the partitioning of a drug within 
different cellular compartments. More stringent sets of criteria have been proposed for initial 
stages of drug discovery. For example; Lead-likeness restricts MW < 350 Da and ClogP < 3 
(Teague et al., 1999).  
 
Astex “Rule of 3” (Ro3) is a set of criteria for describing fragment like molecules: MW ≤ 
300 Da, total polar surface area ≤ 60 Å
2
 and ClogP ≤ 3 (Carr et al., 2005). The rationale for 
choosing lower parameter values for lead-like and fragment-like compounds is that 
compound optimisation almost inevitably increases the molecular weight, complexity and 
hydrophobicity of the molecule by the addition of functionality (Oprea et al., 2007). It is 
therefore important to start drug development with molecules that are small, simple and not 
too hydrophobic.  
 
Experimental data for the above criteria were not available for the majority of the 
compounds in EDULISS 2. This meant it was necessary to base any decision on compound 
inclusion on a descriptor calculated from structure. An interesting observation is that the best 
known and most potent inhibitor of FKBP12 fails Lipinski’s criteria for more than one 
descriptor. Rapamycin has a molecular weight of 914 Da and 13 hydrogen bond acceptors; 
XlogP = 4.3 and MlogP = 1.98 (Cheng et al., 2007). Calculated values of logP (ClogP) are 
generally atom/group additive with the inclusion of a correction factor. ClogP can vary 
considerably for a specific compound when computed using different algorithms. Moreover, 
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FKBP12 has a hydrophobic binding site and one could predict that effective inhibitors would 
be relatively hydrophobic molecules (+ logP). Drugs derived from natural products fail 
Lipinski’s criteria more frequently than synthetic small molecules (Ganesan, 2008). 
However, perhaps the primary consideration was whether the compound would be soluble 
enough in aqueous buffer to use in a laboratory assay. This is discussed further in Chapter 7. 
1.5 Docking  
Virtual screening has had some success in discovering novel inhibitors for protein drug 
targets. Taylor et al. (2008) include a table of nine studies where small molecule inhibitors 
(low micromolar to sub-nanomolar affinity range) were discovered using the programs: 
Catalyst (Greene et al., 1994), DOCK (Ewing et al., 2001), FlexX (Rarey et al., 1996), 
GOLD (Jones et al., 1995) and LIDAEUS (Wu et al., 2003). Of the programs listed above, 
DOCK, FlexX, GOLD and LIDAEUS are docking programs (Catalyst is a pharmacophore 
modelling program). Two docking programs were used in this study LIDAEUS and FlexX. 
This section attempts to summarise (very briefly) a few key features of such programs.  
 
Kuntz et al.  developed the first docking programs in the early 1980s (Kuntz et al., 1982). 
Since then, there has been a divergence of approach to tackling the docking of small 
molecules into proteins. However, the workflow for most programs can be divided up into 
four basic stages. These are illustrated in Figure 1-3. 
 
In the first stage, a 3D structure of the target protein is inputted; generally in the form of a 
PDB file, giving 3D coordinates and connectivity information from the x-ray structure of a 
protein in complex with a ligand. The active site of the protein is defined and a description of 
the site generated, this description can be atomic, surface or grid (Brooijmans and Kuntz, 
2003). In the second stage, the putative ligand is matched or docked into the active site; the 
orientation of the ligand in the active site is referred to as a “pose”. In the third stage, the 
pose is scored. The docking of the ligand into the active site is guided by the posing/scoring 
algorithm. The algorithm accepts or rejects a change in ligand pose based on a score. In the 
final stage, an estimate is made of the free energy change of complex formation; this is used 
to rank the ligands. 
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Figure 1-3 The four stages in a docking experiment 
 
To make the process of docking computationally efficient, it is necessary to limit the 
possible number of orientations of the ligand in the active site and use a strategy that 
efficiently samples the space. When docking small molecules, this is most often done by 
describing the site as a grid of “site-points”. Each site-point is assigned a potential energy 
value calculated from the protein receptor at that point (Goodford, 1985). During the docking 
process, the site-points are matched to atoms in the representation of the ligand using some 
form4 of systematic search.  
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Much consideration has been given to predicting the correct conformation of the ligand in 
the active site. Many programs tackle this problem by breaking the ligand up into fragments. 
A base fragment of relatively rigid conformation is selected and docked in the best scored 
location; the ligand is then reconstructed fragment by fragment (Rarey et al., 1996; Jones et 
al., 1997). This approach is used by DOCK, FlexX and Glide (Friesner et al., 2004). 
Alternatively, small random changes can be made to the ligand using Monte Carlo 
techniques. GOLD uses a genetic algorithm to achieve a solution for the most energetically 
favourable conformation of the ligand in the active site. LIDAEUS tackles the problem by 




Many scoring algorithms in fast docking programs such as LIDAEUS use empirical 
methods, similar to those described by Boehm (Klebe and Boehm, 1997; Boehm, 1998). 
Binding energies are calculated by summation of individual terms for different contributions 
to binding energy such as; ionic interactions, hydrogen bonds and van der Waals forces. In 
Boehm’s work empirical weighting constants were derived from crystallographic data. 
1.6 Tackling the scoring problem  
At the time of writing, it is still not possible to predict the absolute free energy of ligand 
binding with any degree of precision using the scoring functions of high-throughput virtual 
screening programs (Perola et al., 2004; Feher, 2006; Konstantinou-Kirtay et al., 2007; 
Waszkowycz, 2008). This is in part due to the challenges of fully predicting entropic factors 
and to the extremely complex nature of the interaction energy landscape (Klebe and Boehm, 
1997; Friesner et al., 2006). However, docking programs do hope to rank a series of 
compounds so as to increase the probability of activity in the highest scoring hits. This 
inevitably means that when virtual hits are tested in the laboratory a significant portion of the 
hits are found to be false positives or of relatively low affinity for the target. Drug discovery 
is an iterative process, in which virtual screens do not discover final products but aim to 
provide new starting points for lead development. It is therefore advantageous to couple any 
virtual screening program to sensitive experimental assays to extract useful structure-activity 
relationships from low affinity ligands. This has become increasingly important with the 
recent practice of selecting smaller lead compounds. Less chemically complex lead 
compounds allow the medicinal chemist the most scope to optimise ADMET properties early 
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in the drug pipeline. However, smaller leads or fragment-like compounds have a reduced 
potential for making interactions with the target.  
 
This study tackled the scoring problem from two directions. Firstly, by careful consideration 
of “hot spots” in the active site of the protein during virtual screening and secondly, by 
increasing the throughput and optimising the sensitivity of biophysical measurements: 
 
 A careful analysis was made of non-covalent interactions in known FKBP12 
inhibitor complexes to discover amino acids in the active site that made conserved 
interactions with ligands (described in section 1.11.5). This information was used at 
two stages in the docking process. Firstly to guide the site point generation in 
LIDAEUS and secondly to select compounds from the final selection of high 
scoring docked poses that made the most conserved non-covalent interactions. 
 
 Biophysical techniques assays were developed for testing inhibitors of FKBP12 on 
a 96 well plate format. There was particular emphasis placed on the evaluation of 
electrospray ionisation mass spectrometry (ESI-MS) as a sensitive tool to detect 
weak non-covalent interactions. 
1.7 Non-covalent interactions 
That non-covalent interaction is pivotal to biomolecular structure, molecular recognition and 
drug-design is not disputed. However, a full description and deconvolution into individual 
interactions, even in the context of a high resolution crystal structures, is complex. The 
scoring functions of high-throughput docking programs aim to give a fast prediction of the 
energy of the interaction between a posed ligand and a protein. It is therefore useful to 
discuss the nature of non-covalent interactions. Non-covalent interactions are an order of 
magnitude or two weaker than standard covalent bonds and can exist over much greater 
distances. It is the relatively low energy of a binding interface (20 kcal∙mol
-1
 to 0.5 kcal∙ 
mol
-1
) and the relative ease of making and breaking, that makes such bonding so important to 
biological systems (Boehm, 1998; Cerny and Hobza, 2007).  
 
It would be convenient to place non-covalent interactions into groups based on the physical 
origin of the attractive or repulsive forces that govern the interaction. A very broad division 
might place intermolecular forces into two categories: purely electrostatic arising from a 
Coulombic attraction between full or partial charges, and polarisation forces dependent on an 
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induced dipole (permanent or rapidly fluctuating). Such a distinction can be useful when 
deconvoluting bond energies in a vacuum, but in an aqueous environment the polar nature of 
water and its capacity to form networks of hydrogen bonds, both in the active site and around 
a solvated ligand, needs to be considered. Non-covalent interactions are often divided into 
electrostatic, hydrogen bonds, hydrophobic, attractive van der Waals dispersion forces and 
van der Waals repulsive forces. Table 1-1 summarises bond lengths and energies for this 
broad classification.  
 
Care must be taken with terming the hydrophobic effect a non-covalent interaction as it is 
really a macroscopic effect. It results from differences in hydrogen bonding networks in the 
environment of the protein’s active site and the bulk solvent, considered with the associated 
entropic effects (Sturtevant, 1977; Spolar et al., 1989). It is also difficult to assign typical 
bond energy, for example, hydrogen bonds can have a partial covalent character.  Hydrogen 
bonds have much less wave function overlap than is typical for a covalent bond that 
generally has a bond distance less than 2 Å  (Isaacs et al., 1999). In general, the shorter and 
the closer to 180
o
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Table 1-1 Non-covalent interactions 
A summary of energies of interaction and bond distances for a selection of non-covalent interactions. 
ε is the dielectric constant of the medium, rij represents the atom distance between atoms i and j, qi and 
qj their respective charges and A, B, C and D constants.  
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When examining an x-ray structure to determine the interactions between a ligand and 
protein, the usual approach is to measure the distance between a pair of heavy atoms (atoms 
other than hydrogen in this context) involved in the putative interaction, X-H...X. Where: X 
represents a heavy atom that can act as a hydrogen bond donor or acceptor; these atoms are 
O, N and less frequently C. If the distance is between 3.2 and 2.5 Å and the appropriate 
atoms are involved a hydrogen bond may be assigned (Boehm, 1998). This is not necessarily 
clear cut, for example, a distance of up to 3.6 Å for C-H...O can be considered an acceptable 
criterion for a hydrogen bond if the angle made by the three atoms is close to 180
o
. For 
electrostatic interaction formal charges on each atom in the pair are present and the distance 
is shorter than that for a hydrogen bond. For atom pairs where the distance is less than 3.8 Å 
and a hydrogen bond is not an appropriate conclusion, a van der Waals interaction is 
considered.  
1.8 Thermodynamic considerations in drug discovery 
The equilibrium of a protein P with ligand L to form complex PL can be described by the 
equation: 
P L PL  
 
It is usual in biochemistry to quantify the affinity of the ligand for the protein by the 
equilibrium dissociation constant (Kd). Equation 1 describes the ratio of the species at 
equilibrium. This relationship is known as the law of mass action. 






    Equation 1 
For a ligand to bind to a protein under a given set of conditions there must be a negative 
Gibbs free energy change on ligand binding (ΔGbinding). ΔGbinding is made up of both enthalpic 
(ΔH) and entropic terms (ΔS), equation 2  
 
bindingG H T S                        Equation 2 
 
The Gibbs free energy change on binding is related to the equilibrium dissociation constant.  
This is known as the van’t Hoff relationship (Atkins, 1986). 
 
dH T S RTln K         Equation 3 
Where: R the universal gas constant and T the absolute temperature in Kelvin. 
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The term which dominates the free energy change on binding is largely due to the polar 
nature of the participating chemical groups and their conformational freedom. Enthalpic 
contributions to bonding are principally dependent on electrostatic attractive interactions 
such as hydrogen bonds and van der Waals forces. However, there is an unfavourable 
enthalpy associated with breaking hydrogen bonds between water molecules and the polar 
groups of the ligand when the ligand is removed from the solvent (desolvation). 8 kcal∙mol
-1
 
is a recent estimate of the enthalpy of desolvation associated with a polar group (Freire, 
2008). Hydrogen bond energies between ligand and protein are very sensitive to bond 
geometry and distance. Van der Waals interactions are particularly dependent on the 
geometric fit of the ligand in the active site (Cooper, 2005). Therefore the ligand must make 
“good” hydrogen bonds/electrostatic interactions to overcome desolvation effects if there is 
to be a negative free energy change when the ligand binds. It might be argued that a very 
favourable enthalpic term can deliver specificity for a target due to the influence of the 
topography of the active site. 
 
The entropy of binding can be broadly divided up into desolvation entropy and 
conformational entropy (Sturtevant, 1977). It is important to consider both the ligand and the 
protein in the above terms. Solvated unbound ligands have a shell of ordered waters with 
stronger hydrogen bonding than those found in the bulk solvent. Desolvation produces a 
favourable entropic term as the ordered water molecules in the solvation shell lose a 
hydrogen bonding network and become less ordered. From the perspective of the protein, 
there can be a favourable entropic term from the displacement of waters in the active site. 
Crystal structures frequently show conserved hydrogen bonded waters in the active site that 
are displaced on ligand binding. The apo structure of FKBP12 shows three ordered waters in 
the active site, labelled W1, W2 and W3 in Figure 1-9. In addition, proteins are not rigid 
structures and binding of a ligand to a protein may “tighten the structure” and lead to a loss 
in translational and rotational entropy. There are also similar losses of entropy for the ligand 
on binding (Chang et al., 2007).  
 
In the context of drug discovery, one must always consider the strength of a new hydrogen 
bond in the lead optimisation process relative to the enthalpic desolvation of the ligand 
(Cabani et al., 1981). An additional electrostatic interaction may also reduce the 
conformation entropy of the complex. It can be argued that targeting new hydrogen bonds to 
conformationally flexible regions of the protein would confer the maximum unfavourable 
conformational entropy changes. An enthalpic gain can often be accompanied by an entropic 
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loss, meaning little change in ΔG. An interesting example is described by Freire’s group, 
where, in the optimisation of an HIV-1 protease inhibitor, a thioether group was replaced by 
a sulfonyl group. This resulted in an additional strong hydrogen bond to an aspartic acid 
residue. The binding enthalpy was improved by 3.9 kcal∙mol
-1
, however this was balanced by 
an entropy loss that resulted in no increase in affinity (Lafont et al., 2007). This is an 
example of what is often described in the literature as enthalpy/entropy compensation. This 
term is also used to describe the increase in ΔH and the concomitant decrease in a favourable 
entropic contribution (ΔS) that is generally observed as temperature is increased due to 
changes in heat capacity on ligand binding at constant pressure (ΔCp) (Cooper et al., 2007). 
Medicinal chemists can try to restrict an unfavourable entropic change on ligand binding by 
designing conformationally restricted ligands. It has been suggested that the macrocyclic 
immunosuppressive ligands of the immunophilins; rapamycin, FK506 and cyclosporin, have 
increased affinity for their target due to the restricted conformational flexibility afforded by 
the ring (Driggers et al., 2008).  
1.9 FKBP12 as a model protein for structure based studies 
FKBP12 was selected as a suitable target for a project combining virtual and experimental 
methods. The 12 kDa, 108 amino acid protein is present in the cytoplasm and is the most 
abundant FKBP in humans. FKBP12 can be considered a model protein in the FKBP family 
of immunophilin proteins. It represents the smallest member of the family and at least one 
FKBP12-like domain is found in all other family members. There are 15 human FKBPs 
currently identified; they possess a range of functionally significant domains that flank the 
PPIase domain, and are distributed across almost all tissues (Rulten et al., 2006; Somarelli et 
al., 2008). FKBP12 domains are considered a therapeutic target for a number of 
neurodegenerative conditions (Valentine et al., 2007). There are particularly high levels of 
FKBP expression in the brain and increased expression in areas of neuronal damage (Steiner 
et al., 1992; Achim et al., 2004). FKBP inhibitors have been shown to have protective 
effects against nerve damage and in some animal models to aid neuronal re-growth (Poulter 
et al., 2004). The non-immunosuppressive ligand GPI1046 has been shown to have a 
neuroprotective effect in an animal model of nerve damage in HIV induced dementia 
(Steiner et al., 2007). High-resolution X-ray data is available in the Protein Data Bank for 
FKBP12 in complex with a variety of small molecules and there is a wide body of literature 
(Berman et al., 2000; Dornan et al., 2003). There are well established protocols for protein 
production in E.coli developed at Edinburgh University (Wear et al., 2007b). 
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1.10 FKBP- peptidyl-prolyl isomerase, immunophilin or chaperone? 
FKBP12 has been studied from two angles; from a biological standpoint as a peptidyl-prolyl 
isomerase (PPIase) and from a pharmacological perspective in its role in the 
immunosuppressive action of the drugs FK506 and rapamycin (Harding et al., 1989; Braun 
et al., 1995). The term peptidyl-prolyl isomerase and immunophilin are used somewhat 
interchangeably to describe the FKBPs. The immunophilin family are additionally described 
as chaperone proteins. This is in part because the biological roles for the FKBPs have not 
been fully established. All FKBPs contain at least one FKBP12-like PPIase domain, with 
varying degree of affinity for FK506. It is useful to start by considering the repertoire of 
proteins with PPIase sequences.  
 
The cis-trans isomerisation of the peptide bond preceding proline has been shown to be a 
rate-limiting step in protein folding within the cell (Wedemeyer et al., 2002). Proteins that 
catalyse the conversion of this bond between the cis and trans forms are known as peptidyl-
prolyl isomerases (PPIases). PPIases are ubiquitous proteins that can be present in 
concentrations of up to 1 % in the cytosol (Hacker and Fischer, 1993). They form a highly 
conserved multigene family found in a wide variety of prokaryotes and eukaryotes. PPIases 
are divided into three structurally distinct groups: cyclophilins, FKBPs and parvulins (Galat, 
2003). Interestingly, each family of proteins possess a unique proline binding site, a lack of 
sequence homology and have not been found to have common ligands beyond small solvent 
molecules (Burkhard et al., 2000).  
 
The term immunophilin is used to describe the cyclophilins and FKBPs. The immunophilins 
were pharmacologically characterised by their ability to bind a range of immunosuppressant 
drugs that take the place of proline in the active site. Cyclophilins bind cyclosporin A and the 
FKBPs, rapamycin and FK506 (amongst other structurally related macrocyclic lactones). 
The earliest immunophilins to be identified were the small single domain proteins; human 
cyclophilin A (18 kDa) and FKBP12 (12 kDa) (Handschumacher et al., 1984; Harding et al., 
1989; Siekierka et al., 1989). Most eukaryotes have a homologue to these proteins (Page et 
al., 1995). It has been shown that the immunosuppressant drugs do not exert their effect by 
inhibiting the PPIase action of the immunophilins, but by acting as chemical inducers of 
protein dimerisation, bringing together two proteins and forming an immunophilin-drug-
protein ternary complex. It is the inhibition of the second protein that modulates a specific 
cellular signalling pathway leading to the inhibition of T-cell activation (Hamilton and 
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Steiner, 1998). In this study the aim was to find ligands that bound to the PPIase domain of 
FKBP12 and do not form an immunosuppressive complex. 
 
Even considering the simplest of organisms there are a significant number of isoforms within 
both the cyclophilin and FKBP12 families; C.elegans has 18 cyclophilins and 8 FKBPs (Bell 
et al., 2006). The larger immunophilins are multi-domain proteins and their binding partners 
have not been fully characterised. The biological role of an FKBP is often mediated through 
an interaction with a domain distinct from a PPIase domain. The variety of human FKBPs is 
discussed in more detail in the next section. These observations would indicate a high degree 
of redundancy in PPIase activity and lead one to ask the question: why are there so many 
different proteins performing the same role in the cell? These observations suggest that 
FKBPs have evolved diverse biological roles (Somarelli et al., 2008). Current evidence 
would suggest that the defining feature of the immunophilins is not PPIase activity but their 
role as chaperones. It is their ability to recognise a specific structural motif or mis-fold in a 
protein partner that unites them (Ivery, 2000). The biological roles for the immunophilins 
have not been completely elucidated, however, they do include the ability to catalyse the 
refolding of partially denatured proteins, the stabilisation of multiprotein complexes and 
chaperone activity (Barik, 2006). Following these observations one could argue that the 
immunophilin ligands cyclosporin A, FK506 and rapamycin act as peptidomimetics. 
Microbial metabolite antibiotics such as FK506 are perhaps evolved to target proteins that 
are important to the housekeeping functions of the host species (Driggers et al., 2008). 
 
Although inhibition of PPIase activity may not be central to the mode of action of novel 
FKBP12 inhibitors; structural insights into the mechanism of PPIase action and the 
dissection of non-covalent interactions with existing ligands can only enhance the study of 
potential immunophilin binding partners. More practically, measuring the PPIase activity of 
a sample of recombinant protein is a good way of assessing if it behaves in a similar manner 
to the native protein. Likewise, monitoring the inhibition of isomerisation of a known 
substrate is helpful in determining the specificity of an inhibitor for the active site.  
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1.11 The FK506 binding proteins  
1.11.1 Biological diversity and distribution 
 
Figure 1-4 Domain structure of Human FKBPs. 
FKBPs are characterised by the presence of at least 1 FKBP12-like PPIase domain. They are usually 
subdivided by considering the functionally significant domains flanking the PPIase domain and their 
cellular location (Himukai et al., 1999a). The schematic representations in this figure use the 
molecular weight naming system; the black vertical bars indicate the FKBP subdivision. 
 
FKBPs are found in all kingdoms (www.uniprot.org). The total number identified in a given 
organism is dependent on the method of classification. Bioinformatic categorisation relies on 
sequence homology to the FK506 binding domain of FKBP12 (PPIase-like domain). Not all 
FKBPs have been structurally characterised. For those that have, the majority show PPIase 
activity. Surveys by Rulten and Somarelli identify 15 FKBPs in humans (Rulten et al., 2006; 
Somarelli et al., 2008). Galat lists 17 human FKBPs; this author places a greater reliance on 
sequence homology and less on identification of mRNA sequences or protein expression 
(Galat, 2008). The earliest naming convention used FKBP followed by the approximate 
molecular weight in kDa. The naming system for FKBP genes uses FKBP (sometimes FKB) 
followed by a number (and in some cases a letter); FKBP12 is the protein of the gene 
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Table 1-2 Human FKBPs  
Information collated from searches in PubMed (www.ncbi.nlm.nin.org), UniProt (www.uniprot.org) 
and the PDB (Berman et al., 2000); December 2008. “Location” of FKBP in italics indicates that the 
cellular location was determined from mRNA expression sequences. 
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FKBPs are present in almost all human tissues often with high levels of expression. 
Mammalian FKBPs are generally subdivided into 4 groups; cytoplasmic, nuclear, TPR-
domain (tetratricopeptide repeat) and ER (Himukai et al., 1999b). This classification is based 
on functionally significant regions, flanking or contained within the PPIase domains. Figure 
1-4 shows the domain structure of the 15 human FKBPs. Table 1-2 provides a summary of 
human FKBPs, cellular localisation, binding partners and details of x-ray/NMR structures. 
This is large area of research and the following paragraphs only provide a very brief 
summary of research to date. Figure 1-5 shows an alignment of FKP12-like PPIase domains 
from 8 human FKBPs deposited in the PDB (Berman et al., 2000). The PPIase domain of 
FKBP12 is discussed in more detail in section 1.11.5.  
 
It can be seen from Table 1-2 that the cytoplasmic and the TPR domain FKBPs are the best 
characterised. The TPR domain FKBPs, excluding the poorly characterised FKBP37, all 
form a component of a multi protein complex. Hsp90 (heat shock protein 90) has been 
shown to bind to a TPR domain of FKBP51, 52 and 36. FKBP51 and FKBP52 form 
complexes with the progesterone receptor and a variety of heat shock proteins. FKBP52 is 
also thought to have a role in glutocorticoid receptor trafficking into the nucleus. FKBP36 
and FKBP38 are interesting, as they do not act as PPIases. Their PPIase-like domains show 
the most divergence from FKBP12 when considering the residues forming the active site, 
Figure 1-5. FKBP36 is a glyceraldehyde-3-phosphate dehydrogenase inhibitor and is thought 
to have a role in spermatogenesis; it forms a complex with Hsp72 (which binds to the TPR 
domain) and clathrin (which binds to the PPIase-like domain). The N-terminal PPIase 
domain has been crystallised and shows some interesting features. Trp59 forms the base of 
the hydrophobic pocket in most FKBPs; in FKBP36 it is replaced with methionine, Phe46 is 
replaced with Arg81. FKBP38 has a much deeper narrower active site than FKBP12. Trp59 
is replaced with Leu156, Phe36 with Gln138 and His87 with Arg184. Many of the aromatic 
residues lining the active site are replaced with leucine. Interestingly FKBP38 binds 
calcineurin without FK506 acting as a bridging ligand. FKBP38 has been shown to interact 
with Bcl-2 and Bcl-xl (mitochondrial membrane proteins important in cell viability) and the 
presenilins SN1 and SN2. Rheb is thought to act allosterically on FKBP38 to facilitate the 
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Figure 1-5 Alignment of 8 FKBP12-like PPIase domains 
(A) Alignment of human FKBP PPIase domains that have structures deposited in the PDB (Table 
1-2), green bars show residues in the active site that make important non-covalent interactions with 
rapamycin (labelled with the numbering scheme for FKBP12). (B) The active site of FKBP12.  
(C) FKBP12-like PPIase domains all share the same basic topology; most differences are in the 
flexible 80s and 40s loop regions. Structures were aligned to the PPIase domain of FKBP12 
(2ppn.pdb) using PyMol (V1.02, DeLano Scientific). 
     
(B)  “Dipper” shaped binding site of FKBP12 




(C)  Conserved fold 
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The ER FKBPs form the largest, but least investigated group. The proteins all contain 2 
cysteine residues that are thought to form a cystine bond and stabilise the PPIase domain; 
most PPIase domains contain 1 cysteine. It has been suggested that an increased stability is 
important in the extremes of pH present in the secretary tissue where ER FKBPs are most 
highly expressed (Rulten et al., 2006). ER FKBPs also contain a cleavable leucine rich N-
terminal sequence. FKBP22, FKBP23, FKBP60 and FKBP65 contain a calcium binding Ef-
hand motif.  
 
The nuclear FKBP25 is thought to bind to histone deacetylase through its N-terminal nuclear 
localisation sequence and possibly has a role in transcriptional regulation. FKBP12 has been 
extensively investigated and its immunosuppressive and biological roles are discussed in the 
next sections. 
1.11.2 Isomerase activity of immunophilins 
The trans conformation of a proline amide peptide bond (peptidyl-prolyl bond) is sterically 
the more favourable. However, it has been estimated that up to 30 % of prolyl peptide bonds 
exist in the cis conformation in short peptides. If the atomic structures of proteins in the PDB 
are examined, the percentage in the cis conformation is 6% and in the trans 94% (Wang and 
Etzkorn, 2006). Although, cis and trans forms of a Xaa-Pro peptide bond are almost iso-
energetic, the inter-conversion through rotation has a significant energy barrier. The energy 
barrier to rotation is not as high as a typical amide bond but is still appreciable when 
compared to a C-N single bond. FKBP12 acts as a cis-trans isomerase, catalysing the inter-
conversion by reducing the energy barrier to rotation from ~19 to ~11 kcal∙mol
-1
 (Fischer, 









cis-prolyl trans-prolyl  
 
Figure 1-6 Cis and trans forms of the peptidyl-prolyl bond 
The inter-conversion of the cis and trans forms of the peptidyl-prolyl peptide bond has an energy 
barrier of 16-22 kcal∙mol
-1
 due to the partial double bond character of the peptide bond. FKBP12 
catalyses the inter-conversion by reducing the energy barrier by 7.66 kcal∙mol
-1
 (Fischer, 2000). 
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There was early interest in determining the catalytic mechanism of peptide isomerisation by 
FKBP12, particularly as it demonstrates a level of complexity in ligand protein interactions 
beyond the simplistic concept of a lock and key. It has been proposed that non-covalent 
interactions between FKBP12 and peptide substrate result in a transition state in which 
carbonyl group of the peptidyl-prolyl bond can take on a more ketone like character, the C-N 
bond becomes more single bond in character and hence has a lower energy barrier for 
rotation. A “twisted amide bond” transition state is formed and it becomes energetically 
favourable for the peptide to leave the binding state in a trans conformation (Fischer et al., 
1993). Rosen et al. examined inhibition of rotamase activity of FKBP12 by FK506; the 
authors concluded that FK506 acts as a mimic of the twisted amide bond seen in the 
transition state in the natural peptide substrate (Rosen et al., 1990). 
 
In addition changes to the isomeric state of a peptidyl-prolyl bond are also thought to act as a 
molecular switch in protein signalling events. FKBP12 and cyclophilin A can therefore act to 
regulate isomeric switching in signalling pathways (Lu et al., 2007). Another interesting 
example of the importance of PPIase activity is cyclophilin A catalysing the cis-trans 
isomerisation of a peptidyl-prolyl bond in an HIV capsid protein that is necessary for viral 
repackaging (Gamble et al., 1996). 
 
It is clear from the higher levels of mis-folded proteins seen in the production of recombinant 
proteins that the eukaryotic cell contains an efficient apparatus for the recognition of 
incorrectly folded proteins followed by repair or proteolysis (Gething and Sambrook, 1992). 
An incorrectly folded protein may have hydrophobic patches, which are usually buried, 
exposed on the surface of the protein and this can lead to aggregation. Deficiencies in the 
quality regulation systems of neuronal cells have been proposed as the underlying pathology 
in a number of neurodegenerative diseases (Gao and Hu, 2008).  
 
1.11.3 Biological role of FKBP12 and FKBP12.6 
The varied roles of FKBPs, beyond that of PPIase activity, may be summarised by 
considering the PPIase domain as a recognition domain or molecular adaptor facilitating the 
assembly or modulation of the activation state of a macromolecular complex. The 
cytoplasmic FKBPs, FKBP12 and FKBP12.6 consist of one PPIase domain and show close 
sequence and structural homology. FKBP12 has been shown to be involved in Ca
2+
 related 
signalling through interactions with ion channels (Hamilton and Steiner, 1998). FKBP12 
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stabilises the ryanodine receptor (RyR1) and the inositol 1,4,5-triphosphate receptor (IP3R) 
improving the control of Ca
2+
 flux (Barik, 2006; Kang et al., 2008). Calcineurin associates 
with these receptors and controls the gated channel by changes to the phosphorylation state 
of the complex. FKBP12 also interacts with the trans-membrane type I transforming growth 
factor-β (TGF-β) receptor and may mediate interactions between mast cells and neutrophils 
in a manner more reminiscent of a cytokine. FKBP12 stabilises the type 2 ryanodine receptor 
(RyR2) that is highly expressed in cardiac muscle (Deivanayagam et al., 2000; Chelu et al., 
2004). 
1.11.4 FKBP12 and immunosuppression  
 
Figure 1-7 Structures of FK506 and rapamycin 
FK506 and rapamycin share the same FKBP12 binding domain. The pink shades area indicates the 
portion of FK506 that binds to calcineurin. The blue shaded area indicates the portion of rapamycin 
that binds to mTOR. The coloured regions are known as the effector domains. 
 
The natural antibiotic products FK506 and rapamycin were the earliest ligands of FKBP12 to 
be investigated. When 12000 Streptomyces strains were screened, 1 % of secondary 
metabolites were found to bind to FKBP12 (Driggers et al., 2008). Although FK506 and 
rapamycin show structural similarity in the region interacting with FKBP12 their mode of 
action is different (Figure 1-7). They both act as chemical inducers of protein dimerisation 
bringing together two proteins and forming an FKBP12-drug-protein ternary complex. It is 
the inhibition of the second protein that modulates a cellular signalling pathway leading to 
the failure of T-cells to proliferate on response to antigenic stimulation. The effector loop of 
FK506 is solvent exposed on binding to FKBP12 and forms a compound surface with 
rapamycin FK506 
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FKBP12 that interacts with the serine/threonine phosphatase calcineurin. The phosphatase 
activity of calcineurin is thus inhibited. Calcineurin is important in the dephosphorylation of 
the transcription factors NFAT (nuclear factor of activated T-cells). Phosphorylated NFAT 
cannot be transported into the T-cell nucleus or bind to DNA promoting the expression of 
cytokines and cell surface receptors responsible for the amplification of the immune 
response. Rapamycin forms a ternary complex with FKBP12 and mTOR (mammalian target 
of rapamycin) leading to the interruption of cell cycle progression and T-cell proliferation 
(Abraham and Wiederrecht, 1996; Hamilton and Steiner, 1998).  
 
Modifications to the effector domains of FKBP12 and rapamycin can change the 
immunosuppressive properties of the drug. For example, in the natural product ascomycin  
-CH2CH3 replaces -CH2CHCH2 on C21 of FK506. Ascomycin has a similar affinity for 
FKBP12 as FK506 but, different interactions with calcineurin due the subtle difference in the 
effector loop. L-685-818 (x-ray structure 1FKD.pdb represents the complex with FKBP12-
L-685-818) is very similar to ascomycin with only a substitution of -H for –OH on C18 and 
an ethyl for an allyl group on C21  (Babine and Bender, 1997).  The PPIase binding domain 
of the immunosuppressant drugs are discussed in the section 1.11.6 that describes FKBP12 
inhibitors. 
1.11.5 X-ray and NMR structures of FKBP12 
There are 37 X-ray and NMR structures for FKBP12 deposited in the protein data bank 
(PDB, December 2008). These include structures for wild type and mutant FKBP12; free, in 
complex with small molecules and in FKBP12-drug-protein ternary complexes. 14 different 
FKBP12-small molecules complexes have been deposited in the PDB (Structures and Ki 
values for ligands are shown in Appendix 3).  
 
The highest resolution x-ray structure of apo FKBP12 in the PDB is 2PNN.pdb (0.93 Å, 
2008). The structure of FKBP12 is reminiscent of a 6 fingered curled hand, Figure 1-8 (A). It 
consists of a 5 strand anti-parallel β-sheet which can be thought of as fingers of the hand, 2 
short stretches of α-helix and 3 linking loops. The 80s loop forms the thumb extending above 
the longer α-helix and the 40s loop a boundary to the active site. NMR NOE analysis 
indicates these loop regions are the most flexible in solution (Sich et al., 2000). Analyses of 
apo and holo x-ray structures indicate that the 40s and 80s loops are stabilised upon ligand 
binding (Wilson et al., 1995). Superposition of FKBP12 in complex with small molecules 
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shows most variation between protein structure in the 40’s and 80’s loops. Figure 1-8 (A) 
illustrates how the 80s loop moves in and down (folds over) on ligand binding. 
 
The residues surrounding the base of the active site are positioned very consistently in all x-
ray structures. The rim of the main pocket is lower near the top of the α-helix in a gap 
between the 40s and 80s loops, this leads to a channel bounded on one side by the residues 
Gln53 and Glu54. This channel is occupied by portions of the larger ligands, thus making the 
full binding cavity dipper shaped. The active site of FKBP12 is illustrated in Figure 1-5 (B) 
and Figure 1-8 (B). The scoop of the dipper forms the catalytically active proline binding site 
and has a hydrophobic base “floored” by Trp59. Phe36, Phe46 and Phe48 form the walls of 
the pocket. The handle of the dipper and the rim of the proline binding site contain residues 
that can form hydrogen bonding interactions with the larger ligands. Rapamycin makes five 
hydrogen bonds with the protein (Tyr26, Asp37, Gln53 Glu54, Ile56 and Tyr82). There is a 
hydrophobic sub-pocket in the region of His87, Ile90 and Ile91 which is relatively flexible 
and can accommodate various groups. Trp59 moves down (away from His87) to 
accommodate the larger ligands. 
 
There have been attempts to predict the druggability of a protein based on conformational 
dynamics and physicochemical descriptors. A group at Abbott Laboratories has devised a 
druggability coefficient to assess potential drug targets (Brown and Hajduk, 2006). This 
coefficient aims to quantify how the effects of thermal motion and conformational changes 
on ligand binding may influence predictions of protein binding to small molecules. The 
group reports that FKBP12 has a high degree of druggability on the evidence of molecular 
dynamic simulations. FKBP12 appears to present an open, druggable pocket for nearly 90 % 




                    
            
 
Figure 1-8 FKBP12 complexes 
(A) 12 complexes of FKBP12 inhibitors were aligned with a high resolution x-ray structure of apo 
FKBP12 (red ribbon, 2ppn.pdb, 0.92 Å). The 80s loop is stabilised and moves in (towards the base of 
the active site) on ligand binding. The grey inset box shows the 80’s loop rotated 90
o 
anti-clockwise, 
in the vertical axis, relative to the representation of the full structure. (2PNN.pdb, 2DG3.pdb, 
1FKF.pdb, 1FKH.pdb, 1FKG.pdb, 1FKI.pdb 1J4R.pdb, 1J4I.pdb 1J4H.pdb, 1F40.pdb, 1D7I.pdb, 
1D7H.pdb (References and full ligand structures shown in Appendix 3). (B) Schematic diagrams of 
rapamycin in the active site of FKBP12. Black dashed lines to magenta labelled residues represent 
































































(B) Rapamycin in the active site of FKBP12 
Ile90 
His87 





80s loop moves “in” on 
ligand binding 
40s loop  N-terminus  
C-terminus  
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Hydrophobic and hydrogen bonding interactions for 12 of the deposited x-ray structures of 
protein small molecule complexes have been summarised in Table 1-3 (2 ligands have been 
omitted as they share a protein binding domain with rapamycin). Ligand structures (with Ki) 
are shown in Appendix 3. The non-covalent interactions between FKBP12 and FK506 and 
rapamycin have many common features due to the molecules showing structural similarity in 
the FKBP12 binding regions; they have Kd of 0.4 nM and 0.2 nM respectively (Bierer et al., 
1990). Here the non-covalent interactions of FK506 with FKBP12 are described first. The 
pipecolenyl ring is buried deepest in the pocket and forms hydrophobic interactions with 
Trp59 at the base of the pocket. This takes the place of proline in the natural substrates. 
Hydrogen bonding interactions are predicted with four residues. The C1 carbonyl on FK506 
acts as a hydrogen bond (H-bond) acceptor to hydrogen donated by the main chain N of 
Ile56 (see Figure 1-7 for numbering scheme). The amide oxygen on C8 forms a H-bond 
acceptor for the H of Tyr82. A hydroxyl group on C10 of the pyranosyl ring forms an H-
bond with Asp37 and there is a further H-bond to the main chain carbonyl of Glu54 from the 
C24 hydroxyl. The second carbonyl C9 of the twisted diketo moiety between the pipecolenyl 
ring and the pyranosyl ring forms weak hydrophobic interactions with Tyr26, Phe36 and 
Phe99. There are further hydrophobic interactions with Phe46 and Val55. The methyl group 
on C11 lies in the His87-Ile91 hydrophobic sub-pocket. In the rapamycin complex there is an 
additional H-bond from the C40 hydroxyl to the main chain carbonyl of Gln53 and more 
extensive hydrophobic interactions between the protein and cyclohexyl ring.  
 
The 10 additional complexes are detailed in Table 1-3. They show a similar binding mode to 
FK506 and rapamycin. 7 of the ligands have a 5 or 6 member heterocyclic aliphatic ring that 
lies deepest in the pocket in a position analogous to proline in the natural substrate and the 
pipecolenyl ring of FK506 and rapamycin. 9/10 of the ligands make a hydrogen bonding 
interaction with the main chain N of Ile56 through a carbonyl group equivalent to the C1 
carbonyl of FK506 that forms part of an ester linker. Interestingly the heterocyclic rings all 
possess a chiral center at C2. This is the S form in all x-ray structures. The same is noted for 
the majority of the inhibitors listed in Table 1-4.  7/10 possess a carbonyl oxygen analogous 
to the C8 carbonyl oxygen (FK506) that makes a hydrogen bond with the hydroxyl of Tyr82. 
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PDB Ligand Tyr26 Phe36 Asp37 Phe46 Gln53 Glu54 Val55 Ile56 Trp59 Tyr82 His87 Ile90 
2DG3 rapamycin   2.61   2.63 2.67  2.93  3.45 2.66    
1FKJ FK506   2.78    2.68  2.80  3.44 2.76    
1fkh SBX         2.89  3.34 2.64    
1fkg SB3         2.89  3.54 2.62    
1fki SB1         2.87  3.47 2.75    
1j4r FK001      2.66   2.98  3.34 2.75    
1j4i 308         2.76  3.25 2.65    
1j4h 107         2.89  3.44 2.66    
1f40 GPI1046            3.28    
1d7j HB         2.94  3.49     
1d7i DSS         2.85       
1d7h DMSO         2.85       
 
Table 1-3 Summary of non-covalent interactions in FKBP12-inhibitor complexes 
A comparison of possible hydrophilic (highlighted in blue, shortest heavy atom distance in Å) and 
hydrophobic (highlighted in green, shortest heavy atom distance in Å) interactions between ligands 
and FKBP12 from x-ray structures deposited in the PDB (distances were measured in PyMOL V1.02, 
DeLano Scientific). Ligand structures are illustrated in Appendix 3. Figure 1-9 shows a portion of the 
active site of the x-ray structures of complexes aligned with 2ppn.pdb. 
 
 
It is worth noting that ligand oxygen atoms making hydrogen bonding interactions with the 
main chain N of Ile56 and Tyr82 occupy very similar positions to the oxygen atom of the 
water molecules labelled W1 and W2 seen in the apo structure of FKBP12, Figure 1-9. The 
carbonyl oxygen, equivalent to the C9 carbonyl of rapamycin, occupies a similar position to 
water molecule W3 of the apo structure. The displacement of these waters on ligand binding 
is predicted to provide favourable entropic contribution to free energy of binding (Connelly 
et al., 1993). These observations suggest that Ile56, Tyr82 and Trp59 can be considered “hot 
spots” in the active site of FKBP12.  
 
When docked ligand poses of similar score were visually examined during the selection of 
compounds for purchase the presence of the conserved non-covalent interactions between a 
ligand and a “hot spot” residue: Tyr82, Ile56 and Trp59 were noted. If docked poses 
replicated these interactions the pose represented a protein-ligand conformation where the 





Figure 1-9 Small molecule inhibitors in complex with FKBP12 
Ligand oxygen atoms making hydrogen bonding interactions with the main chain N of Ile56 and 
Tyr82 occupy very similar positions to the oxygen atom of the water molecules in the apo structure 
labelled W1 and W2. The carbonyl oxygen, equivalent to the C9 carbonyl of rapamycin, occupies a 











1.11.6 FKBP12 inhibitors 
FKBP12 inhibitors can be broadly divided into immunosuppressants (FK506, rapamycin and 
similar macrocyclic antibiotics) and inhibitors that target the PPIase domain of FKBP12, the 
latter group are by far the more numerous. PPIase inhibitors include compounds that have 
been specifically designed for the treatment of degenerative neurological conditions 
(Hamilton and Steiner, 1998). There is also good evidence for certain solvents binding with 
low affinity; this has relevance for binding assays (Burkhard et al., 2000). FKBP12 
inhibitors have been reviewed by Babine et al., , Dornan et al., and Wang at al., in some 
detail (Babine and Bender, 1997; Dornan et al., 2003; Wang and Etzkorn, 2006). Within the 
constraints of a brief review this section attempts to summarise common features between 
inhibitors.  
  
Many synthetic ligands are based on the FKBP12 binding domains of FK506 (binding loop) 
and rapamycin, Figure 1-7. Removing the effector loop and replacing it with a variety of 
aliphatic chains, rings or an aromatic group has proved successful. Replacement groups have 
been attached to the diketo moiety and ester linkage flanking the pipecolenyl ring resulting 
in acyclic ligands. Many of these have high affinity for FKBP12 and are potent isomerase 
inhibitors with Ki values for FKBP12 in the low nanomolar range, Table 1-4. Christner et al., 
(2001) produced a reduced binding model pharmacophore providing flexibility between a 5 
and 6 member ring and emphasizing the importance of the α-keto amide functionality 
(Christner et al., 2001).  
 
For example, the pyranosyl ring in FK506 was replaced with a (dimethyl-ethyl)methyl group 
and the ester beyond the pipecolenyl ring linked to rings in the ligand SB3, the complex 
described by 1FKG.pdb (Holt et al., 1993; Holt et al., 1994). A 3,4,5-trimethoxy phenyl 
group has also been used to replace the pyranosyl ring (Armistead et al., 1995). In Table 1-4 
an attempt has been made to illustrate the effect of replacing key elements/functional groups 
in the core binding motif of FK506 and rapamycin. The core FK506/rapamycin binding 
motif consists of a pipecolenyl ring with a diketo linker on N7 (α-keto amide) and an ester 
linker on C2. A general structure is shown in Figure 1-10. Replacements to the diketo groups 
and ester linkage with bio-isosteres has received much attention, particularly by the groups 

















rapamycin 0. 2 nM 
(Figure 1-7) 
(Bierer et al., 
1990) 






















GPI-1046 7.5 nM 
(Holt et al., 1993; 




























































(Wei et al., 2002) 
 























Core name Core Structure “Best”  in series, Ki  Reference 
M6 
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IC50≥670 nM  
(Limburg et al., 
2003) 




































































IC50≥650 nM  
(Limburg et al., 
2003) 
M15   Kemp et al. 
(Pfizer). Patent 
number: 6372736 
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≥ 7000 nM 
(Burkhard et al., 
1999) 
Table 1-4 Core structures FKBP12 inhibitors (Part 3) 


































A simplistic summary of these modification strategies might be: substitutions to the linkers 
to the pipecolenyl ring aims to reinforce H-bond interactions; principally with Ile56, Tyr82 
and Glu54. Addition of aromatic hydrophobic groups in place of the pyranose or cyclohexyl 
rings aims to contribute to hydrophobic interactions, particularly in the hydrophobic pocket 
adjacent to His87 (pyranose ring replacement). Table 1-4 shows how it is possible to 
substitute in the linker regions without too much of a decrease in affinity for FKBP12 (cores 
M1-10). Choi et al. found that including a hydrophobic group on a 3-4 carbon linker to the 
C1 ester improved activity (Choi et al., 2002). The length of the linker presumably 
facililitates positioning of a group analogous to the cyclohexyl ring in the hydrophobic 
trench adjacent to Gln53 and Glu54. Appendix 3 includes two examples of a series of 
ligands in which the C8 carbon of the diketo moiety of FK506 has been replaced by sulfur 
(M5; 1J4H.pdb and 1J4I.pdb, (Sun et al., 2003)). Many core structures have been filed as 













Figure 1-10 Core binding motif of many FKBP12 inhibitors 
Summary structure of acyclic derivatives of FK506/rapamycin and some examples of substituted 
elements/groups investigated in the literature.  
 
An inhibitor with a ring containing sulfur and nitrogen (M20) has been reported (Zhao et al., 
2006). The top hit in this series is very similar to compound GPI-1046 (M2) apart from the 
heterocyclic ring mimicking proline in the active site. 
 
Inhibitors with a scaffold not based around the pipecolenyl ring are less numerous and, as a 
generalisation, of lower affinity. There has been some interest in more rigid inhibitors, such 
as cyclic urea derivatives, the aim being to produce better mimic the twisted intermediate 
implicated in the model of PPIase action (Dragovich et al., 1996). Burkhard et al., (1999) 
discovered some novel inhibitors using the molecular docking program SANDOCK (Sandoz 
Pharmaceticals, Basel, Switzerland). These include the steroids 5β-pregnan-3-20-dione, 5β-
pregnan-3α-ol-20-one and  benzyloxycarbonyl–L-proline derivatives (Burkhard et al., 1999). 
Other interesting compounds are the bicyclic ring system reported by Limburg et al. (2003) 
X =H, O, CH2, CH3, F2  R1=H, Me, Ph, (CH2)nPh, COOCMe3 
Y =C, N, S  R2=H, CHMe2, CH2CH2Ph, (CH2)3-3-Pyr 
Z =H, N, O   R3=c-hexyl, CMe2Et, 3,4,5MeO3Ph,  
W=N, O   n = 1, 2  
Note: some element changes result in a change in C hybridisation from Sp2 to 




and the polycyclic aza-amide compounds described by Hudack et al., (2006) (Limburg et al., 
2003; Hudack, Jr. et al., 2006).  
  
There has been relatively little published on novel FKBP12 inhibitors in the last two years. 
There have been two studies reporting fragment based approaches. San Diego Centre for 
Chemical Genomics carried out a high-throughput NMR screen of 3775 fragment-like 
compounds (Stebbins et al., 2007). Section 4.4.2 describes structure activity relationships for 
the most active cluster of compounds. The active compound 2-[(4-methylphenyl)sulfonyl]-1-
(morpholin-4-yl)ethan-1-one (SD1) has been used as a medium affinity positive control in 
this study. SD1 has a Kd of 6.8 μM for FKBP12 but is around 100x more soluble in aqueous 
buffer than the low nanomolar affinity immunosuppressive drugs. A study by Rohrig et al. 
builds on the SAR by NMR studies of Fesiks’ group and the work on linkers by Armistead 
(Armistead et al., 1995; Shuker et al., 1996; Rohrig et al., 2007). Rohrigs’ study does not 
offer any novel scaffolds to replace the core motif of rapamycin.  
1.11.7 FKBP12 inhibitors and neurological conditions  
It was found that FKBP12 has an up to 40 % higher level of expression in the rat brain 
compared to cells of the immune system. This led to supposition that FKBP12 is involved in 
neurological function. Levels were particularly high in regions of the brain that have 
implications for Parkinson’s and Alzheimer’s disease. It has been reported that FK506 can 
enhance neurite out growth in cultures of rat PC12 pheochromaocytoma cells and sensory 
ganglia and FKBP12 inhibitors may be useful in cases of neuronal damage (Lyons et al., 
1994). Other studies showed a neuroprotective role for FK506 in a model for cerebral 
ischemia, a condition observed in stroke patients. This was explained by interaction of 
FK506 with the calcium-calmodulin dependent enzyme nitric oxide synthase (NOS) by 
blocking the action of calcineurin and keeping NOS in a hyperphosphorylated state 
(Hamilton and Steiner, 1998; Brecht et al., 2003). Moreover, neurotrophic effects were 
observed for non-immunosuppressive inhibitors of the PPIase domain of FKBP12 that do not 
bind to calcineurin or mTor (Edlich et al., 2006). The neurotrophic effect is therefore not 
exclusively dependent on ligand binding to calcineurin. The mechanism of neurotrophic 
effects has not been fully explained. The understanding is complicated by the presence of 
PPIase domains in all members of the FKBP family of proteins. It has also been argued that 
the rotamase function of FKBP12 rescues mis-folded proteins and can in certain 
circumstances lead to the formation of undesirable protein plaques in the brain.   
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1.12 Project outlines 
1.12.1 Chapter 2: Protein Production  
The six histidine N-terminal construct of FKBP12 was over expressed in E.coli and purified 
to greater than 95 % purity. The protein was biochemically and biophysically characterised 
prior to experimental ligand screening experiments. 
1.12.2 Chapter 3: ESI-MS in drug discovery 
An aim of this part of the study was to find the correct solution and instrument parameters 
for flying the six histidine N-terminal construct of FKBP12 and preserve protein in complex 
with ligand. The project examined correlations between rank orders of ligand affinity 
determined in ESI-MS and experiments carried out in solution using a test set of structurally 
diverse inhibitors in the nano to millimolar range.  
1.12.3 Chapter 4: Hydrophobic effects versus electrostatic interactions in ESI-
MS? 
A series of experiments tested the hypothesis: complexes with a significant enthalpic 
contribution to the free energy of binding arising from electrostatic interactions dissociate 
less in electrospray. One might make the assumption that the active site of a protein contains 
amino acids complementary to physiologically important binding partners; in respect to both 
charge and hydrophobicity. Does it therefore follow that some proteins may be more 
amenable to screening using ESI-MS than others? This study compared the behaviour of 
FKBP12 in electrospray with two protein-ligand complexes where electrostatic contributions 
to binding provide the dominant energy term. VC50 (cone voltage required to dissociate 50 
% of the complex) were compared to Kd and thermodynamic profiles determined by 
isothermal titration calorimetry. 
1.12.4 Chapter 5: The Spectral Ghost 
During the initial experimentation it became apparent that preserving complex for medium 
affinity ligands (1 μM to 100 μM) of FKBP12 was challenging. This raised practical 
difficulties, the majority of the compounds in the test set had affinity in the micromolar 
range. High/medium affinity ligands are also much less likely than low affinity ligands to be 
picked up in the early stages of the drug discovery process. However, careful examination of 
the electrospray spectrum, with and without the presence of a ligand, showed changes to the 
charge-state distribution of the protein and the possibility of using charge-state shift as a 
sensitive tool to screen for weak non-covalent interactions.  
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1.12.5 Chapter 6: Biophysical and biochemical ligand binding studies of 
FKBP12 
The ligand test set was used to compare results from ESI-MS with other biophysical and 
biochemical techniques. 
1.12.6 Chapter 7: Screening for Inhibitors of FKBP12  
X-ray structures of FKBP12 were used as docking templates for virtual screening 
experiments using the programs LIDAEUS (Wu et al., 2003) and FlexX (Rarey et al., 1996). 
3D structures of ligands were used by UFSRAT, a ligand similarity based method, where 
known inhibitors of FKBP12 were compared to molecules in a virtual library (Steven Shave, 
Edinburgh University). A Bayesian machine learning method was used to assign a relative 
activity probability to a compound in a library (Angelopoulos et al., 2009). Compounds from 
four libraries were screened against FKBP12; EDULISS 2 (3.8 M unique compounds from 
commercial and academic sources (Hsin, 2009) ; a subset of the Specs catalogue (15 000, 
commercially available compounds. Specs, Delft, The Netherlands); a fragment library (96 
compounds selected from The Maybridge Ro3 collection, UK) and the KB series (a library 
designed to target immunophilins). 
1.12.7 Chapter 8: Human Cyclophilin A – Testing the KB series  
The KB series of compounds were tested against the immunophilin cyclophilin A by 
biophysical assay and x-ray crystallography. This enzyme is structurally different to 
FKBP12 but does exhibit peptidyl-prolyl isomerase activity. Crystals of hcypA were grown 
and then soaked in saturated solutions of potential inhibitors. This method has proved useful 
in characterising the binding of very weak inhibitors. 
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2 Chapter 2  Protein Production  
2.1 Introduction 
Recombinant human N-terminal hexa-histine tagged FKBP12 (FKBP12, Figure 2-1) was 
expressed in E.coli and purified under native conditions following a modified version of the 
protocol described by Wear et al., 2007b. Pure protein yields were initially in the order of  
6 mg∙L
-1
 culture. These were improved 1.5 fold by the use of a 10 L fermentor (Bioflo 4500 
fermentor, New Brunswick Scientific) and cell disruption (Constant Cell Disruption 
Systems). Cell disruption was found to give more consistent cell lysis than sonification. 
Modification to the affinity chromatography protocol increased the purity of the sample after 
step one of the purification and reduced losses in the concentration steps. Final protein yields 
were in the region of 14 mg∙L
-1
 culture.  
 
        10         20         30         40         50         60  
MRGSHHHHHH GSMGVQVETI SPGDGRTFPK RGQTCVVHYT GMLEDGKKFD SSRDRNKPFK  
 
        70         80         90        100        110        120  
FMLGKQEVIR GWEEGVAQMS VGQRAKLTIS PDYAYGATGH PGIIPPHATL VFDVELLKLE 
 
Figure 2-1 Sequence of recombinant human N-terminal hexa-histidine tagged FKBP12. 
Sequence in black is that of wild type human FKBP12, sequence in blue was added to allow an 




FKBP12 was judged to be greater than 95 % purity by SDS-PAGE (Laemmli, 1970). The 
protein was active as a peptidyl-prolyl isomerase with a turnover number (Kcat) of   
300 ± 40 s
-1
 for the preferred peptide substrate N-succinyl-Ala-Leu-Pro-Phe-p-nitroaniline; 
this is in agreement with accepted values (Kofron et al., 1991). Recombinant FKBP12 
exhibited an affinity for rapamycin in agreement with the literature (Bierer et al., 1990; 
Connelly and Thomson, 1992; Wear and Walkinshaw, 2007; Wear et al., 2007b). 
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2.2 FKBP12 Expression and Purification  
2.2.1 Transformation and overexpression of FKBP12 in E.coli 
The plasmid for recombinant FKBP12 was constructed by Dr. Alan Paterson and consisted 
of an open reading frame for FKBP12 inserted and ligated into a pQE-30 vector via the 
HindIII and BamHI sites (Wear et al., 2007b). Competent E.coli cells (BL21 Star
TM
, 
Novagen) were transformed using the manufacturer’s standard protocol. Transformed cells 
were grown from a single colony in two times TY media, 100 μg∙ml
-1
 carbenicillin at 37 
o
C 
with 260 rpm shaking, to an Absorbance600nm ~ 0.6. Over expression of FKBP12 was 
induced by addition of 1 mM IPTG and cells harvested after a further 4 hours (Figure 2-2). 
Protein yields were increased around 1.5 fold in a 10 L Bioflo 4500 fermentor (New 
Brunswick Scientific) compared to growth in 2 L conical flasks in 500 ml batches. It is 
believed that increased levels of cell mass obtained in fermentor runs are in part attributable 
to higher levels of aeration (Bauer and Shiloach, 1974). 
 
 
     MW       C1     C2       C3      C4     C5      C5(T0) 
 
Figure 2-2 Overexpression of 6H-FKBP12. 
15 % acrylamide SDS-PAGE denaturing gel showing overexpression of FKBP12 in E.coli 
(recombinant strain BL21star
TM
-pQE30-6H-FKBP12) grown in 2xTY media at 37 
o
C with 260 rpm 
shaking. Cells were induced after reaching an optical density of A600nm ~ 0.6 with 1 mM IPTG. Lanes 
C1 to C4 show soluble fraction from four separate colonies, grown in 500 ml batches, after 4 hours 
induction with  IPTG. Lane C5 shows whole cell extract from colony 5 grown under similar 
conditions in a 10 L fermentor after 4 hours induction with IPTG  and lane C5(T0) the sample C5 
prior to induction. FKBP12 runs at 14.6 kDa in SDS-PAGE (15 % acrylamide).The gel was stained 
with Coomassie blue stain (Brilliant blue R, Sigma-Aldrich). Molecular weight marker (MW) Sigma 
wide range (Sigma-Aldrich).  
 
Cell cultures were centrifuged at 50000 g for 30 minutes at 4 
o
C; the pellet was frozen in 
liquid nitrogen and stored at -80 
o
C until required. Active protein was successfully purified 
from cell pellets up to 1 year old. 
29 kDa 




2.2.2 Affinity chromatography 
Cell pellets were rapidly defrosted and re-suspended in ice cold PBS, pH 7.5; 1 mM sodium 
azide; 0.1 % TX-100; 100 mM PMSF; 100 μM benzamidine; 5 mM β-mercapto ethanol; 
protease inhibitors (2 mini protease inhibitor cocktail tablets per 1 L culture, Roche);  
(30 ml∙L
-1
 of original culture). All further purification steps were carried out at 4 
o
C. Cells 
were lysed by single pass cell disruption (Constant Cell Disruption Systems) at 25 psi. The 
cell extract was centrifuged at 50000 g for 1 hour, the supernatant collected, filtered to  
0.2 μm and adjusted to 20 mM imidazole by the addition of a concentrated imidazole 
solution buffered to pH 7.5. The extract was passed over a HisPrep FF 16/10 nickel 
sepharose column (20 ml, GE Healthcare) using Acta-FPLC (GE Healthcare) equipment at a 
flow rate of 0.7 ml∙min
-1
. The column was washed using at least 4 column volumes of PBS, 
pH 7.5; 1 mM sodium azide; 5 mM β-mercaptoethanol. The FKBP12 was eluted with a 
gradient of 4 - 100 % 500 mM imidazole, pH 7.5 over at least 15 column volumes at a flow 
rate of 2.5 ml∙min
-1
. The protein elution peaked at 330 mM imidazole (Figure 2-3).  
 
It became necessary to modify the initial two-step purification protocol after the increased 
protein yields afforded by the use of the fermentor and cell disruption apparatus. High levels 
of FKBP12 expression were accompanied by expression of an impurity of relatively low 
solubility at 4 
o
C. This impurity bound non-specifically to the nickel affinity column. This 
impurity elution peak had a significant overlap with the elution peak for FKBP12. 
Precipitation of impurities during sample concentration prior to gel-filtration pulled down a 
proportion of FKBP12, thus reducing yields. This problem was addressed in two ways. Raw 
cell extract was loaded onto the Ni
2+
-affinity column with the addition of a low concentration 
of imidazole (20 mM). This reduced non-specific binding. In addition, use of a 20 ml  
Ni
2+
 affinity column gave some chromatographic separation between the eluted impurity and 
FKBP12. 1 ml fractions were collected and analysed by SDS-PAGE (Laemmli, 1970). 
Fractions containing FKBP12 were pooled and concentrated by spin concentrator (Vivaspin, 
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Figure 2-3 Nickel affinity Chromatography. 
Use of a larger volume column and modified protocol removed a greater proportion of the impurities 
at the first step of purification. (A) Elution profile for FKBP12 using a 5 ml Ni
2+
-NTA column 
(Superflow resin, Quiagen) eluted by imidazole gradient (0-100% 500 mM imidazole over 20 column 
volumes). (B) 15 % acrylamide SDS-PAGE gel showing FKBP12 after the 1st step of purification 
using a 5 ml Ni
2+
-NTA column. (C) Elution profile for FKBP12 using a 20 ml HisPrep FF 16/10 
column (GE Healthcare) eluted with 4 - 100 % 500mM imidazole over 15 column volumes.  
(D) 4 - 15 % gradient SDS-PAGE gel showing FKBP12 after the 1st step of purification using a 20 ml 
HisPrep column. Molecular weight marker (MW) Sigma wide range, lane L is the sample loaded on 
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2.2.3 Size exclusion chromatography 
An S200 HiPrep gel filtration column (120 ml, GE Healthcare) was pre-equilibrated with 
PBS, pH 7.5; 1 mM DTT; 0.5 mM EDTA, and loaded with a concentrated sample of the 
protein from the 1st stage of purification. The protein was loaded and eluted at a flow rate of 
0.5 ml∙min
-1
. The majority of the sample eluted corresponded to monomeric FKBP12. 
FKBP12 fractions were pooled and concentrated prior to exchange into the appropriate 
experimental buffer. Buffer exchange was carried out manually on PD10 rapid desalt 
columns (GE Healthcare) or on an Acta FPLC system using HiPrep Desalt columns (26/10, 
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Figure 2-4 Size exclusion chromatography. 
Elution profile from a S200 HiPrep gel filtration column (GE Healthcare) showing a dominant peak 
corresponding to monomeric FKBP12. Eluted with PBS, pH 7.4; 1 mM DTT; 0.5 mM EDTA; at a 
flow rate of 0.5 ml∙min
-1
. Fractions E9 to F8 were pooled; shown by the green double-headed arrow. 
Molecular weight marker (MW) Sigma wide range, labelled in kDa. Gels were stained with 
























2.3 Physical and Biochemical characterisation of FKBP12 
2.3.1 SDS-PAGE 
Protein samples were assessed for purity by 15 % acrylamide SDS-PAGE on the Mini-
PROTEAN Tetra Cell system (Bio-Rad). Proteins were stained using Coomassie Brilliant 
Blue R (Sigma-Aldrich). Protein purity and molecular weight was estimated from band 
intensity and location using a Molecular Imager Gel Doc XR gel scanner and Quantity One 
V4.6.5 software (Bio-Rad). Figure 2-5 shows FKBP12 purity to be greater than 95 % for the 
pooled fractions as determined by band densitometry. 
 
 
   1       2        3      4        5       6        7        8       9      10     11      12      13     14 
 
Figure 2-5 Assessment of protein purity by SDS-Page band densitometry. 
Representative 15 % SDS-PAGE denaturing gel, FKBP12 in 50 mM ammonium acetate, pH 6.8.  
Lane 1 molecular, weight marker Sigma wide range. Lanes 2-14 elution fractions from rapid desalt 
column (HiPrep 26/10, GE Healthcare). (A) Densitometric analysis; red bars show % intensity of each 
band by lane. Fraction in lane 1 was excluded from pooling. (B) Marker bands are labelled with blue 
bars (kDa). Lanes 2-14 bands are labelled with red bars for impurities and green bars for FKBP12. 
FKBP12 ran at 14.65 kDa relative to the molecular weight standards. The gels were stained with 
Coomassie blue stain. 
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Protein was stored on ice for up to 6 weeks in a buffered solution, pH 7.4. SDS-PAGE 
showed a small proportion (~ 5 %) of the sample to have a mass less than that of FKBP12 
after ~ 8 weeks. FKBP12 showed slightly less breakdown in 50 mM ammonium acetate at 
pH 6.8 than PBS at PH 7.4.  
2.3.2 Determination of Protein Concentration  
Protein concentration of FKBP12 was routinely determined from absorption at 280 nm 




. The extinction 
coefficient was calculated using the ExPASy ProtParam server 
(www.expasy.org/tools/protparam.html, June 2008), (Gasteiger et al., 2005)). Protein 
concentration was also determined by the bicinchoninic acid (BCA) assay with bovine serum 
albumin standard (Brown et al., 1989). The BCA colour change relies on the reduction of 
copper. Therefore, any reducing agents will contribute to the colour change. FKBP12 and the 
protein standard were precipitated and re-suspended to remove possible interfering 
substances prior to the assay. 
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Figure 2-6 BCA assay calibration curves  
 (A) Net absorbance as a function of BSA concentration. (B) Absorbance of a serial dilution of an 
unknown concentration of FKBP12. All results are an average of 3 experiments, standard errors are 
shown. 
 
Figure 2-6 shows a typical BSA (Bovine serum albumin) calibration curve and absorption of 
a serial dilution of an unknown concentration of FKBP12. Measurement by absorption at 




2.3.3  ESI-MS and MALDI Mass Spectrometry 
The MALDI mass spectrum of FKBP12 was recorded on a Voyager DE-STR MALDI-TOF 
(Applied Biosystems) instrument using a sinapinic acid matrix (0.5 μl of 2 mg∙ml
-1
 FKBP12, 
0.5 μl of matrix) The ESI-MS analysis was performed as described in 3.6.1. 
 
The MALDI spectrum was dominated by a monomeric peak corresponding to 13286 a, 
Figure 2-7. There was an additional signal at 13469 Da, this formed less than 5 % of the total 
observed intensity. The mass of the dominant peak is consistent with that measured in  
ESI-MS (13282±4 Da. The calculated average mass of FKBP12 is 13349.1 Da and the 
monoisotopic mass 13340.7 Da (www.expasy.org/tools/protparam.html, June 2008), 
(Gasteiger et al., 2005)) The majority of the sample (> 95 %) is within 1 % of the calculated 
value. The difference between the calculated value and the experimental value is around  
80 Da. It has been suggested that post translational N-terminal deletions are a source of mass 
discrepancies in MS for recombinant proteins expressed in E.coli. However, the observed 
data is inconsistent with methionine deletion. Additionally, methionine aminopeptidase from 
E.coli does not usually show substrate specificity for sequences with arginine following 
methionine at the N-terminus (Frottin et al., 2006).  
The 13469.12 Da mass component (Δm = 183 Da) seen on the MALDI spectrum (B) was 
seen in ESI-MS for some protein batches, there was considerable variability between grow-
ups; it was always less than 5 % of the signal. The presence of the species in ESI-MS and 
MALDI spectra suggests that the increase in mass is not due to a sinapinic acid adduct (MW 
= 224 Da). The illustrated ESI-MS spectrum, (A), exhibits no clear peak above the envelope 
at this mass. We considered the possibility that this signal was due to plasticizer adducts. The 
phthalate esters plasticizers are commonly leached from plastic ware and were seen in ESI-
MS spectrum as MH
+
 ions. Low plasticizer laboratory ware or glass was used in all 
experiments. This hypothesis was tested by adding a cocktail of common plasticizers over 
the appropriate mass range. All flew well as MH
+
 ions but did not form adducts with 
FKBP12; the hypothesis was rejected. The increased mass would be consistent with 
glycation of lysine. Glycation is a non-enzymatic process in which lysines react with 
reducing sugars at the ε amino group, this is thought to be catalysed by lysine next to a lysine 
in the primary sequence of a protein (Johansen et al., 2006). The NetGlycate 1.0 Server 
(http://www.cbs.dtu.dk) predicts a score of 0.958 for K35 in FKBP12 (a number between -1 
and 1; when the score is above 0 the residue is a predicted glycation site). K34 is contiguous 




Figure 2-7 Mass spectra of FKBP12. 
 (A) The transformed ESI-MS spectrum of 12.5 μM FKBP12 in 10 mM ammonium acetate, 10 % 
methanol (v/v) at pH 6.8. The dominant signal was at 13281.±4 Da. The spectrum was background 
corrected, smoothed and transformed using MassLynx V4.1 (Waters). (B) The MALDI mass spectrum 
of FKBP12 recorded on a sinapinic acid matrix. The major monomeric peak corresponds to  
13286 Da with a small subsidiary signal at 13469 Da. 
 




ESI-MS provided a convenient method of checking both the purity of FKBP12 and the 
presence of denatured protein. Low molecular weight breakdown products have been 
observed on SDS-PAGE gels over 8 weeks storage at 0 
o
C. These were easily picked up on 
an ESI-MS spectrum.  
 
Globular proteins exhibit a narrow range of charge-states; 13+ to 7+ are characteristic of the 
six histidine tagged construct of FKBP12. Denatured protein exhibits a spectrum with a 
wider charge-state distribution with more highly charged ions indicative of basic residues 
exposed and available for protonation in the unfolded state. Figure 2-8 shows the effect of 
pH on the charge-state distribution of FKBP12. At pH 2.5, FKBP12 unfolds. 
 
cV32V sbt 80oC dt 100oC 10ul/min 12.5uM FKBP12 25mM ammonium acetate pH6.8
m/z
























Figure 2-8 Effect of pH on the charge-state distribution of FKBP12. 
 (A) Representative ESI-MS spectrum of 12.5 μM FKBP12 in 20 mM ammonium acetate, 10 % 
methanol (v/v) at pH 6.8. Inset is a schematic of FKBP12 at pH 6.8. (B) ESI-MS spectrum of 12.5 μM 
FKBP12 in 20 mM ammonium acetate, 10 % (v/v) methanol at pH 2.5. Inset is a schematic of 
FKBP12 at pH 2.5 showing loss of tertiary structure. Species are labelled with charge-state; for 
























































2.3.4 Protein characterisation by dynamic light scattering 
Dynamic light scattering (DLS) experiments were performed on dilute aqueous solutions of 
FKBP12 in 10 mM ammonium acetate, pH 6.8 and PBS at pH 7.5 to examine the quaternary 
structure and possible aggregation of FKBP12 in dilute solutions of common buffers 
(Horizon DLS, Viscotek). 
 
DLS is a useful indicator of the oligomeric state of a protein and the detection of aggregate 
species in solution. Molecular diffusion is function of particle size. The effective 
hydrodynamic radius of a protein species can be estimated from the intensity of fluctuations 
in laser light scattered by molecules undergoing Brownian motion in solution. Correlation 
between intensity fluctuations and diffusion rates for molecules of different sizes can be 
made because intensity fluctuations are not random. Intensity functions may be modelled and 
correlated with the observed intensities (Wyatt, 1993). The scattering intensity of a molecule 
is proportional to the cube of its molecular mass and the molecular radius to the sixth power. 
DLS is therefore a sensitive tool to pick up changes in molecular radius of the species 
scattering the light, and hence the oligomeric state of the protein. Large species such as 
protein aggregates or unwanted particulate matter are easily detected.  
 
Figure 2-9(A) shows an intensity distribution for an aqueous solution of FKBP12 in two 
common experimental buffers. The dominant species seen was a narrow peak centred 
between 2.4 and 2.6 nm hydrodynamic radii. The small peaks representative of larger 
particles are disproportionably abundant due to the non-linear relationship between 
scattering intensity and size (I α Radius
6
). When the data is presented as a mass distribution 
the radius of the dominant species are better represented as the mass contribution of the 
larger species are negligible, Figure 2-9(B). A radius of 2.5 nM is consistent with a monomer 
of FKBP12 at low concentration in ammonium acetate and phosphate buffers. These results 




Figure 2-9 Dynamic Light scattering analysis of dilute aqueous solutions of FKBP12 
A01 45 μM FKBP12, 50 mM ammonium acetate, pH 6.8; A02: 19μM FKBP12, PBS, pH 7.4, 1 mM 
DTT and 0.5 mM EDTA (A) Intensity distribution histogram, the x-axis shows hydrodynamic radius 
(nm) Inset shows a cartoon representation of FKBP with the molecular diameter labelled (PyMol 
V1.02, DeLano Scientific). (B) Mass distribution histogram, the x-axis shows hydrodynamic radius 
(nm). As the intensity of scattering from a particle is not directly proportional to size  
(Intensity α Radius
6
) large particles of aggregated protein appear disproportionately abundant when 
viewed as an intensity distribution (A). If the data is transformed to a mass distribution as in Figure 
2-9 (B) the distribution is a better representation of the relative proportions of the different species in 
solution. 
d = 4.97 nm 






Data suggests that the sample is 
predominantly a monomer in 
solution. This is consistent with 
gel-filtration results. 
v.small fraction of the 





2.3.5 Determination of protein activity 
The FKBP12 construct used in this study to produce recombinant protein has been shown 
have ≥ 90 % activity for rapamycin when compared to wild type protein (Wear et al., 
2007b).  
 
A Peptidyl-Prolyl Isomerase (PPIase) assay was carried out to determine the activity of 
batches of a purified FKBP12. The assay was performed as described in 6.3.1, following the 
method of Kofron et al. 1991.  
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3  Chapter 3 ESI-MS in drug discovery 
3.1 Introduction 
Electrospray ionisation mass spectrometry (ESI-MS) is an established tool for the study of 
non-covalent protein-ligand interactions in drug discovery (Hofstadler and Sannes-Lowery, 
2006). It is a soft ionisation technique with the capacity to retain both tertiary structure and 
intact complexes (Ganen et al., 1991; Loo, 1997). So called “direct detection methods” use 
syringe pump infusion of an analyte into the mass spectrometer and measure the relative 
abundance of different protein species. It is possible to obtain the mass of a ligand, the mass 
of the protein, binding stoichiometry and absolute equilibrium dissociation constants (Kd) for 
non-covalent interactions (Tjernberg et al., 2004).  
3.2 An experimental MS study of protein-ligand interactions 
This study aimed to answer a number of key questions in the study of protein-ligand 
interactions by ESI-MS. Two questions are addressed in this chapter:  
 
- What are the optimum conditions for observing protein-ligand interaction in MS for 
FKBP12? 
 
- How do rank orders of affinity and Kd compare with data from experiments carried 
out in solution?  
 
The binding of FKBP12 to FK506 and rapamycin were early examples of ESI-MS being 
used to examine a protein-ligand complex (Ganen et al., 1991). The high molecular weight 
(>800 Da), natural product immunosuppressants FK506 (0.4 nM) and rapamycin (0.2 nM) 
have high affinity for FKBP12 (Bierer et al., 1990). The non-covalent interaction profiles for 
FK506 and rapamycin are complex and include multiple hydrogen bonds and hydrophobic 
contacts (Van Duyne et al., 1993). These ligands are therefore not particularly representative 
of the lower molecular weight compounds that are commonly selected at the early stage of 
the drug discovery process. It is thought that ESI-MS preferentially preserves complexes 
with a predominance of electrostatic interactions. It has been suggested that the influence of 
the hydrophobicity is less important in the gas phase due to the significant role for solvent 
(Robinson et al., 1996; Daniel et al., 2002). These observations are perhaps at odds with 
both the potential importance of hydrophobicity in contributing to a favourable Gibbs free 
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energy of binding between a target and potential drug. The active site of FKBP12 consists of 
a shallow hydrophobic pocket; it is therefore desirable to be able to detect relatively low 
affinity ligands where hydrophobic effects form a significant contribution to binding. In the 
context of screening collections of compounds against FKBP12, it is important to understand 
how ratios of complexed versus uncomplexed protein in the gas phase, compare with those 
in the solution for ligands with a range of affinity, hydrophobicity and mass. The 
applicability of the technique for diverse protein targets and the correlation of ESI-MS Kd 
with data derived from ITC or biochemical studies are still under much debate.  















































































Figure 3-1 Schematic diagram of ion production during electrospray ionisation. 
Charged drops are formed at the capillary tip and accelerate in an electric field. Drops are desolvated 
with the aid of a heated desolvation gas (N2) and undergo repeated fission until a charged 
macromolecular ion formed. 
 
In direct infusion ESI-MS run in the positive ion mode, the analyte is injected into a stainless 
steel capillary by means of a syringe pump. Basic residues on the surface of the globular 
protein become charged through reaction with NH
4+
 ions present in the analyte solution 
(Peschke et al., 2002). In this study of FKBP12, ESI-MS was carried out at pH 6.8; at this 
pH the protein retains its folded conformation. Solution pH is a compromise between residue 
ionisation and maintaining the protein in the higher order structure. Denatured protein (pH 
2.5) flies very well but is only useful in the accurate determination of protein mass. It is 
obviously desirable to test ligands at a physiologically relevant pH. The theoretical pI of 
FKBP12 is estimated to be 8.79 by the ExPASy ProtParam server 
(www.expasy.org/tools/protparam.html, June 2008, (Gasteiger et al., 2005)). 
 
Under the action of a strong electric field in the region of the capillary, cations in solution 
experience a force and undergo electrophoretic movement in the direction of the grounded 
plate (Figure 3-1). Surface tension counteracts the force experienced by the ions and a Taylor 
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cone of analyte, rich in positively charged ions, is formed at the capillary tip. Positively 
charged droplets break away from the Taylor cone and accelerate towards the plate. 
Evaporation of solvent from the charged drops is aided by collisions with a sheath of heated 
N2 gas, the desolvation gas, Figure 3-2. 
 
The explanation for the formation of desolvated protein ions has been much debated. The 
consensus is the charge residue model (CRM) better explains the production of 
macromolecules in electrospray and the ion evaporation model (IEM) best describes the 
production of small ions (Fernandez de la Mora, 2000). The CRM proposes that drops 
contract by the evaporation of solvent until they reach their Rayleigh stability limit 
(Rayleigh, 1882) and undergo Coulombic fission (Dole et al., 1968). Repeated fission leads 
to droplets containing a single analyte molecule. The analyte molecules retain the droplet 
charge and become gas phase ions that subsequently enter the mass analyzer. The IEM 
model (Iribarne and Thomson, 1976) proposes that single solvated analyte ions are desorbed 





capillary voltage = 3.3KV
cone voltage = 30V
back plate
Ion block








Figure 3-2 Schematic diagram Micromass ZMD under standard operating conditions. 
In the Micromass ZMD spectrometer ions of the appropriate mass to charge range are taken through a 
“Z-bend” to the single quadrupole mass analyzer by a series of orthogonal electric fields. The diagram 
represents the stepped pressure reduction in the system by intensity of blue background. Un-
desolvated charged drops do not enter the mass analyzer and hit the back plate.  
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3.4 The ESI-MS spectrum 
A distinguishing feature of ESI-MS is that a single point experiment provides an electrospray 
spectrum with multiple signals. Each signal envelope results from a related population within 
the sample (Figure 3-3). The electrospray spectra of a protein, from a solution under 
conditions that retain tertiary structure, exhibit a characteristic series of multiply charged 
positive ions. The charge on the ion is referred to as the charge-state of the protein. Each 
charge-state represents a population with a defined mass to charge ratio. A charge-state 
spectrum with a narrow range of charge-states is indicative of the protein retaining its folded 
conformation (Peschke et al., 2004b). When proteins are folded only basic residues on the 
surface of a globular protein are exposed for protonation.  
 
In the analysis of small molecules by mass spectrometry, the deliberate fragmentation of a 
molecule often aids structural elucidation. The consideration of the instrument induced 
dissociation of a complex and the understanding that can be gained from that, if any, is a 
central theme that links many of the experiments in this study. The main instrument 
parameters that influence the dissociation of a protein-ligand complex are as follows: 
 
- Source block temperature 
- Desolvation gas temperature 
- Capillary voltage 
- Cone voltage 
 
Results for optimising retention of the protein-ligand complex are presented in the following 




Figure 3-3 ESI-MS spectrum for FKBP12 and FKBP12 in complex with the 
immunosuppressant FK506. 
 (A) The electrospray spectrum of uncomplexed FKBP12. 10 μM FKBP12 in 10 mM ammonium 
acetate, 10 % methanol (v/v) at pH 6.8 recorded between 1000 - 2500 m/z. The charge-states 12+ to 
7+ are labelled P12+ to P7+, the 8+ charge-state dominates the spectrum. (B) The electrospray 
spectrum showing the majority of the protein in complex with FK506. 10 μM FKBP12, 7 μM FK506 
in 10 mM ammonium acetate, 10 % methanol at pH 6.8 recorded between 1000 - 2500 m/z. The 8+ 
and 7+ charge-states for FKBP12 are labelled P8 + to P7+; the 8+ and 7+ charge-states for the 
FKBP12-FK506 complex are labelled PL8+ and PL7+. Spectra were an average of 20 scans and have 
been background corrected and smoothed using a Savisky-Golay smoothing algorithm as part of 
















3.5  Influence of instrument parameters on preservation of complex 
3.5.1 Default instrument parameters 
Parameter optimisation in ESI-MS is an iterative process (Figure 3-4). This is mainly 
because the conditions required to preserve the complex are mutually exclusive with a good 
signal to noise ratio. The specific influence of each instrument parameter is dealt with 
separately in the following sections, although the parameter set should be considered as a 
whole.  
 
          
Figure 3-4 Parameter optimisation. 
Parameter optimisation is an iterative process. 
 
Electrospray mass spectrometry was carried out on three single quadrupole instruments, all 
employed atmospheric electrospray ionisation. Two were Z-spray devices; the Micromass 
ZMD and ZQ (Waters) and the third an ion-trap; the LCQ
TM
DECA (ThermoQuest). FKBP12 
was prepared and characterised as described in Chapter 2 and exchanged into 10-20 mM 
ammonium acetate, pH 6.8 at concentrations between 5 μM - 20 μM using pre-packed PD-10 
rapid desalt columns (GE Healthcare). 10 % methanol (v/v) (HPLC grade, BDH) was added 
and thoroughly mixed by pipette prior to direct infusion. Methanol aided the desolvation 
process. Protein was denatured, by the addition of 2 % formic acid (v/v) to obtain a pH close 
to 2.5, and flown under the same conditions. All reagents were of the highest grade available. 
 






Standard operating conditions for ligand binding studies using the Micromass ZMD 




analyte flow rate 15 μl∙min
-1
; 
capillary voltage 3.3 KV; cone voltage 15 – 30 V; source block temperature 80 
o
C and 
desolvation gas temperature 100 
o
C. Spectra were acquired over at least 20 scans (5s per 
scan), averaged, background corrected and smoothed using the Mass Lynx MS software 
package, V4.1 (Waters). Conditions for the Micromass ZQ were very similar to those of the 
ZMD (analyte flow rate 10 μl∙min
-1
). The flow rates in the Z-spray devices are influenced by 
instrument dimensions and geometry. 
  
 
Standard operating conditions for the LCQ
TM
DECA were as follows: nitrogen flow rate  
100 units, analyte flow rate 6 μl∙min
-1
, capillary voltage 3.5 KV, cone voltage 25 V and 
capillary temperature 50 
o
C. Spectrum were averaged over 300 scans (2s per scan) and 
processed using the Bioworks Browser V 3.0 software package (ThermoScientific). 
 
Any changes to the standard operating conditions are detailed in the text. 
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3.5.2 Effect of source block temperature on the fraction of complex 
preserved in ESI-MS 
The van’t Hoff equation (equation 3) describes how the ligand Kd shows a dependence on 
temperature (Chaires, 1997). It would therefore seem desirable to perform electrospray 
screening experiments close to a physiologically relevant temperature. However, this is was 
not possible for the instruments employed in this study. Signal strength in electrospray is a 
function of temperature. ESI-MS analysis of small organic molecules is routinely carried out 
above 140 
o
C to increase the signal to noise ratio and give good desolvation. These 
temperatures are obviously incompatible with preserving the integrity of the protein. In 
addition, measuring absolute temperatures in electrospray is difficult. The source block, 
containing the electrospray capillary, is held at a user defined temperature. However, the 
analyte does not necessarily reach the source block temperature during rapid capillary transit. 
In addition evaporation of the solvent from charged drops reduces analyte temperature. The 
internal energy distribution of the analyte molecules is strongly influenced by the expansion 
of the ions entering the first low pressure sector of the instrument. The pressure differential 
between the spray region and the mass analyzer sector of the instrument causes a supersonic 
expansion that has the effect of reducing molecular internal energy (Gabelica and De, 2005). 
This “cooling” effect is opposed by the acceleration of the ions in the medium pressure 
sectors of the instrument and is a function of the cone voltage. The final temperature at the 
end of desolvation is almost certainly lower than the measured source block temperature. 
Van’t Hoff analysis using source block temperature as a measure of T did not give 
meaningful results for known protein-ligand systems (data not shown).  
 
It can be seen in Figure 3-5 (A and B) that the fraction of protein seen in complex with 
ligand reduced as source block temperature increased. The intensity signals corresponding to 
FKBP12 in complex with FK506 (PL) and uncomplexed FKBP12 (P) were seen to diverge 
above 90 
o
C. Source block temperature was set at a default value of 80 
o
C; this was felt to be 
the lowest temperature at which signal to noise ratio was acceptable. Ammonium ions have a 
low energy of dissociation; temperatures above 25 
o
C should be sufficient for thermal 
dissociation (Peschke et al., 2004a). 
 
The relatively high capillary temperature of the Micromass ZMD and ZQ (Waters) 
electrospray source was probably a limiting factor in detecting low affinity ligands. 
Experiments carried out on the LCQ
TM
DECA (ThermoQuest) allowed lower capillary 
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temperatures to be used (50-70 
o
C). This instrument had the additional disadvantage of slow 
acquisition times due to the increased noise in the electrospray spectrum. The increased 
noise is in part due to the direct path from capillary to ion-trap; solvated macromolecular 
ions and buffer ions directly enter the mass measuring sector of the instrument due to the 
absence of the “Z-bend” (ZMD and ZQ instruments). Cone voltage induced dissociation was 
less straightforward on this instrument (described in section 3.5.4). Increasing cone voltage 
increased all species, not just the species of interest, leading to both signal to noise problems 
and collision induced dissociation (data not presented). These factors outweighed the slightly 
lower capillary temperatures possible on this instrument. 
3.5.3 Effect of desolvation gas temperature on the fraction of complex 
preserved in ESI-MS 
Increasing the desolvation gas temperature between 40 
o
C and 120 
o
C had little effect on the 
proportion of FKBP12 seen in complex with the ligands tested, Figure 3-5 (C and D). 
However, it did affect the degree of desolvation of the protein. This has implications for 
measurement of the protein and complexed species during screening experiments. ESI-MS 
spectra from an analyte that had undergone good desolvation showed charge-state envelopes 
with a small adduct tail. The adduct tail is the result of incomplete dissociation of non-
specifically bound low molecular weight species such as water. This means that the 
maximum peak intensity for a charge-state envelope can be used to calculate the fractional 
contribution of the species. Good desolvation leads to little overlap between the adduct tail 
of the uncomplexed protein envelope and the peak corresponding to a protein-ligand 
complex. Minimising overlap removes the need for mathematical deconvolution. An analysis 
of the influence of desolvation on the estimation of Kd was carried out on the LCQ
TM
DECA 
(ThermoQuest) and is described in section 5.7. The desolvation gas temperature was set at a 
default value of 100 
o
C on the Micromass ZMD and ZQ (Waters). The desolvation gas 




 It is also worth considering how possible changes to the hydration of a protein affect its 
structure. It is not possible to determine structure directly in ESI-MS; however investigation 
of non-covalent interactions by this method makes the assumption that there are no radical 
changes to structure on desolvation. Computational simulations of desolvation suggest that 
the RMSD of a desolvated structure compared to a reference structure increases with 
increasing desolvation (Patriksson et al., 2007). It would seem reasonable not to over 
 59 





























































































































Source block temperature (
o
C)
8+  charge state protein (P)












































 Desolvation gas temperature (
o
C)
8+  charge state protein (P)




Figure 3-5 Fraction of protein complex preserved in electrospray is a function of source block 
temperature.  
(A) Shows the fraction of a FKBP12-FK506 complex preserved as a function of source block 
temperature. Increasing capillary temperature above 90 
o
C lead to a rapid decrease in the proportion of 
complexed protein seen in the electrospray spectrum. (B) Shows the absolute signal intensities for 
uncomplexed FKBP12 and FKBP12 in complex with FK506 as a function of source block 
temperature. (C) Desolvation gas temperature had little effect on the fraction of complex observed 
between 40 and 110 
o
C. (D) Shows the absolute signal intensities for uncomplexed FKBP12 and 
FKBP12 in complex with FK506 as a function of desolvation gas temperature.  5.5 μM FKBP12,  
2 μM FK506 in 10 mM ammonium acetate, 10 % methanol (v/v) at pH 6.8. Data is an average of 20 




3.5.4 Effect of cone voltage on fraction of complex preserved in ESI-MS 
Electrospray uses a source at atmospheric pressure; pressure is therefore reduced in stages as 
ions are drawn through the instrument to the mass analyzer. Ions pass from one region to 
another through a series of orifices or cones. The cone in an ESI-MS instrument can be set at 
a user defined potential to control the flow of ions through the instrument. Setting the cone 
voltage to an appropriate value is a very important part of parameter optimisation. The 
proportion of the protein seen to fly in complex with ligand is strongly correlated with cone 
voltage, Figure 3-6. Raising the cone voltage increases the speed of the macromolecular 
ions. An increase in speed increases the frequency and energy of molecular collisions and 
can result in dissociation of non-covalently bound complexes (Touboul et al., 2008b). 
Deliberate dissociation by this method has been referred to as pseudo MS/MS (Yin et al., 
2008). The fraction of the protein that dissociates at a given cone voltage is a function of the 
affinity of the ligand and the nature of the molecular interactions (Rogniaux et al., 1999) 
 
Preserving non-covalent complexes of FKBP12 and the immunosuppressants FK506 and 
rapamycin in ESI-MS was relatively straightforward at low cone voltages. However, the 
signal corresponding to the FKBP12-FK506 complex rapidly diminished above 35 V, the 
signal for un-complexed FKBP12 increased. Section 4.3 discusses differences in cone 
voltages dissociation profiles for a range of ligands of FKBP12. Profiles are discussed in the 
context of the character of the non-covalent interactions between protein and ligand.  
 
It is interesting to note that signal for the charge-state envelope at 10 V was more heavily 
adducted than charge-state envelopes seen at higher voltages. Figure 3-6 illustrates the 
reduction in the charge-state adduct tail as voltage increased and is consistent with higher 
cone voltages giving a cleaner signal with fewer non-specifically bound species. The 
variability in non-specifically bound adducts is investigated in section 5.7. The default value 
for cone voltage was set to 15 V for the Micromass ZMD and ZQ (Waters) and 25 V for the 
LCQ
TM
DECA (ThermoQuest). This formed a starting point that was adjusted in individual 
experiments (values are detailed in the text). 
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Figure 3-6 Fraction of non-covalently ligand bound to protein is a function of cone voltage. 
Cone voltage had a significant influence on the fraction of complex preserved in electrospray. High 
cone voltage caused collision induced dissociation of the complex. (A) Raw spectra acquired between 
10 and 60 V, data normalized for the largest peak in the spectrum. The pink highlight corresponds to 
FKBP12 flying in complex with FK506. The free protein signal is annotated with a blue star and the 
complex with a blue star and pink diamond. (B) The concentration of complex seen as a function of 
cone voltage calculated from peak intensities of the 8+ charge pair (section 3.6.3). 5.5 μM FKBP12, 
5.5 μM FK506 in 10 mM ammonium acetate, 10 % methanol (v/v) at pH 6.8. Data is an average of 20 
scans acquired on a Micromass ZMD instrument (Waters). 
 
FKBP12  
FKBP12 in complex with FK506 
(A) 
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3.5.5 The influence of protein-ligand ratio on estimated affinity 
The experiment to induce dissociation of the FKBP12-FK506 complex was repeated at two 
different ratios of protein to ligand. One at a 1.1 ratio of protein (FKBP12) to ligand (FK506) 
and another at 5:2 protein to ligand. The inverse relationship between the concentrations of 
complex (FKBP12-FK506) observed in ESI-MS and cone voltage is similar (inset diagram, 
Figure 3-7). The complex is very sensitive to cone voltage above 35 V for both analyte 
ratios. At a cone voltage of 60 V almost no complex is observed. The ratio of concentrations 
of complex observed in the two different analytes was used as a metric to compare cone 
voltage induced dissociation at different protein ligand ratios and given the symbol W. 
 
W= [PL]1:1 ratio/ [PL]5:2 ratio  
 
W was plotted in Figure 3-7 as a function of cone voltage (red line in Figure 3-7). The law of 
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Figure 3-7 Does the analyte ratio influence complex dissociation in electrospray? 
The black dashed line shows the theoretical solution phase ratio (W = 2.3) of FKBP12-FK506 
complex for 1:1 and 5:2 ratios of protein to ligand in solution as calculated by the law of mass action. 
The experimental W is shown as red points. Inset diagram shows the concentration of complex as a 
function of cone voltage for the two protein ligand ratios. 5.5 μM FKBP12, 5.5 and 2 μM FK506 in 10 





C, cone voltage 10  to 50 V. Data is an average of 20 scans acquired on a Micromass 












































The actual ratio of complex measured in ESI-MS was compared to the theoretical solution 
phase ratio for each cone voltage calculated from the law of mass action (equation 1). The 
ESI-MS ratio was found to be very close to theoretical values for low voltage but diverged as 
cone voltage increased. This suggested that the electrospray ion intensities of P and PL are a 
better approximation to concentrations in solution if cone voltage is kept low. It is possible 
to rationalize these results in terms of the momentum of a given species and collision 
probability. More massive PL ions would have a lower mean speed (both in respect to their 
acceleration under the action of an electric field and the Maxwell-Boltzmann distribution). 
However, the PL ion would also have the larger collisional cross-sectional area and a slightly 
increased momentum. Do ions have a higher probability of dissociation if PL collides with 
PL rather than P hitting PL?  
3.5.6 Conclusions 
The six-histidine construct of FKBP12 flew well on the instruments tested and gave a narrow 
charge-state distribution dominated by the 8+ charge-state. The earliest ESI-MS studies on 
FKBP12, using His-tag free protein, found the charge-state distribution to be dominated by 
the 7+ charge-state (Ganen et al., 1991). The difference in this study is likely to be due to the 
extra arginine present in the linker between the His-tag and native sequence, Figure 2-1 
(Wear et al., 2007b). A protein concentration between 5 and 10 μM was required to give a 
good signal to noise ratio; this was instrument dependent.  
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3.6 Estimating Kd from a titration experiment 
3.6.1 Materials and Methods 
For titration experiments, ligand was added at concentrations between 0.5 μM and 2 mM 
from stock solutions dissolved in the methanol fraction, no additional solvents were used. 
Ligands were stored at -80 
o
C in methanol, at concentrations between 25 mM and 100 mM 
(dependent on ligand solubility). The only exception to this rule were the experiments on hen 
egg white lysozyme (HEWL) where the addition of methanol was found to give a protein 
spectrum with poor desolvation. In the series of experiments with N, N’, N’’-
Triacetylglucosamine (NAG3) the ligand was dissolved in deionised water. NAG3 was 
found to have very low solubility in methanol. Analyte solutions were carefully mixed by 
pipette and allowed to incubate at room temperature for at least 10 minutes. 
 
The PL/P intensity ratio (R) was measured for the 8+ charge-state pair and Kd determined by 
the least squares fit of the data to equation 12 using the non-linear regression program 
KaleidaGraph version 4.03 (Synergy Software) as described in 3.6.3. 
3.6.2 Estimating ligand affinity by the titration method 
The calculation of the equilibrium dissociation constant from the relative signal intensities 
corresponding to complexed (PL) and uncomplexed protein (P) in a titration experiment is 
dependent on several assumptions. The principal assumption is that the ratio of ion 
intensities of PL (IPL) and P (IP) are proportional to those in solution. In addition, it is 
assumed that equilibrium relaxation times are long compared to solvent evaporation time. If 
the analyte concentration increases as solvent evaporates and the equilibrium shifted towards 
PL it is possible that the affinity of a ligand may be over estimated. The opposing effect of 
collision induced dissociation of weak non-covalent complexes would result in the affinity of 
the ligand being underestimated. A third assumption is that very weak non-specific 
interactions are not retained in the final desolvation step. This study found that complete 
desolvation is incompatible with conditions necessary to preserve non-covalent interactions 
between protein and ligand. Mass spectra peak envelopes inevitably show adduct tails under 
ligand screening conditions. Peschke et al. (2004a) examined the above assumptions in the 
context of the charge residue model. The researchers concluded that deviations from the 
above assumptions increase as the ligand approaches the mass of the protein. The ligands of 
FKBP12 examined in this study are all < 10 % of the protein mass.  
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3.6.3 Calculating ligand mass and the equilibrium dissociation constant  
Figure 3-3 (A) shows the spectra for a sample of FKBP12 and Figure 3-3 (B) a similar 
spectrum after the addition of the high affinity ligand FK506. The spectrum shown in Figure 
3-3 (B) can be viewed as two distinct charge-state distributions; one for the free protein and 
one for the protein in complex with FK506 (see peak annotation). For a charge-state of a 
given magnitude there are two peak envelopes. One represents the free protein and one the 
ligand in complex with the protein; this is referred to as a charge-state pair. Figure 3-8 
illustrates the 8+ charge-state pair for FKBP12 and the FKBP12-FK506 complex. When 
viewing the full m/z range, spectrum for the complex can be thought of as a separate charge-
state distribution (in addition to that of the free protein) transposed towards a larger m/z. It is 
possible to calculate the mass of a ligand bound to protein from any charge-state pair. For 
example, the mass of FK506 may be calculated from equation 4 using the 8+ charge pair. 
 
PL8 P8
FK506m 8((m / z) (m / z) )    Equation 4 
 
Where: mFK506 is the mass of FK506, (m/z)
PL8+ 
the mass to charge ratio of the FKBP12-
FK506 complex and (m/z)
P8+
















Figure 3-8 ESI-MS spectrum for the 8+ charge-state pair of FKBP12 free (P) and in complex 
with the immunosuppressant FK506 (PL). 
10 μM FKBP12, 7 μM FK506 in 10 mM ammonium acetate, pH 6.8; 10 % methanol recorded 
between 1000 - 2500 m/z. Spectra were averaged over 20 scans, background corrected then smoothed 




















The relative affinity of ligand for a protein may be estimated from the ratio, R, of signal 
intensity for complexed (IPL) and uncomplexed protein (IP) in a charge-state pair. The 
equilibrium dissociation constant, Kd, can be calculated using a model based on the law of 
mass action (equation 1, section 1.8). The method used in this study was based on that of 
Tjernberg et al. (2004). 
 
For the purpose of the calculation, the assumption made was that ratio of species in the gas 







    Equation 5 
Where: R is the ratio of intensity of complexed to un-complexed protein in the gas phase 
measured by ESI-MS; [PL](aq) is the concentration of complex and [P](aq) is the concentration 
of free protein in solution at equilibrium.  
 
The equilibrium between free protein and protein in complex with ligand is represented by 
equation 6. Square brackets have been omitted to aid clarity. 
 
P L PL         Equation 6 
 
Where: P is the concentration of the free protein, L the concentration of the free ligand, PL 
the concentration of the protein-ligand complex. 
 
It is known that the sum of concentrations of free protein, P and complexed protein, PL is 
equal to the total protein concentration, Pt; represented in equation 7. Equation 8 represents 
the similar relationship for the ligand. Where: Lt is the total concentration of the ligand. 
 
tP P PL      Equation 7 
 
tL L PL      Equation 8 
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                   Equation 9 
 
Equation 9 allows one to calculate PL for each point in the titration by measuring IPL and IP 
in ESI-MS and calculating R using equation 5 (each titration point employs a different Lt  
and Pt is fixed). The law of mass action is represented in equation 1 (section 1.8) Where: Kd 
















   Equation 10 
Expanding equation 10: 
 
2
d t t t tK PL P L P PL L PL PL  
 
Rearranging equation 10 to give a quadratic leads to equation 11. 
 
2
t t d t tPL (P L K )PL P L 0   Equation 11 
 




t t d t t d t t(P L K ) (P L K ) 4P L
PL
2
  Equation 12 
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The equilibrium dissociation constant, Kd, can be calculated by the best fit of ESI-MS 
titration data to equation 12 using a non-linear regression program. 
 
It is of course possible to determine the mass of many of the different species in solution if 
they charge positively during electrospray. The dominant species in the spectrum is often the 
[L + H]
+
 ion where L is the ligand. The intensity of this peak is dependent on the gas phase 
basicity of the ligand, the fraction of the total ligand in complex with the protein in solution 
and the degree of dissociation of the complex during electrospray. The sodium adduct of the 
ligand, [L + Na]
+
 is also often seen. Sodium ions are largely removed from protein solutions 
by desalting columns. However, there can be sodium ions associated with the ligand. 
3.6.4 Correlation of affinity measured by ESI-MS titration and in solution 
Kd values were estimated for the nanomolar affinity ligands of FKBP12 (rapamycin and 
FK506) and compared to those determined in the solution, Figure 3-9. The PL/P intensity 
ratio (R) was measured for the 8+ charge-state pair (the dominant protein charge-state) over 
a range of concentrations of inhibitor while fixing the concentration of protein. Kd was 
determined by fitting equation 12 to the data using the non-linear regression program 
KaleidaGraph (version 4.03, Synergy Software). The Kd apparent for rapamycin in complex 
with FKBP12 was very close to literature values. The Kd apparent for FK506 was 
underestimated by a factor of around 10. Figure 3-6 shows that at the experimental cone 
voltage necessary for a very good signal to noise ratio (30V) there was measurable collision 
induced dissociation; this is consistent with an underestimation of Kd apparent for FK506. 
The crystallographic evidence suggests that FK506 makes one fewer hydrogen bond with 
FKBP12 than rapamycin (2DG3.pdb, 1FKJ.pdb; described in Table 4-3). The extra hydrogen 
bond may account for the greater robustness of the FKBP12-rapamycin complex. 
 
It is important to note that biophysical and biochemical affinity is not reported at a standard 
temperature in the literature. Temperature correction is possible when full thermodynamic 
data is available. However as previously discussed, accurate temperature measurements were 
difficult for the ESI-MS instruments used in this study.  
 
The physical processes that govern the validity of the assumptions regularly employed in 
ESI-MS titration studies are complex; they are protein, ligand and instrument dependent. 
This is due to differences in temperature, spray drop size, desolvation time/efficiency and the 
nature of the non-covalent interactions between binding partners (Benkestock et al., 2004). It 
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was therefore important to establish the sensitivity of a given instrument using a test set of 















































































a (Bierer et al., 1990), b (Wear and Walkinshaw, 2007), c (Wear et al., 2007b), d (Connelly and Thomson, 1992) 
 
Figure 3-9 Measuring Kd by ESI-MS titration. 
Typical experimental data from titration experiments with high affinity ligands. (A) 5 μM FKBP12,  
0 to 40 μM rapamycin. (B) 5 μM FKBP12, 0 to 20 μM FK506. Analytes were dissolved in 10 mM 
ammonium acetate, pH 6.8: 10 % methanol (v/v). (C) A comparison of Kd from the literature with 
those measured by ESI-MS. Data is an average of 20 scans acquired on a Micromass ZMD instrument 
(Waters) under standard operating parameters (cone voltage 30 V). The solid lines are least squares fit 
to equation 12 using KaleidaGraph version 4.03 (Synergy Software). 
Kd (nM) Ligand Radio ligand 
displacement 




 (25  oC) 
PPIase 





FKBP12 rapamycin 0.2a 1.67 ± 0.16b 7.8 ± 3.7c 1d 0.18 ± 6.4 
FKBP12 FK506 0.4   0.5 d 59.6 ± 15.6 
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3.7 Screening the inhibitor test set  
3.7.1 Compound selection 
One of the principal aims of this project was to explore medium throughput biophysical 
screening strategies for testing hits from virtual screening programs. To this end, it was 
necessary to compile a test set of compounds. Molecules were selected considering mass, 
structural diversity and affinity for FKBP12. 
 
The inhibitor test set was used to examine the relative sensitivity of the ESI-MS instruments 
used in this study and to investigate the fraction of protein seen in complex in the gas phase 
compared to that seen in solution for a diverse series of ligands. All ligands have been 
reported to bind specifically to the active site of FKBP12 (Bierer et al., 1990; Stebbins et al., 
2007; Wear et al., 2007b). Early versions of the test set included compounds that were 
insufficiently soluble or active to be useful; these were removed. The final version is shown 
in Table 3-2 Ligand test set.. The ligands were detected as [L + H]
+ 
ions and as the major 
ionisable species under non-fragmenting conditions (positive ion mode, where L is the 
screening compound). Compounds SD1 to SD12 were selected from a high-throughput 
NMR screen of small molecules against FKBP12 performed by the San Diego Centre for 
Chemical Genomics. Affinity data was retrieved from the PubChem BioAssay database 
(SDCCG-A014-FKBP12-NMR, http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=608, 
September 2008,  (Stebbins et al., 2007). The data set is referred to as the San Diego data set 
in this thesis. Test set compounds were selected by choosing the most active purchasable 
member of a chemically similar cluster. Compounds were soluble to at least 25 mM in 




Affinity Mass No. of rings No. of hydrogen 
 bond donors  
No. of hydrogen 
bond acceptors 
MlogP 
0.2 nM - 686 μM 201 –  914 Da 2 - 3 0 - 4 3 - 14 0.44  –  2.05 
 
Table 3-1 Physicochemical descriptor ranges for the ligand test set. 
Affinity data from the literature (Bierer et al., 1990; Stebbins et al., 2007). Descriptors were 
calculated using the program Accord for Excel V6.1 (Accelrys Software Inc.). Note: the maximum 








rapamycin 0.0002 914.2 
 
(Bierer et al., 1990; Wear and 
Walkinshaw, 2007; Wear et al., 
2007b) 
FK506 0.0004 804.0 
 
(Bierer et al., 1990) 
SD1 9 
(6.8) * 
251.1  (Stebbins et al., 2007) 
SD12 56 201.0  (Stebbins et al., 2007) 
SD2 95 283.1  (Stebbins et al., 2007) 
SD3 157 259.1  (Stebbins et al., 2007) 
SD4 221 278.1  
 
(Stebbins et al., 2007) 
 
Table 3-2 Ligand test set. 
Structure, mass and affinity data for the FKBP12 test set. Ligands were selected for specificity to the 
active site of FKBP12, range of affinity and solubility in aqueous buffer. * Determined in this study 

































SD5 270 278.1  (Stebbins et al., 2007) 
SD6 277 288.1  
 
(Stebbins et al., 2007) 
SD7 286 209.1  (Stebbins et al., 2007) 
SD8 385 266.1  (Stebbins et al., 2007) 
SD9 435 249.1  (Stebbins et al., 2007) 
SD10 440 233.1  (Stebbins et al., 2007) 
SD11 686 282.1  (Stebbins et al., 2007) 
 
Table 3-3 Ligand test set (continued) 
Structure, mass and affinity data for the FKBP12 test set. Ligands were selected for specificity to the 


































3.7.2 The protein: ligand screening ratio 
We were interested in the suitability of ESI-MS for estimating the affinity of a ligand and 
creating a rank order of affinity. Some consideration was given to the ratio of protein to 
ligand most appropriate for an experiment at a single ligand concentration. To minimise 
uncertainties in the data it was desirable to measure IPL and IP when both signals had a good 
signal to noise ratio. Protein charge-state envelopes, under standard operating parameters, 
showed small adduct tails. We determined that an IPL/IP ratio, R ≥ 0.1 provided a reasonable 
degree of certainty that the species was due to the protein ligand complex and not a random 
adduct. The m/z of a species is obviously important in deciding whether a peak corresponds 
to a protein complex or a non-specific adduct/noise. The MassLynx software was set up to 
label ion series. A screening ratio of 1:10 was selected; a protein concentration of 10 μM and 
ligand of 100 μM. This ratio was chosen as a compromise between detecting low affinity 
ligands and reducing the possibility of non-specific interactions (Sun et al., 2007). Careful 
examination of the law of mass action (equation 1, section1.8) shows that at this ratio, a 
ligand with a Kd of 500 μM (single site) would result in 16.4 % of the protein being in 
complex with the ligand in solution (R ~ 0.2). Many screening compounds were not very 
soluble in the analyte solution, it was important to select a screening concentration at which 
the ligand dissolved.  
3.7.3 Suppression of the protein signal 
An additional consideration was the charging of screening compounds during electrospray, 
these frequently appeared as both [L + H]
+ 
and [L + Na]
+ 
 ions in the spectrum. High 
concentrations of easily ionisable ligands dominated the ion current, suppressing the protein 
signal and leading to a very poor signal to noise ratio for the protein. This effect was 
particularly evident with the addition of DMSO to analyte solutions. A 1 % solution of 
DMSO is equivalent to a 141 mM solution. DMSO is routinely excluded from MS analytes 
or chromatographically separated prior to analysis. This study found a concentration of  
0.25 % (35 mM) to be the maximum working value. It was also important to remember that 
DMSO had been shown to bind to FKBP12 with a Kd of  20 mM (Burkhard et al., 2000). 
Thus adding DMSO to any screening experiment with FKBP12 leads to competition for the 
active site (this is discussed further in section 6.2).  
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3.7.4 Rank orders of affinity from ESI- MS 
The desolvation or “cleaning-up” process is designed to remove the majority of water and 
buffer components non-specifically bound to the protein. However as discussed in 3.5.4, 
over-zealous desolvation greatly reduced the sensitivity for weak non-covalent interactions. 
Various cone voltages were tested for each instrument and are detailed in the text. 
 
 
Table 3-4 Summary ESI-MS results for ligand test set. 
Standard instrument parameters, cone voltage 15 V. Data in italics employed a screening ratio of  
9.5 μM FKBP12, 10 μM rapamycin/FK506. Standard typeface: 10 μM FKBP12, 100 μM SD1, SD2, 
SD3, SD4, SD5. Analytes were dissolved in 20 mM ammonium acetate, pH 6.8; 10 % methanol (v/v). 




 indicates a Kd measured in this study by ITC and 
PPIase respectively, section 6.3.1. Other values are quoted from the literature; see Table 3-2. 
 
The nanomolar affinity ligands rapamycin and FK506 were seen to fly in complex with 
protein at well below standard screening ratios on all instruments (Figure 3-9). However, 
they were relatively insoluble in the analyte (10 μM FKBP12; 10 mM ammonium acetate,  
pH 6.8; 10 % methanol (v/v). Rapamycin and FK506 were soluble to 10 fold higher 
concentration when methanol was included compared to a similar solution excluding 
methanol. Rapamycin, FK506, SD1, SD2 and SD3 were seen in complex with FKBP12 on 
the LCQ
TM
DECA (cone voltage of 25 V) and the ZQ instruments (cone voltage 15 V). 
Figure 3-10 shows typical spectra for these ligands, blue diamonds mark ions corresponding 
to FKBP12 in complex with ligand. Results are summarized in Table 3-4. Rank orders were 





(calc. from Kd) 
Micromass ZQ 




Rank (cone=15 V) 
LCQTMDECA 
Rank (cone=25 V) 
rapamycin 0.002 914.2 99.6 98±4 1  1 
FK506 0.004 804.0 99.3 83±1 2 2 
KB2_61D 6.6‡/2.1† 368.4 94.4 75±10 3 3 
SD1 6.8‡ 251.1 91.9 32±15 4 4 
SD12 56 201.0 62.6 - destabilizes protein destabilizes protein 
SD2 95 283.1 50.0 19±4 5 5 
SD3 157 259.1 38.0 12±8 6 6 
SD4 221 278.1 30.5 - no complex no complex 
SD5 270 278.1 26.5 
 
- no complex no complex 
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in agreement with the literature for both instruments except for compound SD12. The 
spectrum for this ligand suggests that the tertiary structure of the protein had changed; the 
protein spectrum was characteristic of partial unfolding. Changes to the spectrum was time 
dependent (data not shown), there was no signal corresponding to FKBP12 in complex with 
ligand. 
 
High resolution x-ray structures often show water mediating hydrogen bond bridges between 
protein and ligand (Helms and Wade, 1998; Taylor et al., 2008). The water molecule may be 
thought of as an extension to the protein surface. If a water molecule is integral to ligand 
binding and is effectively trapped at the protein-ligand interface it should be possible to 
detect the mass of the water in MS. For example, if one water molecule were present the 
minimum mass of the signal corresponding to the complex would be [P + L + H2O]. The 
minimum mass in a charge-state envelope were compared for the signal corresponding to the 
free protein and the protein in complex with the ligand (section 3.6.3). A peak was present in 
the spectrum corresponding to un-adducted protein plus the mass of ligand for all charge-
states for the rapamycin, FK506, SD1, SD2 and SD3 complexes; no trapped waters were 
detected. X-ray structures do not suggest that hydrogen bonds between rapamycin and 
FK506 and FKBP12 are mediated by water. The ESI-MS data was consistent with the 
crystallographic data.  
 
The fraction of the protein in complex with the ligand was calculated from the 8+ charge-





Figure 3-10 ESI-MS spectra for FKBP12 and ligands over a range of affinity.   
Representative ESI-MS spectra for FKBP12 and a range of ligands, (1000 to 2000 m/z) ligands from 
the LCQ
TM
DECA instrument. Ligand SD12 is shown between 550 and 2000 m/z to illustrate the 
destabilizing effect of the compound on the protein. A spectrum of free FKBP12 is shown for 
comparative purposes. 5 μM FKBP12, 100 μM ligand dissolved in 20 mM ammonium acetate, pH 
6.8; 10 % methanol (v/v). Blue diamonds mark peaks corresponding to FKBP12 in complex with 































































































































3.7.5 Influence of charge-state on estimated affinity 
It is interesting to note that there were subtle differences in the state distributions 
corresponding to the complex of some low affinity ligands with FKBP12. Free FKBP12 and 
FKBP12 in complex with the high affinity ligands rapamycin and FK506 have distributions 
dominated by the 8+ charge-state.  SD1 and SD2 have distributions with a higher proportion 
of the complexed species flying in a charge-state > 8+. This phenomenon was not instrument 
dependent; similar spectra were obtained for both the ZQ and LCQ
TM
DECA instruments. 
The effect was most marked for ligand SD1 on the LCQ
TM
DECA, Figure 3-10. It is clear that 
changes to the charge-state distribution on ligand binding have implications for calculating 
PL from the peak intensities in a single charge-state pair. The 8+ charge-state was the 
dominant charge-state for free protein and protein complex in the majority of experiments 
and gave the best affinity discrimination between ligands in the test set at standard screening 
conditions. 
3.7.6 Increasing the ratio of ligand to protein 
SD1, SD2, SD6 and SD10 were titrated against 5 μM FKBP12 in a series of experiments on 
the Micromass ZMD. These ligands were selected for their range of affinity and solubility  
(0 to 1000 µM in analyte buffer). The cone voltage was set to 30 V, this was necessary to 
account for suppression of protein signal due to the high concentration of ligand. SD1 was 
not seen to fly in complex, SD2 was seen to fly in complex above 500 µM, SD6 above  
250 µM and SD10 was never seen in complex. Titrations were also performed for the 
negative controls N-phenyl-naphthylamine (NPN), imidazole and adenosine monophosphate 
(AMP). These compounds were chosen as they are not known to bind to FKBP12 and charge 
differently in solution at pH 6.8. NPN and imidazole did not fly in complex with FKBP12 at 
the screening concentration. FKBP12 was seen to form a complex with AMP at a 
concentration above 500 µM.  
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347 51.49 48.45 0.06 0 
Table 3-5 Negative controls. 
Negative controls were chosen as examples of molecules that charge differently at pH 6.8 and are not 
known to bind to FKBP12. Charge micro species were calculated using the Marvin pKa calculator 
(Chemaxon, http://www.chemaxon.com/demosite/marvin/index.html, June 2008). The dominant 
species is shown in bold typeface. 
 
3.7.7 Ranking the test set by affinity 
To conclude, data from the test set suggested that a Kd of around 150 μM was the lowest 
affinity ligand that can be seen flying in complex with FKBP12 at a protein ligand ratio of 
1:10 on the instruments tested. Single concentration measurements were sufficient to predict 
a rank order under very mild ESI-MS conditions. Absolute affinities were always 
underestimated for the test set. Moreover, the factor by which the affinity was 
underestimated was not consistent. Our results suggested that screening at a high ligand 
concentration could lead to unreliable rank orders of affinity (above 250 μM). AMP was 
seen to fly in complex at very high ligand to protein ratios. The major micro species for 
AMP was predicted to carry a charge of -2 at pH 6.8. Theses results suggest that non-specific 
binding was not a problem for a charged ligand at low ligand concentrations. Results for 
compounds tested in other ligand series (section 7.8.3) added weight to hypothesis that a 
single ligand concentration ESI-MS experiment was not a particularly good fine 
discriminator of ligands in the low micromolar range. Nevertheless, ESI-MS successfully 
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discriminated between nanomolar, low micromolar (1 – 100 μM) and higher micromolar 
affinity ligands (> 100 μM).  
3.8 Discussion and conclusions  
Titration experiments gave an estimated Kd close to the value measured in solution for 
ligands with low nanomolar affinity. The lowest affinity ligand seen to fly in complex with 
FKBP12, SD3, had an affinity of 157 μM. Cone voltage dissociation experiments established 
15 V to be the minimum cone voltage required to screen a series of compounds on the ZQ 
instrument using standards screening ratios. Although this voltage led to dissociation of a 
fraction of the FLBP12:SD1 complex, a lower voltage made it difficult to rank a series of 
compounds. The variance in repeat measurements (Table 3-4), and a factor in the 
significance of the rank of a compound, is a function of cone voltage (gross analyte signal to 
noise), the ease of ionisation of the ligand (degree of suppression of the gross protein signal) 
and the affinity of the ligand (signal to noise ratio for the protein complex).   
 
An additional consideration of the ranking of compounds by affinity is the nature of the non-
covalent interactions between protein and ligand. This is discussed in depth in the next 
chapter. 
 
Mass spectrometry has the advantage over many biophysical techniques of directly 
determining the accurate mass of both protein and ligand. Accurate mass determination of 
recombinant proteins is particularly useful. Single point experiments in electrospray are 
relatively information rich. Screening experiments carried out at a single ligand 
concentration give data on the mass of a ligand, its relative binding affinity/stoichiometry 
and additionally screen for protein stability. A ligand that induces protein destabilization and 
subsequent unfolding gives a much broader charge-state distribution with an increased 
population of higher charged species indicative of unfolded protein. ESI-MS has the 
potential to quickly rank order ligands by a methodology that has great transferability 
between different protein systems.  
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4 Chapter 4 Hydrophobic Effects versus 
Electrostatic Interactions in ESI-MS? 
4.1 Introduction 
A long standing criticism of investigating protein-ligand interactions by ESI-MS is that the 
water free environment of a desolvated macromolecular ion is so different to conditions in 
solution that affinity measurements are compromised. It has been reported that some protein-
ligand complexes survive ESI-MS better than others and that the robustness of a complex 
under a given set of experimental conditions is related to the type as well as the magnitude of 
the non-covalent interactions between the protein and the ligand (Hernandez and Robinson, 
2007). If the affinity of a ligand is to be quantified by the relative proportions of ions 
representing free protein and protein-ligand complex these observations are of considerable 
importance. In this section a series of experiments tested the hypothesis: complexes with a 
significant enthalpic contribution to the free energy of binding arising from electrostatic 
interactions dissociate less in electrospray.  
 
Non-covalent interactions arise from a variety of physical phenomena and exert an attractive 
force over different ranges and preferred geometries, Table 1-3 (Daniel et al., 2002). It is 
interesting to note that interaction energies based on charges, dipoles and polarisability are 
all inversely proportional to the dielectric constant of the medium. Water has a dielectric 
constant of 78.4 at 25 
o
C; estimates for the interior of a protein vary between 1 and 20 (Karp 
et al., 2007). It would therefore seem reasonable to suppose that electrostatic interactions, 
between protein and ligand, are strengthened when solvent is removed in the desolvation 
step of electrospray. Conversely, one would expect hydrophobic effects to be less important 
under the same conditions. When considering protein complexes in solution, the 
hydrophobic effect is central to explaining the favourable free energy change on the removal 
of a hydrophobic ligand from water into a hydrophobic pocket. An additional important 
consideration is that after desolvation the complex is not in equilibrium with the free protein 
and ligand; dissociation may occur but association is very unlikely. Such arguments have 
been used to question the suitability of ESI-MS as a technique for screening small molecules 
against a target protein (Yin et al., 2008). In a study by Robinson et al. (1996) a series of 
non-covalent complexes between acyl CoA binding protein and acyl CoA derivatives 
differing by the length of the hydrophobic acyl chain were investigated by ESI-MS. The 
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fraction of protein seen in complex with ligand in ESI-MS showed poor correlation with 
ligand affinity in solution. This was rationalized as the increased affinity of the longer chain 
ligands in solution, due to hydrophobic effect, did not contribute to improving affinity in the 
gas–phase. It has therefore been proposed that charged ligands, capable of making strong 
electrostatic interactions, will appear too highly ranked or as false positives in an ESI-MS 
screen, while complexes where hydrophobic effects are important could be under valued. 
Complexes of low affinity ligands less reliant on electrostatic interactions may not survive 
electrospray at all. One could argue that these effects rather than a disadvantage could, when 
combined with other biophysical and biochemical data, allow one to dissect the relative 
contributions of different components of the free energy of binding and therefore aid the 
drug design process.   
 
A metric is required to follow the dissociation of a complex in electrospray. A study by 
Rogniaux et al., (1999) investigating series of aldose reductase complexes found that VC50 
(cone voltage required to give 50 % dissociation of the complex) correlated with electrostatic 
and hydrogen bond interactions (calculated from x-ray structures) and not IC50. In this study 
the cone voltage induced dissociation profiles for a range of ligands of FKBP12 were 
examined for a correlation of the VC50 with the affinity and thermodynamic profile of the 
ligand measured in the solution by ITC. ITC was used to measure affinity in solution and to 
dissect the free energy of binding into enthalpic and entropic terms (thermodynamic profile). 
Increasing the cone voltage in ESI-MS raises the speed of macromolecular ions entering the 
low pressure sector of the instrument. This increases the frequency and kinetic energy of 
molecular collisions and can result in dissociation of the complex. The aim of this series of 
experiments was twofold. The primary aim was to establish the sensitivity of ESI-MS over a 
full range of cone voltage and to define a default cone voltage for screening experiments. 
The more ambitious aim was to test the hypothesis; complexes with a significant enthalpic 
contribution to the free energy of binding arising from electrostatic interactions dissociate 
less in electrospray. Could this information complement structure activity relationships 
derived from measurements in solution and docking studies to predict ligand binding modes 
if a crystal structure were not available?  
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4.2 Cone voltage induced dissociation 
4.2.1 Materials and Methods 
Analytes were dissolved in 20 mM ammonium acetate, pH 6.8; 10 % methanol (v/v). 
Protein-ligand ratios were chosen so that the majority of the protein was in complex in 
solution. The ligands investigated by cone voltage induced dissociation are described in 
Table 4-1. Ratios were calculated using from the law of mass action and Kd values from 








rapamycin 914.1 0.0002, 
0.0078 
 
(Bierer et al., 1990; Wear and 
Walkinshaw, 2007; Wear et al., 
2007b) 
FK506 804.0 0.0004, 
0.001 
 















Top hit in a series of compounds 
synthesised to target 
immunophilins; the KB series. 
Described in section 7.7.2 
SD1 251.1 6.8
‡
  (Stebbins et al., 2007) 
Table 4-1 Ligands investigated by cone voltage induced dissociation 
Kd is quoted from the literature for rapamycin and FK506; values for KB2_61D and SD1 were 
determined by ‡ITC (25 
o
C) and †PPIase assay (4 
o






The analyte was equilibrated on ice for 5 minutes prior to injection and directly infused into 
the instrument (Micromass ZQ, Waters) at a flow rate of 10 μl∙min
-1
 using the instrument 
syringe pump. Data acquired was an average of 59 scans between 1000 and 2000 m/z, 
background subtracted and smoothed in Micromass MassLynx V4.1 (Waters). The 
concentration of the protein-ligand complex was calculated from the ratio of intensity of 
complexed to uncomplexed protein in the 8+ charge-state pair using the method described in 
Section 3.6.3. Protein-ligand complex was dissociated by increasing the cone voltage on the 
instrument between 10 and 120 V. Above this voltage protein fragmentation was observed. 
The maximum voltage in a given experiment was ligand dependent. The data was recorded 
for at least 20 V above the voltage where complex could no longer be observed.  
 
The cone voltage required to give 50 % dissociation of the complex (VC50) was estimated 
from the least squares fit to a generalized reverse sigmoid curve (equation 13) using 








    Equation 13 
 
Where: PL is the protein-ligand complex concentration calculated from equation 9, PLmax the 
maximum value of the curve, VC50 the cone voltage required to give 50 % dissociation of 
the complex, V the cone voltage and n a constant (the steepness of the curve). 
 
 84 
4.2.2 Cone voltage induced dissociation profiles 
Figure 4-1 shows the cone voltage dissociation profiles for 4 ligands of FKBP12 (affinity 



















































Figure 4-1 Cone voltage induced dissociation. 
Cone voltage induced dissociation profiles for complex of FKBP12 and a range of ligands. 9.5 μM 
FKBP12; 10 μM rapa/FK506 or 100 μM KB2_61D/SD1; dissolved in 20 mM ammonium acetate, pH 
6.8; 10 % methanol (v/v). Micromass ZQ instrument, and default parameters, cone voltage 9 to 100 V. 
Data was acquired over 59 scans; background corrected and smoothed in MassLynx V4.1 (Waters). 
[PL]μM was calculated from the 8+ charge-state pair. Kd is quoted from the literature for rapamycin 
and FK506 (Bierer et al., 1990; Stebbins et al., 2007; Wear et al., 2007b), the value for KB2_61D and 
SD1 were determined as part of this study by ITC at 25 
o
C. The affinity value for KB2_61D in 





Ligand MW (Da) Kd (μM) in  solution VC50 (V) Reference 
rapamycin 914.1 0.0002, 0.0078 48.8 (Bierer et al., 1990; Wear et al., 2007b) 
FK506 804.0 0.0004, 0.001 45.8 (Bierer et al., 1990; Connelly and Thomson, 1992) 
KB2_61D 368.4 6.6‡/2.1† 27.1 EAB Section 7.8.2 
SD1 251.1 6.8‡ 11.7 (Stebbins et al., 2007), EAB Section 6.4.2 
 
Table 4-2 Correlation of VC50 and solution Kd.   
The VC50 was estimated from the least squares fit to a generalized reverse sigmoid curve (equation 
13) to the data presented in Figure 4-1, KaleidaGraph version 4.03 (Synergy Software). Kd is quoted 
from the literature for rapamycin and FK506, values for KB2_61D and SD1 were determined by ‡ITC 
(25 
o
C) and †PPIase assay (4 
o
C) as part of this study. 
 
Table 4-2 shows that for the compounds tested the ligands of nanomolar affinity for FKBP12 
had a much higher VC50 than the micromolar affinity ligands. FK506 and rapamycin are 
large ligands that bind to FKBP12 with multiple hydrogen bonds and hydrophobic 
interactions. Interestingly, compounds KB2_61D and SD1 have similar Kd in solution (ITC 
measurements in this study) however, SD1 was by far the more fragile in electrospray. 
Dissociation profiles for rapamycin and FK506 have a “horizontal” section, between 10 and 
~30 V, where there was less influence of cone voltage on the fraction of complex retained 
(Figure 4-1). The presence of this section was less clear for KB2_61D, interpretation being 
more difficult as signal to noise ratios were poor at very low cone voltages. This data 
suggests that 15 V is close to the minimum value for screening experiments on the 
Micromass ZQ instrument. Results were in agreement with data obtained on the Micromass 
ZMD instrument (Figure 3-6), VC50 = 45.1 V for FK506.  
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4.3  VC50 and H-bonding from crystal structure  
It is important to consider any thermodynamic analysis in a structural context. The difference 
in number of hydrogen bonds between FK506 and rapamycin and FKBP12 was investigated 
as a simple metric to compare the electrostatic component of non-covalent interactions. 
Table 4-3 lists hydrogen bond distances (2.5 to 3.3 Å) seen in crystal structures of FKBP12 
in complex with FK506 and rapamycin (Figure 4-2 (A)). A hydroxyl group on the 
cyclohexyl moiety of rapamycin makes an additional hydrogen bond to FKBP12, when 
compared to that of FK506, due to the closer proximity of Gln53. An early structure of the 
FKBP12-FK506 complex from Schreiber’s group predicted a water mediated hydrogen bond 
between the equivalent hydroxyl on FK506 and Gln53 (Van Duyne et al., 1991). Not all 
deposited structures report this water. Rapamycin is a more massive ligand than FK506 and 
there are additional van der Waals contacts with the 50’s loop region of FKBP12 in the 
region of Glu54. It is important to note that the portions of FK506 and rapamycin that 
occupy the bulk of the active site are almost identical and are closely aligned in the 
superimposed structures (Figure 4-2 (B)). The increased VC50 for the rapamycin complex is 
consistent with the hypothesis that complexes with a larger number of electrostatic 
interactions require more energy to dissociate in the gas phase. The crystal structure of the 
FKBP12-FK506 complex is more ordered than that of the FKBP12-rapamycin complex. The 
entropic penalty for increased structural order has been proposed as contributing to the 
reduced affinity of FK506 for FKBP12 compared to rapamycin.  
 
Atom: ligand Atom : protein Type Distance (Å) Distance (Å) Atom : ligand Atom : protein Type 
FK506:O6 A:37:ASP:OD2 H-bond 2.78 2.61 rapa:O6 A:37:ASP:OD1 H-bond 
    2.64 rapa:O13 A:53:GLN:O H-bond 
FK506:O10 A:54:GLU:O H-bond 2.69 2.67 rapa:O10 A:54:GLU:O H-bond 
FK506:O2 A:56:ILE:N H-bond 2.80 2.93 rapa:O2 A:56:ILE:N H-bond 
FK506:O3 A:82:TYR:OH H-bond 2.76 2.66 rapa:O3 A:82:TYR:OH H-bond 
 
Table 4-3 A comparison of probable hydrogen bonds and FK506 and rapamycin to FKBP12 
derived from x-ray structure.  
FKBP12-FK506: 1FKJJ.pdb, FKBP12-rapamycin: 2DG3.pdb (Fulton et al., 2003). Inter-atomic 
distances (heavy atom to heavy atom distances in angstrom) were calculated using the program PyMol 
V1.02 (DeLano Scientific). The additional hydrogen bond in the interaction with rapamycin is shown 
in bold.  
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Figure 4-2 Details of x-ray structures of FKBP12 in complex with rapamycin and FK506. 
 (A) The blue block arrow shows the additional hydrogen bond is gained on rapamycin binding to 
FKBP12 (2DG3.pdb) when compared to the structure of FK506 in-complex with FKBP12 
(1FKJ.pdb). This is the result of the hydroxyl group on the cyclohexyl ring being closer to Gln53 in 
the rapamycin structure. The putative hydrogen bond is shown as a dashed line, distance is labelled in 
angstrom. (B) The common structural elements of FK506 and rapamycin occupy very similar 
positions in the interior of the hydrophobic pocket. Trp59 is shown highlighted; this forms the “floor” 






4.4 Correlation of VC50 and binding mode from docking experiments 
4.4.1 Docking SD1 into FKBP12 
It was not possible to crystallise FKBP12 in complex with SD1 or KB2_61D in this study. 
Docking experiments were carried out for compounds SD1 and KB2_61D using FlexX 
(Rarey et al., 1996) and LIDAEUS (Wu et al., 2003) to generate binding mode hypotheses.  
Docking strategies employed in this project are described in Chapter 7. 
 
Modelling of SD1 into the active site of FKBP12 was carried out using the docking 
programs LIDAEUS and FlexX, and a protein template from a high resolution x-ray of the 
FKBP12-rapamycin complex (2DG3.pdb, 1.7 Å resolution). The two clusters of high scoring 
poses suggested by FlexX are illustrated in Figure 4-3. Poses were analysed for correlation 
with structure activity relationships derived from NMR data. The SAR analysis is described 
in 4.4.2. The top scoring FlexX pose for SD1 fitted well with the SAR analysis. This pose 
predicted one hydrogen bond between the amide oxygen of SD1 and the hydroxyl of Tyr82 
(mode 1, Figure 4-4). The top scoring example in an alternative cluster of poses is also 
shown in Figure 4-4 (mode 2). In mode 2 the ligand lies less deeply in the active site, the 
morpholine ring makes fewer van der Waals contacts with Trp59. Docking using LIDAEUS 
and a resolution of 0.06 Å suggested a very similar array of preferred orientations in the 
active site. 
 
Figure 4-3 Top 50 docked poses of SD1 
The top 50 FlexX poses for SD1 were clustered into two regions of the active site. FlexX V3.0.2 






Figure 4-4 Predicted binding modes for SD1 in complex with FKBP12  
Binding mode 1 (grey carbon skeleton). The top scoring pose makes a hydrogen bond with the 
hydroxyl group of Tyr82, the morpholine ring is placed deepest in pocket and the phenyl ring in a 
hydrophobic trench close to Phe36. This pose fits best with the SAR analysis, 4.4.2.  
Binding mode 2 (green carbon skeleton), the ligand makes a hydrogen bond with the proton on the 
main chain nitrogen of Ile56. Important residues in the active site of FKBP12 are shown with blue 
carbon skeletons. FlexX V3.0.2 (Rarey et al., 1996). 
 
In Figure 4-5 (A) the top scoring docking solution for SD1 (mode1) has been aligned with 
the x-ray structure of rapamycin in complex with FKBP12 (2DG3.pdb). Parts (B) and (C) 
show 2D schematic diagrams of non-covalent interactions for the FKBP12:rapamycin 









Binding mode 1 


























































Figure 4-5 Modelling SD1 into the active site of FKBP12. 
 (A) The highest scoring docked pose of SD1 is shown with a purple carbon skeleton. Rapamycin is 
shown as green carbon sticks; hydrogen bonds from rapamycin to FKBP12 are shown as blue dashed 
lines and labelled in angstrom. The solvent exposed loop of rapamycin has been hidden for clarity. 
Key protein residues are highlighted. An electrostatic surface was generated to illustrate the geometry 
of the active site; PyMol V1.02 (DeLano Scientific). (B) 2D Schematic representation of the non-
covalent interactions between rapamycin and FKBP12 (2DG3.pdb). (C) 2D Schematic representation 
of the top scoring docked pose of SD1. Hydrogen bonds are shown as dashed lines; selected 
hydrophobic interactions are shown as green arcs. Docking was performed  in FlexX V3.0.2 using the 
x-ray structure 2DG3.pdb as a template protein structure (Rarey et al., 1996). 
(B) FKBP12:rapamycin 

























4.4.2 Structure activity relationships within the San Diego data set 
The small molecules in published crystal structures of FKBP12 complexes are not 
structurally diverse (Table 1-4). The majority share a core motif with rapamycin and FK506 
and bind in a very similar mode (Figure 1-9). Crystal structures were only available for two 
members of the test set; it was felt that structure activity relationship (SAR) analysis for the 
San Diego data set would be helpful in devising binding mode hypotheses for the 
compounds lacking an x-ray structure. The San Diego data set comes from a high-throughput 
NMR screen against FKBP12; it is described in section 3.7.1. This data set was particularly 
valuable as it contained experimental data on actives and in-actives. The library was 
complied with knowledge of the target and contained clusters of relatively close analogues. 
Of the 3775 compounds 44 were reported to be active (Kd ≤ 500 μM). The data set was 
analysed for chemical similarity. A 2D chemical fingerprint was written for each compound 
and an inter-compound pair-wise comparison made by means of a Tanimoto similarity 
coefficient (Hert et al., 2006; Eckert and Bajorath, 2007). Many of the higher affinity 
compounds in the San Diego data set were structurally similar to compound SD1. These 
compounds consist of a morpholine ring with an amide bond and a –CH2-S- linker to an 
aromatic ring. Figure 4-6 summarises the finding of the SAR study, using SD1 as the 



























-S- > –SO2- > -O- >-CH2-
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Figure 4-6 Structure activity relationships for the SD1 cluster. 
The blue box illustrates the effect of substituting the phenyl group of SD1. Replacing sulfur in the 
linker is shown in the yellow box and replacement of the morpholine ring in the pink box. SDCCG-
A014-FKBP12-NMR, http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=608, September 2008.  
 
4.4.3 A binding mode hypothesis for SD1 
Evidence from docking and SAR suggests that the morpholine ring of SD1 mimics the 
pipecolate ring of rapamycin by making contacts with Trp59 at the base of the hydrophobic 
pocket (Figure 4-5 (A)). This is supported by the evidence that the addition of two methyl 
groups ortho to the oxygen on the morpholine ring greatly reduced activity. Docking studies 
indicated that these substitutions make the ring too bulky to occupy the base of the pocket. 
The amide oxygen is important for activity; shortening the linker between the rings (deletion 
of the carbonyl group) removed activity. Docking suggested that the amide oxygen may 
make a hydrogen bond with the hydroxyl of Tyr82, mimicking the hydrogen bond seen with 
the amide oxygen of rapamycin. Substitution to the aromatic ring in the para position has a 
negligible effect on activity with the exception of the most active member of the cluster 
where the substitution of an isopropyl group for the methyl of SD1 in the para position 
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significantly increased activity. Modelling suggested that allowing the 80’s loop region of 
FKBP12 to move out would accommodate the isopropyl group in the hydrophobic pocket 
formed by the 80’s loop, rotating the ligand slightly from the mode proposed for SD1 (anti-
clockwise, consider an axis orthogonal to the plane of the paper through the carbon of the 
amide, Figure 4-5 (A)). It is worth noting that NMR is not usually considered the best 
technique for estimating the affinity of ligand in the nanomolar range. There is likely to be a 
considerable degree of uncertainty in the reported Kd for this particular ligand. Additions to 
the ring at ortho and meta positions reduced affinity. This is consistent with the aromatic 
ring of SD1 lying in a narrow hydrophobic trench adjacent to Asp37 and Phe36. Making the 
aromatic ring wider by substitution in the ortho and meta positions would make the ring too 
broad to fit into this trench. Substitution in the para position does not preclude binding in 
this mode as para groups would become solvent exposed. An alternative binding mode for 
SD1, suggested by docking experiments, proposed that the aromatic ring lies in the 
hydrophobic trench bound by Gln53 (mode 2, Figure 4-4). This mode suggested that the 
amide oxygen made a hydrogen bond with the hydrogen of main chain nitrogen of Ile56, 
mimicking the hydrogen bond between Ile56 and the lactone oxygen of rapamycin. This is 
less likely as the Gln53 hydrophobic trench is more accommodating than the trench bounded 
by Asp37 and additions to the ring in the ortho and meta positions would be less likely to 
“push” the ligand out of the pocket thus reducing the number of non-covalent interactions. 
Substituting –S- in the linker region for -SO2-, –O- or –CH2- reduced activity. These 
substitutions have the effect of altering the geometry of the molecule and reducing van der 
Waals contacts. 
 
These observations are dependent on there being no gross changes to protein structure on 
ligand binding. Evidence from numerous crystal structures of complexes indicate that 
FKBP12 does not change significantly on ligand binding, but there are localized changes in 
the loop regions (Van Duyne et al., 1991; Wilson et al., 1995). Changes in this loop region 
are observed in x-ray structures and are considered to be important most significant for the 
FKBP12-ligand interface required for the immunosuppressant action of rapamycin and 
FK506.  
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4.4.4 Docking compound KB2_61D 
 
Figure 4-7 Stereochemistry of compound KB2_61D. 
Structural elements of compound KB2_61D that make it difficult to predict the isomer/conformer for 
use in docking experiments. 
 
Proposing a binding hypothesis for KB2_61D is less straightforward than for SD1. The 
compound was not made by a stereospecific route (use of racemic ethyl pipecolate as a 
reagent). KB2_61D contains two chiral centers, two amide bonds with restricted rotation 
(two dominant rotamers) and a di-keto linker where the torsion angle between the two 
carbonyl groups is difficult to predict (Figure 4-7). The NMR spectrum of the sample was 
characteristic of a mixture and it proved impossible to predict the relative proportions of 
each isomer (Dr. Kevin Bailey, University of Manchester). A cursory inspection of the 
molecule would indicate that KB2_61D has more potential for making electrostatic 
interactions than SD1. It was decided that docking every diastereomer and a wide range of 
likely conformers would probably not be helpful. A non-exhaustive search exploring various 
degrees of freedom did not produce a clear cut result. An alternate strategy was adopted. 
KB2_61D is a symmetrical analogue of the pipecolate ring and the di-keto moieties found in 
FK506 and rapamycin. The conformation of rapamycin and FK506 have been discussed in 
the literature (Wilson et al., 1995). In the bound forms, both FK506 and rapamycin have 
orthogonal carbonyl groups in the di-keto moiety (O-C-C-O torsion ~ 90
o
) and the amide in 
the trans form. It was decided to model compound KB2_61D on the pipecolate ring and di-
keto group of rapamycin. This was done by fixing the chirality of one pipecoate ring to that 
of rapamycin (S). The torsion angles were set to similar values to those in rapamycin and 
then minimized using a MFF94 force field in SYBYL (Tripos Software). Minimisation gave 











? restricted rotation 
chiral center? 
planarity of N? 
ring conformation? 
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were docked using FlexX V3.0.2 (Rarey et al., 1996). The best solution (lowest energy) is 
shown in Figure 4-8. 
 
 
Figure 4-8 Docking pose for compound KB2_61D. 
The best pose for compound KB2_61D ((S),(R) form). Two proposed hydrogen bonds are shown as 
blue dashed lines, labelled in angstrom. FlexX V3.0.2 (Rarey et al., 1996).  
 
This pose fits with SAR derived from the KB2 series (Figure 7-18, SAR showed that an 
ortho substituted ester increased activity as did the second pipecolate ring when compared to 
a non-symmetrical analogue, 62D). This pose predicted 2 hydrogen bonds; Ile56 –NH to the 
carbonyl on one pipecolate ring and Tyr82-OH to an amide carbonyl of the same ring (first 
carbonyl of the di-keto moiety). The second carbonyl of the di-keto moiety occupied the 
same small hydrophobic pocket adjacent to Phe99 as the analogous group in 
rapamycin/FK506.  
 
The docking results suggested that KB2_61D makes more electrostatic interactions than 
SD1. This would be in agreement with the hypothesis, complexes with a predominance of 
electrostatic interactions survive electrospray better. However, there is a caveat to this 
conclusion. KB2_61D is a mixture of diastereomers. If the synthesis shows no chiral 
selectivity, only 25 % of the compound is the diastereoisomer shown in Figure 4-8. 










active site. The chirality of the pipecolate positioned deepest in the active site was most 
important for the probability of making two hydrogen bonds with the protein. We would 
suggest that not all diastereomers of KB2_61D are equally active and that having one 
pipecolate in the (S) form improves activity relative to the (R) form. Thus, the solution Kd is 
not representative of the most active diastereomers. In addition, it makes the assumption that 
rotamers are inter-convertible. Inter-conversion of rotamers is particularly interesting in the 
context of FKBP12 as a peptidyl-prolyl isomerase. To further resolve these issues it would 
be necessary repeat the affinity experiments with a single diastereomers of KB2_61D also to 
crystallise each respective complex. A first step might be to try to separate diastereomers on 
a C18 reverse-phase HPLC column. 
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4.5 Exploring collision induced dissociation in different protein 
systems 
4.5.1 Introduction 
Preliminary data from the collision induced dissociation of FKBP12 complexes supported 
the hypothesis: complexes with a significant enthalpic contribution to the free energy of 
binding arising from electrostatic interactions dissociate less in electrospray. To further this 
study required additional experimental data for ligands with nano to low micromolar affinity 
for FKBP12. As additional ligands were not available, two different model protein systems 
with low micromolar affinity ligands were investigated. The proteins selected had similar 
molecular weight and solvent exposed surface area to FKBP12, but structurally and 
chemically different ligands. It was important to select proteins that flew in electrospray with 
sufficient charge to be observable in the m/z range of the instrument. The proteins selected 
were all weakly basic and had similar pIs. 
 






pIcalc Ligand Kd (μM) 
(ITC, 25 oC, 
 pH 6.8)  
FKBP12 2DG3.pdb 1.7 13348 6091 8.79 SD1 6.8 
HEWL 1HEW.pdb 1.75 14313 6904 9.32 N, N’, N’’-
Triacetylglucosamine 
8 
RNaseA 1ROB.pdb 1.6 13690 7010 8.64 2’-cytidine monophosphate 1.5 
Table 4-4 Summary protein properties for the model systems. 
Molecular weight and pI were calculated from protein sequence using the ExPASy ProtParam server 
(www.expasy.org/tools/protparam.html, June 2008, (Gasteiger et al., 2005). Surface area was 
calculated using a probe radius of 1.4 Å and a Connolly surface, PyMol V1.02 (DeLano Scientific). 




Table 4-4 summarises basic structural descriptors and affinity for FKBP12, hen egg white 
lysozyme (HEWL) and ribonuclease A (RNaseA) and their respective ligands. Figure 4-9 
shows x-ray structures of FKBP12, HEWL and RNaseA with their respective ligands and 2D 





Figure 4-9 Representation of protein-ligand interactions in three model systems. 
(A) Top scoring docking pose of SD1 and FKBP12 (2DG3.pdb protein template). Schematic diagram 
of predicted non-covalent interactions between FKBP12 and SD1. (B) X-ray structure of HEWL and 
N, N’, N’’-Triacetylglucosamine (NAG3) and schematic diagram of non-covalent interactions 
(1HEW.pdb). (C) X-ray structure of ribonuclease A (RNaseA) and schematic diagram of electrostatic 
interactions (1ROB.pdb). Protein-ligand electrostatic interactions are represented by dashed lines and 









































































































































The electrostatic surfaces shown in Figure 4-9 illustrate the different nature of the binding 
sites for the three protein systems. FKBP12 has a predominantly hydrophobic pocket. 
HEWL has a negatively charged cleft that binds polysaccharide substrates. Aspartic acid and 
glutamic acid residues are important for the catalytic activity of the enzyme. RNaseA has a 
positively charged cleft that binds RNA; two histidine residues are important for catalytic 
action. 
4.5.2 Hen egg-white lysozyme and N, N’, N’’-Triacetylglucosamine  
N, N’, N’’-Triacetylglucosamine (NAG3) is a tri-saccharide that binds specifically to hen 
egg-white lysozyme (HEWL) in a 1:1 ratio non-covalently bound complex. HEWL functions 
as a hydrolase, with specificity for β(1-4) glycosidic bonds between N-acetylmuramic acid 
and N-acetylglucosamine (NAG). NAG3 does not undergo hydrolysis when bound to the 
enzyme. High purity HEWL (lyophilised, salt-free) and NAG3 (> 95 %) were purchased 
from Sigma, UK. HEWL was dissolved in 50 mM ammonium acetate solution, pH 6.8 and 
NAG3 in water. The HEWL:NAG3 complex has been studied using a variety of electrospray 
mass spectrometry approaches (Jecklin et al., 2008). NAG3 has been shown to fly in 
complex with HEWL under conditions that retain active enzyme. 
 
HEWL has theoretical molecular weight of 14313 Da, it flew in electrospray with an 
apparent mass of 14311.2 Da. The complex of HEWL and NAG3 had an apparent mass of 
14938.4 Da, this was an addition of 627.2 Da. 2’-CMP has a mass of 627.6 Da, this suggests 
that the complex is a 1:1 ratio of protein to ligand and that there were no additional water 
molecules present for the dominant species. This is interesting as the x-ray structures of 
HEWL in complex with NAG3 show 2 hydrogen bonded water molecules bridging protein 
and ligand. These are apparently not required for binding in the gas-phase. 
 
Figure 4-10 (A) shows how the fraction of complex decreased as the cone voltage was raised 
from 10 to 80 V. The VC50 was 47.5 V; there was no complex present after 70 V. The 
affinity of NAG3 for HEWL is 8.0 μM at pH 6.8, ITC data, Figure 4-10 (B). Binding was 
exothermically driven, ΔH = -12.5 kcal∙cal
-1
. However, there was an entropic penalty for the 
bound state, TΔS = -5.5 kcal∙cal
-1
. The ITC data was consistent with literature values; the 
binding of carbohydrates to proteins is typically enthalpically driven (Garcia-Hernandez et 
al., 2003). Interestingly, the VC50 is similar to that of the FKBP12-FK506 complex (a much 












































Figure 4-10 Influence of cone voltage on HEWL-NAG3 preserved in ESI-MS 
(A) Fraction of complex preserved as a function of cone voltage. The data was normalised to the 
fraction of complex at a cone voltage of 10 V. 20 µM HEWL, 100 µM NAG3, 20 mM ammonium 
acetate, pH 6.8. (B) Raw ITC data. 0. 5 mM NAG3 was injected into 1.42 ml, 32 μM HEWL in 25 x 
10 μl injections (3 μl 1st injection), 180 s apart at 25 
o
C. All reagents were dissolved in  
50 mM sodium phosphate, pH 6.8 (Bottom panel) Integrated heat data fit to a standard 1:1 binding 
model (MicroCal Origin software, V4.0). 
(B) ITC 
Kd = 8.01 μM 
ΔG = -7.0 kcal∙mol
-1
 
ΔH = -12.5 kcal∙mol
-1 
TΔS = -5.5 kcal∙mol
-1 
N = 0.99  
 
 
VC50 = 47.5 V 
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4.5.3 Ribonuclease A and 2’-Cytidine monophosphate  
2’-Cytidine monophosphate (2’-CMP) is a nucleotide mimetic that binds specifically to 
Bovine pancreatic ribonuclease A (RNaseA) in a 1:1 ratio non-covalently bound complex 
(Lisgarten et al., 1993). RNaseA is an endonuclease, it catalyses the cleavage of 
phosphodiester bonds of ribonucleotides, the mechanism of action is well understood. This 
enzyme is known to be particularly stable and has been extensively used as a model protein 
system. Cytidine monophosphate (2’-CMP) acts as an inhibitor of the natural substrate of 
this enzyme, the phosphate group is not cleaved by the enzyme because of the 2’, rather than 
3’ link between the phosphate group and the ribose ring. The enzyme was purchased as a 
lyophilised powder and dissolved in 50 mM ammonium acetate buffer, pH 6.8 (Ribonuclease 
A from bovine pancreas, Type XII-A, ≥90 % (SDS-PAGE), Sigma, UK). 2’-CMP was 
dissolved in methanol (Sigma, UK).  
 
RNaseA has theoretical molecular weight of 13690.2 Da, it flew in electrospray with an 
apparent mass of 13686.8 Da. The complex of RNaseA and 2’-CMP had an apparent mass of 
14009.1Da, this was an addition of 322.3 Da. 2’-CMP has a mass of  323.2 Da, this means 
that the complex is a 1:1 ratio of protein to ligand and that there were no additional water 
molecules present for the dominant species flying in ESI-MS. This is consitent with the x-ray 
data (1ROB.pdb) where no water molecules are seen to bridge between the ligand and the 
protein. 
 
Figure 4-11 (A) shows how the fraction of complex decreased as the cone voltage was raised 
from 10 to 80 V. The VC50 was 55.8 V; there was no complex observed after 80 V. The 
affinity of RNaseA for 2’-CMP 1.5 μM at pH 6.8. Binding was exothermically driven,  
ΔH = -16.9 kcal∙cal
-1
. However, there was an entropic penalty for the bound state, TΔS = -
8.7 kcal∙cal
-1
.  ITC data (Figure 4-11) showed ligand binding to be exothermic however there 
was a very significant entropic penalty on binding. ITC data was consistent with literature 










































Figure 4-11 Influence of cone voltage on RNaseA-2’-CMP complex preserved in electrospray. 
(A) Fraction of complex preserved as a function of cone voltage. The data was normalized to the 
fraction of complex at a cone voltage of 10 V. 42.5 µM RNaseA, 75 µM 2’-CMP, 20 mM ammonium 
acetate, pH 6.8. (B) Raw ITC data for 2’CMP injected into RNaseA  All reagents were dissolved in  
50 mM sodium phosphate, pH 6.8, 25 
o
C. (Bottom panel) Integrated heat data fit to a standard 1:1 
binding model (MicroCal Origin software, V4.0). (ITC data courtesy of Dr Samantha Rutherford, 
Organon). 
(B) ITC 
VC50 = 55.8 V 
Kd = 1.5 μM 
ΔG = -8.2 kcal∙mol
-1
 
ΔH = -16.9 kcal∙mol
-1 
TΔS = -8.7 kcal∙mol
-1 




4.5.4 Correlation between VC50 and thermodynamic data 
 














FKBP12 SD1 1 11.7 -6.09 0.96 -7.05 0.96 6.8 
FKBP12 KB2_61D 2 27.1 -11.7 -4.6 -7.1 0.89 6.6 
FKBP12 FK506 4 45.8 (-14.2) (-2.3) (-12.3) NA 0.0004 
FKBP12 rapamycin 5 48.8 (-16.4) (-3.49) (-12.7) NA 0.0002 
HEWL NAG3 6 47.5 -12.49 -5.53 -6.96 0.99 8.0 
RNaseA 2’-CMP 7 55.8 -16.92 -8.69 -8.23 0.94 1.5 
 
Table 4-5 Correlation between VC50 and thermodynamic data. 
VC50 is the cone voltage required to give 50 % dissociation of the complex. VC50 was determined by 
least squares fit of cone voltage dissociation data to equation 13 using KaleidaGraph version 4.03 
(Synergy Software). Thermodynamic data is from this study except values in brackets which are 
reproduced from (Connelly and Thomson, 1992). The number of predicted hydrogen bonds is from x-
ray data, except SD1 which is from the model described in section 4.4.3 (shown in italics). Kd for 
















































Figure 4-12 Correlation between V50 and enthalpic contribution to binding 
There is a correlation between VC50 and the enthalpic contribution to the Gibbs free energy change 
for the protein ligand interaction. 
 
Table 4-5 shows that there is a correlation between VC50 and the number of hydrogen bonds 
between the ligand and complex predicted from an x-ray structure/molecular model. A 
correlation is seen between the VC50 and ΔH measured by ITC, Figure 4-12 (A). There is no 
correlation between VC50 and ΔG, Figure 4-12 (B). These results, although limited in scope, 
confirm the hypothesis that complexes with a predominance of electrostatic interactions 
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survive electrospray better. The RNaseA-2’-CMP and HEWL-NAG3 complexes both form 
multiple hydrogen bonds between protein and ligand. The binding of both proteins to their 
respective ligands is enthalpically driven with a significant entropic penalty.  
4.6 Discussion and conclusions 
4.6.1 Minimum cone voltage 
Setting cone voltage in ESI-MS is always a compromise between sensitivity and good signal 
to noise ratio. Every protein-ligand complex has an optimum cone voltage for 
characterisation of the interaction by MS; for example, estimating the affinity of the 
interaction by the titration method. This study confirmed the finding in Chapter 3 (3.7) that 
15 V was the lowest cone voltage that could be used in screening experiments on the 
Micromass ZQ instrument. Cone voltage dissociation profiles proved to be a useful tool to 
quantify the relative fragility of a particular complex in electrospray. In this study, titration 
experiments were carried out at a cone voltage where the fraction of complex observed was 
not exquisitely sensitive to voltage. 
4.6.2 VC50, affinity and enthalpy 
Studies have suggested there might be a correlation between VC50 and affinity for a series 
of chemically similar ligands (Daniel et al., 2002; Woods and Ferre, 2005). In this study 
VC50 appears to be a poor indicator of affinity in solution. However, there was correlation 
between VC50 and the enthalpic contribution to the free energy of binding (ΔHITC). There 
was also correlation with the number of hydrogen bonds between protein and ligand 
predicted by x-ray crystallography. It is worth noting that for the ligands selected with a 
similar affinity, if there is a correlation between VC50 and ΔH there will also be a 
correlation with TΔS as ΔG is similar. 
 
The protein binding domains of the macrocyclic ligands FK506 (0.4 nM) and rapamycin (0.2 
nM) are very similar. The enthalpic contribution to the free energy of binding for the 




4 hydrogen bonds are seen 





5 hydrogen bonds are seen between protein and ligand. These complexes 
did not dissociate under moderate cone voltages; VC50 were 45.8 and 48.8 V respectively. 
The x-ray structure of HEWL in complex with NAG3 predicts 6 hydrogen bonds between 
protein and ligand; this would suggest a large enthalpic stabilisation. The large enthalpic 
contribution to binding was confirmed by ITC, ΔHITC = -12.49 kcal∙mol
-1
. In solution, the 
 105 
affinity was only in the low micromolar range (8 μM), this is explained by an unfavourable 
entropic contribution to binding, TΔSITC = -5.53 kcal∙mol
-1
. The complex proved to be robust 
in electrospray, VC50 = 47.5 V. The interaction between RNaseA and 2’-CMP showed a 
similar thermodynamic profile. The x-ray structure of RNaseA in complex with 2’-CMP 
suggested 7 hydrogen bonds between protein and ligand. Charge-charge interactions are 
observed, non-covalent interactions of this type exhibit interaction energies much greater 
than a typical hydrogen bond, and this could account for enhanced stability of this complex 
in MS. A large enthalpic contribution to binding is confirmed by ITC (ΔHITC = -16.92 
kcal∙mol
-1
). In solution the affinity is in the low micromolar range (1.5 μM) due to an 
unfavourable entropic contribution, TΔSITC = -8.69 kcal∙mol
-1
. This complex was particularly 
robust in electrospray, VC50 = 55.8 V. High stability for ribonuclease-nucleotide complexes 
was recently reported by Loo’s group (Yin et al., 2008). Woods and Ferre (2005) performed 
collision-induced dissociation on a complex with an arginine-phosphate charge-charge 
electrostatic interaction using collision gas in a cell (ESI-MS/MS). Their complex consisted 
of a basic epitope containing adjacent arginine residues and an acidic epitope containing a 
phosphorylated serine. The authors describe how collision energies similar to covalent 
complexes were required for dissociation, they refer to this as a “covalent like” stability 
(Woods and Ferre, 2005). One might postulate that protein-DNA/RNA interactions might be 
particularly suitable for investigation by MS. In contrast to the studies mentioned, the FKBP- 
SD1 complex was prone to dissociation in MS but showed similar low micromolar affinity in 
solution (6.8 μM). The modelling studies predicted a lower enthalpic contribution to binding; 
only one hydrogen bond was predicted and there was a reduction in buried surface area 
compared to that seen in the x-ray structures of the more massive ligands in complex with 
FKBP12. This is the only complex in this study that showed a positive ΔS in ITC; ΔHITC = -
6.09 kcal∙mol
-1
; TΔSITC = 0.96 kcal∙mol
-1
. Additional evidence of a hydrophobic contribution 
to binding is provided by surface plasmon resonance. SPR was carried over a range of 





 for ΔCp. A negative value for ΔCp is indicative of a system where hydrophobic 
surface is removed from solvent into a nonpolar environment (Spolar et al., 1989).  
 
Evidence from the HEWL-NAG3 and RNaseA-2’-CMP systems support the hypothesis; 
complexes with a significant enthalpic contribution to the free energy of binding from 
electrostatic interactions survive electrospray better, is confirmed.  
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5 Chapter 5  The Spectral Ghost  
– Influence of collision induced dissociation on charge-state distribution  
5.1 Introduction 
For the compounds tested in this study, it was not possible to see protein flying in complex if 
the ligand had a solution Kd > 160 μM. However, it was apparent that there were subtle 
changes to the charge-state distribution of the protein. In particular, the 8+ to 7+ intensity 
ratio appeared to reduce with an increasing concentration of ligand for those compounds 
known to bind in solution. We were interested if this effect were the result of complex 
dissociating under the electrospray conditions or if it were purely a consequence of 
increasing concentrations of ligand in the analyte solution. We considered the origin of 
charge on protein in electrospray and speculated if an extension to the charge residue model 
(CRM) proposed by Dole could explain the charge-state shifts in terms of the dissociation of 
the protein complex.  The CRM proposes that drops contract by the evaporation of solvent 
until they reach their Rayleigh stability limit (Rayleigh, 1882) and undergo Coulombic 
fission (Dole et al., 1968).  
5.2 The origin of charge on multiply-protonated native FKBP12  
In this study FKBP12 (5-20 μM) was sprayed from an aqueous solution of 10 mM 
ammonium acetate. The ratio of protein molecules to ammonium ions is in the order of 
1:1000. It is thought that macromolecular charging is, in the most part, due to reaction of 
ammonium ions with basic residues on the surface of globular proteins (Felitsyn et al., 2002; 
Touboul et al., 2008a). The reaction of an ammonium ion with an amine leading to a proton 
bridged adduct is shown in equation 14. This process occurs in solution.   
 
Z (Z 1)




 is the charge-state of the protein and the –NH2 group is part of a basic amino acid. 
 
The complete proton transfer is thought to occur during dissociation of the adducted 
molecule during desolvation, equation 15.  
 
(Z 1) (Z 1)
2 3 3 3(FKBP12 NH H NH ) (FKBP12 NH ) NH   Equation 15 
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However, it is also possible that a charged ammonium ion, NH4
+
, can dissociate leaving a 
protein ion with no additional charge, equation 16. 
 
(Z 1) Z
2 3 2 4(FKBP12 NH H NH ) (FBP12 NH ) NH   Equation 16 
 
Therefore, the final charge-state is not only a function of tertiary structure of the protein (the 
number of exposed basic residues) but also of the protein’s ability to hold onto protons 
during dissociation of an adducted species.  
 
The intrinsic gas-phase basicity of base B is defined as the free energy change ΔG
o
 on the 
loss of a proton, equation 17. 
 
BH B H    Equation 17 
 
When considering the likelihood of an amino-acid chain becoming protonated, by the 
mechanism described in equations 14 and 15, one must consider the gas-phase basicity of the 
side chain. This can be thought of as the gas-phase equivalent of the pKa of a side chain in 
solution. Felitsyn et al., (2002) considered the gas-phase basicities of basic residues on the 
surface of proteins and compared them to that of ammonia. The authors argue that it is 
possible for an NH4
+
 ion to protonate basic residues because the gas phase basicity of 
ammonia is less that that of arginine, histidine, lysine and to a lesser extent tryptophan and 
proline.  
 
The usual assumption in ESI-MS is that a protein retains a correctly folded tertiary structure 
if the electrospray spectrum exhibits a narrow range of charge-states. The charge-state 
distribution for FKBP12 under standard ESI-MS conditions is dominated by the 8+ charge-
state (Figure 2-8). In an acid solution (pH 2.5), FKBP12 denatures, more basic amino acids 
are exposed to solvent, and the electrospray spectrum shifts to a distribution centered on the 
16+ charge-state (Figure 2-8). 
 
The above argument possibly has relevance for the dissociation of protein-ligand complexes 
during the desolvation stages of ESI-MS. Is it possible for a ligand, of sufficient gas-phase 
basicity, to leave with a proton? This would have an effect of shifting the charge-state 
distribution to lower m/z. If this process occurs it should be possible to detect binding in 
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solution when no protein-ligand complex is observed as an ion in the ESI-MS spectrum due 
to dissociation.  
5.3 Estimating the affinity of a ligand from a charge-state shift 
Examining the charge-state distribution from titration experiments under mildly dissociating 
conditions revealed a charge shift with increasing concentration of ligand. Figure 5-1 (A) 
shows the ESI-MS spectrum of free FKBP12. Figure 5-1 (B) and (C) show the same protein 
solution with increasing concentrations of the 0.4 nM inhibitor FK506. The cartoon “blue T” 
represents the ligand and the “red sphere” FKBP12 in the FKBP12-FK506 complex flying as 
an 8+ charge-state (8+ molecular ion). Interestingly, these spectra showed the 7+ charge-




Figure 5-1 Changes to the charge-state distribution as a function of ligand concentration. 
Analytes were dissolved in 10 mM ammonium acetate, pH 6.8; 10 % methanol (v/v). (A) 5 μM 
FKBP12, 0 μM FK506 (B) 5 μM FKBP12, 1 μM FK506 (C) 5 μM FKBP12, 3  μM FK506. The peak 
for the 8+ complex is labelled with a blue T in a red sphere. Data is an average of 20 scans acquired 
on a Micromass ZMD instrument (Waters). 
 
One hypothesis to explain the above spectra is that the loss of a protonated ligand during 
collision induced dissociation can reduce the charge-state of the protein. Hence, the 7+ signal 
is made up of macromolecular ions that initially charged at 7+ plus those that were in 
complex with FK506 (charged 8+) and then dissociated; FK506 leaving with a charge of 1+. 
FK506 is seen to fly as a [FK506+H]
+
 ion in the electrospray spectrum. This process can be 
described by equation 18.  
 
Z (Z 1)[FKBP12 L] [FKBP12] L    Equation 18 
 
Where: L represents the ligand and Z+ the charge on the molecular ion prior to dissociation 






1μM FK506 0μM FK506 
(A) (B) (C) 
3μM FK506 
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To investigate a correlation between the charge-state shift and the fraction of protein that had 
been in complex with ligand in solution, a metric was required that could follow changes to 
the CS spectrum of the protein. The metric chosen was the ratio of the intensity of the 8+ CS 






Intensity of 8 CS I
Intensity of 7 CS I
 
 
Figure 5-2 shows data from a series of titration experiments. Ligands were a selection from 
the test set (3.7.1). The x-axis shows an increasing total concentration of ligand. The y-axis 




 and the right hand axis the concentration of the 
protein ligand complex, [PL], calculated from the ratio of complexed to un-complexed 
protein (this method is described in section 3.6.3). In Figure 5-2 (A) and (B) [PL] was 
calculated from the spectrum. For Figure 5-2 (C) – (F) no complex was observed and [PL] is 
calculated from solution Kd (equation 12). To distinguish calculated and experimental [PL]; 
the experimental values are plotted in blue (solid line) and the calculated values in red 
(dashed line). The solid blue and dashed red lines are a least square fit to equation 12 using 





data to a logarithmic function as an aid to visualisation. 
 





 ratio, and the fraction of protein in complex in solution. Alternative assays have 
detected complexes between the SD series and FKBP12 in solution (see section 6.4.6 
(Stebbins et al., 2007)). However these complexes with FKBP12 appeared not to be robust 
enough to survive ESI-MS. The dissociation of the complex could be described as leaving a 
ghost on the charge-state distribution (the spectral ghost of the title). 
 




 was plotted against fraction of protein that was in a complex with ligand 
in the solution phase. These results raise the intriguing possibility that it might be possible to 
estimate the affinity of a ligand by monitoring the charge-state shift under conditions that 
dissociate complex. This would extend the sensitivity of our instruments to beyond 160 μM. 
Detecting binding from the free protein spectrum has the additional advantage of not 
requiring the ligand mass to locate the signal from the protein in complex. This would mean 
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Figure 5-2 Charge-state shifts correlates with concentration of complex 
Analytes were dissolved in 10 mM ammonium acetate, pH 6.8; 10 % methanol (v/v). (A) 5 μM 
FKBP12, 0-20 μM rapamycin (0.2 nM) (dashed blue). (B) 5 μM FKBP12, 0-20 μM FK506 (0.4 nM). 
(dashed blue) (C) 5 μM FKBP12, 0-1000  μM SD1 (8 μM) (dashed red). (D) 5 μM FKBP12,  
0-1000 μM SD2 (95 μM) (dashed red). (E) 5 μM FKBP12, 0-1000 μM SD6 (277 μM)  (dashed red). 
(F) 5 μM FKBP12, 0-1000 μM SD10 (440 μM) (dashed red). Data is an average of 20 scans acquired 




Kd  = 0.2 nM Kd  = 0.4 nM 
Kd  = 8 μM Kd  = 95 μM 
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Figure 5-3 Charge-state shifts correlate with fraction of protein in complex with ligand in 
solution. 
5 μM FKBP12. Analytes were dissolved in 10 mM ammonium acetate, pH 6.8, 10 % methanol (v/v) 
acquired on a Micromass ZMD instrument (Waters). The fraction of the protein in complex with the 
ligand was calculated from the concentration of the protein, the concentration of the ligand and the 
equilibrium dissociation constant using equation 12. Structures for each of the ligands are shown in 
Table 3-2 Ligand test set. 
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5.4 Collision induced dissociation and charge-state shift 
To further investigate charge-state shifts and the ghosting effect; the charge-state shift of 
FKBP12 was examined under conditions of increasing collision induced dissociation. This 
was achieved by changing the cone voltage from 10 to 100 V. Dissociation caused by 
increasing cone voltage occurs in the late stages of the instrument after desolvation of the 


























































Figure 5-4 Charge-state shifts is a function of complex dissociation. 
Analytes were dissolved in 10 mM ammonium acetate, pH 6.8; 10 % methanol (v/v); 5 μM FKBP12; 
10 μM FK506 (0.4 nM). Data is an average of 20 scans acquired on a Micromass ZMD instrument 
(Waters). 
 
The results shown in Figure 5-3 show that there is a correlation between the fraction of the 
protein in complex with the ligand and the charge-state distribution of the protein, as 




. Careful examination of a series of spectra produced by 
increasing cone voltage, as seen in Figure 3-6 (A), would suggest that loss of the ligand from 
a molecular ion charged 8+ can go through two mechanisms. At lower cone voltages (10 -  
40 V) the spectra suggested that the dominant mechanism is the dissociation of the complex 
molecular ion (8+ CS) through loss of a protonated ligand (L+) to give a 7+ free protein ion 
as described by equation 18. At low cone V the 7+ and 8+ CS for the free protein were minor 
components within the spectrum (dominated by the 8+ CS for the FKBP12-FK506 
complex). As the cone V increased the 7+ CS for the free protein increased at a faster rate 
than the 8+ charge-state for the free protein. This remained the case up to 30 V when the 
fraction of the 8+ CS for free protein increased to become the dominant species. The 
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increase in the 8+ CS for the free protein is explained by the loss of a neutral ligand ion from 
the complex. 
5.5 Estimating the affinity of a ligand from a charge-state shift under 
dissociating conditions 
To further test the hypothesis that the dissociation of the ligand is in the latter stages of the 
electrospray process caused a charge-state shift, a titration experiment was performed 
between FKBP12 and FK506 under fully dissociating conditions, Figure 5-5. The titration 
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Figure 5-5 Charge-state shifts correlate with fraction of protein in complex with ligand under 
dissociating conditions. 
Analytes were dissolved in 10 mM ammonium acetate, pH 6.8; 10 % methanol (v/v). 5 μM FKBP12, 
0-20 μM FK506 (0.4 nM). Dashed red line is the calculated fraction of FK506 in complex with 
FKBP12 scaled between 0 and 1. Data is an average of 20 scans acquired on a Micromass ZMD 
instrument (Waters). 
 
The results represented in Figure 5-5 showed that it was possible to estimate the fraction of 
protein in complex with ligand in solution under conditions of complete dissociation by 






5.6 Charge-state shift as a function of complex dissociation in other 
protein systems 
A change in charge-state distributions on dissociation of the complex are also observed for 






Figure 5-6 Dissociating the HEWL-NAG3 complex 
Analytes were dissolved in 20 mM ammonium acetate, pH 6.8 at the concentrations detailed on the 
spectra. Spectra are annotated with cone voltage. Complex ions and free protein ions are labelled with 
icons to aid identification (blue “T” represents the ligand and the “red sphere” the protein). The free 
protein ion series are labelled with A9 and A8, representing the 9+ and 8+ charge-states. The complex 
ion series are labelled with B and the charge-state. 
 
There is evidence from Figure 5-6 (A) and (B) that at a cone voltage of 50 V the 9+ complex 
ion (HEWL-NAG3) has dissociated into an 8+ free protein ion in the dominant dissociation 
pathway, as described by equation 18.  
  
20 uM HEWL 100uM NAG3 10% MeOH 20mM am ac pH cV 50V sdT80oC dT100oC pH6.8
m/z





























(B) 20 μM HEWL, 100 μM NAG3, 50V 
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Figure 5-7 Dissociating the RNaseA-2’CMP complex. 
Analytes were dissolve in 20 mM ammonium acetate, pH 6.8 at concentrations detailed on the spectra. 
Spectra are annotated with cone voltage. Complex ions and free protein ions are labelled with icons to 
aid identification (green “T” represents the ligand and the “magenta sphere” the protein). The free 
protein ion series are labelled with A8 and A7, representing the 8+ and 7+ charge-states. The complex 
ion series are labelled with B and the charge-state. 
 
There is evidence from 5.7 (A) and (B) that when the cone voltage is increased from 30 V to 
80 V the 8+ RNaseA- 2’-CMP complex ion dissociated into a 7+ free protein ion and 2’CMP 
(not seen in the illustrated mass range). The mechanism for this could be described by 







(B) 42.5 μM RNaseA, 75 μM  2’CMP  80V 
(A) 42.5 μM RNaseA, 75 μM  2’CMP  30V 




5.7 How consistent is desolvation? 
The desolvation of the protein has implications for the quantification of affinity for both the 
direct measurement of peak intensities and indirectly from a charge-state shift. Under 
conditions necessary to preserve the complex in electrospray each charge-state has an adduct 
tail indicative of incomplete desolvation. The minimum m/z value for a given charge-state 
was defined as the base peak; this represents the ion that has undergone the most complete 
desolvation, Figure 5-8 (A). The adduct tail corresponds to ions with an increased m/z due to 
non-specific binding of species present in the analyte that have not been removed by 
desolvation. Examples of non-specific binders are H2O and NH4
+
. The Micromass ZMD and 
ZQ instruments (Waters) were found to have reasonably consistent desolvation with 
relatively small adduct tails for each charge-state. The LCQ
TM
DECA (ThermoQuest) was the 
more sensitive instrument in terms of retaining low affinity ligands in complex with protein. 
However, desolvation appeared to be less consistent from visual inspection of the spectra. 
The titration data also showed more variability than that obtained with the Micromass 
ZMD/ZQ. Data acquisition with this instrument was approximately 3 times longer than with 
the Waters instruments. 
 
It would be convenient to use the base peak as an approximation for the whole charge-state 





 charge-state ratio of the free protein were investigated for 7 samples 
of FKBP12 flying under optimized conditions on the LCQ
TM
DECA. The intensity of the 
charge-state was calculated from the summation of ion intensities in the charge-state 
envelope. The study investigated how much of the adduct tail needed to be included in the 




 charge-state ratio with low variance. The intensity of the charge-













 is the total intensity for a specific charge-state envelope, m is the base peak 
for the charge-state and Δm is the mass equivalent above the base peak mass that is included 
in the intensity summation. 
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)Δm , plotted against Δm, where Δm has been rounded to the nearest integer. Rounding 
Δm to the nearest integer was necessary when combining data from more than one 








)Δm becomes asymptotic when Δm > 200 




 (N=7) reaches a steady value with reduced 
variance when Δm > 200 Da.  Considering a model adduct with a mass of 20 Da one can 
deduce that there is most variability in desolvation for the final 10 non-specifically bound 
species under the experimental operating parameters. It is interesting to note that in the 
rapamycin and FK506 titration data the charge-state envelope corresponding to the protein in 
complex with the ligand shows better desolvation than the free protein. This would be 
consistent with hypothesis that ligand occupies the active site of FKBP12 and solvent 
molecules have lower affinity out-with the active site. There are 3 conserved water 
molecules in the apo structure of FKBP12 (2PPN.pdb, Figure 1-8). Displacement of ordered 
water on ligand binding has been calculated to give a favourable entropic contribution the 
free energy of binding (Connelly et al., 1993). 
 
Figure 5-8 (D) shows titration data plotted using the base peak (dotted green) and values 
calculated using a summation of Δm = 200 Da (solid blue). Visual inspection of the data 
shows a lower value for the saturation concentration of complex for the data including Δm = 
200 Da (solid blue) in the summation.  The conclusion was that there were no appreciable 
benefits in including the adduct tail in the estimation of ligand affinity.  
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Figure 5-8 Does inclusion of the adduct tail lead to better agreement with solution phase affinity 
data? 
(A) Annotated 8+ and 7+ charge-states of FKBP12 showing adduct tails. (B) A typical plot of the 
difference in I8+/I7+ as a function of Δm, (I8+/I7+)Δm+1- (I8+/I7+)Δm , plotted against Δm, where Δm has 
been rounded to the nearest integer. (C) Mean I8+/I7+ as a function of Δm, error bars are the standard 
deviations for N=7. Data (A), (B), (C) 4 μM FKBP12, in 10 mM ammonium acetate, pH 6.8; 10 % 
methanol (v/v). (D) Titration experiment, points are a mean for N=3. 4 μM FKBP12, 0-10 μM FK506, 
in 10 mM ammonium acetate, pH 6.8; 10 % methanol (v/v). Each scan was an average of 300 scans 
acquired on a LCQ
TM
DECA (ThermoQuest) instrument; capillary voltage 3.52 KV, cone voltage 25 V 


































































5.8 Discussion and conclusions 
The use of charge-state shifts to assess the affinity of weak ligands that dissociate under 
electrospray conditions is an intriguing concept. There is preliminary data to support the 
method having enhanced sensitivity compared to detecting binding from the presence of a 
complex ion in a standard ESI-MS screening experiment. This technique may have particular 
application when screening small fragment-like molecules which have affinity in the 
micromolar range but become potential lead compounds after fragment linking or chemical 
modification.  
 
However, measuring ligand binding by this method is still at a preliminary stage of 
investigation. It would seem reasonable to suggest that the mechanism of charge division is 
very likely to be ligand dependent in any given protein system. The gas phase basicity of the 
ligand must have an influence on the dissociation pathway, as must the nature of the non-
covalent interactions between ligand and protein. It is however useful to observe that a 
charge-state shift might indicate the dissociation of a complex in electrospray and that 
further investigation is required. If time had allowed we would have investigated carbonic 
anhydrase, many small soluble inhibitors are available over a range of Kd (Krishnamurthy et 
al., 2008). For a larger data set it would be interesting to relate charge state-shifts to the 
relative basicity of hydrogen bond acceptors on ligands. Laurence et al. have collated a 
database of constants measuring the hydrogen-bond basicity of organic species towards a 
reference hydrogen-bond donor (Laurence et al., 2009). 
  
The conclusion reached in the experiments investigating “adduct tails” was that there were 
no appreciable benefits in including the adduct tail in the estimation of ligand affinity by 
summation. 
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6 Chapter 6 Biophysical and Biochemical 
Ligand Binding Studies of FKBP12 
6.1 Introduction 
This study employed a variety of biophysical and biochemical techniques to characterise 
non-covalent complexes of FKBP12. One of the principle aims of the project was to explore 
medium throughput biophysical screening strategies for testing hits from virtual screening 
programs. Electro-spray ionisation mass spectrometry (ESI-MS) is discussed in detail in 
chapters 3, 4 and 5. It was important to compare results from ESI-MS with other 
experimental approaches. Choice of biophysical method required balancing throughput, 
sensitivity and the richness of thermodynamic data. Compounds from the ligand test set were 
used to compare different methods (section 3.7 describes the selection of the test set). 
 
It is useful to make a distinction between a screening experiment in which a large number of 
ligands are tested at a single concentration and the thermodynamic characterisation of a 
specific complex where some form of titration is employed. The estimation of affinity at a 
single ligand concentration is inherently less accurate than a titration method. However, the 
increased throughput outweighs this disadvantage when used as the first experimental step in 
the drug design process. Some methods are more suitable for screening at a single ligand 
concentration because of a low level of variance between repeats. Other techniques have the 
advantage of a 96-well plate format or in the degree of automation of data collection. Some 
methods are particularly prone to false positives. Coloured ligands can be a problem for 
assays that are dependent on a colour change such as the PPIase assay. Similarly the 
potential for ligand fluorescence must be considered. 
 
The threshold affinity for the detection of a complex, at a specific protein/ligand screening 
ratio, is of significance. Fragment-based screening approaches are of current interest in drug 
design. Fragment-like ligands are generally defined as those with a MW ≤ 350 Da (Carr et 
al., 2005). This tends to limit the number of non-covalent interactions accessible for a 
specific fragment when compared to that of a larger drug. Equilibrium dissociation constants 
(Kd) of hits from fragment screens are often between 50 and 150 μM (Congreve et al., 2008). 
These ligands can be challenging to detect by some biophysical techniques, particularly if 
they are relatively insoluble. 
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6.2 General screening considerations   
It is self-evident that the protein/ligand screening ratio determines the minimum affinity of 
ligand detected and the range of affinity over which there is good discrimination between 
ligands of close affinity. For each assay, there is minimum protein concentration required to 
give sufficient response; for FKBP12 this is around 10 μM for the biophysical techniques 
used in this study. This concentration of protein necessitates a ligand concentration of 
between 100 and 250 μM to detect micromolar affinity ligands in a screen. To illustrate this 
it is useful to consider a weak inhibitor with Kd = 250 μM. At a screening concentration of 
100 μM 28 % of the protein would be in complex with the ligand and at  
250 μM 50 %, this not a linear relationship. However, for the thermal denaturation assay a 
ligand screening concentration of 250 μM equates to a change in melting temperature of less 
that 1 
o
C for this ligand; small compared to the standard deviation for three repeats which is 
in the order of 0.5 
o
C. There are often solubility issues for ligands at a concentration of  
250 μM in an aqueous buffer. Compounds from screening libraries are routinely dissolved in 
DMSO or DMSO is added to an analyte solution to aid solubility. Screening compounds 
against FKBP12 is complicated by the fact that DMSO binds to the protein with an affinity 
in the low millimolar range (Burkhard et al., 2000). 5 % DMSO is equivalent to a 0.7 M 
solution; a close to saturating concentration if no competing ligand is present. Introducing a 
low % of DMSO into solution can lead to significant competition for the active site with a 
weakly binding screening compound at the usual protein/ligand screening ratios.  
 
Table 6-1 illustrates the effect of 0 – 5 % DMSO in 3 hypothetical experiments with a high 
affinity ligand (Kd = 0.7 μM), a medium affinity ligand (Kd = 7 μM) and a low affinity ligand 
(Kd = 70 μM).  The model assumes 10 μM FKBP12, 250 μM screening ligand and a Kd =  
30 mM for DMSO. The ligand simulation assumes the law of mass action and that the 
DMSO and the screening ligand compete for the same binding site. A solution of the 
algebraic equation describing complex formation as a function of total ligand concentration 
was arrived at using the program Berkley Madonna (V.8.3.11, Macey and Oster). The 
concentrations of the protein complexes and free protein were calculated at equilibrium. For 
the 0.7 μM ligand a low % of DMSO has little effect on the proportion of protein seen in 
complex with the screening ligand. However, there is significant competition for the binding 
site for the ligand with a Kd = 70 μM.  This result has implications for including DMSO, or 
any solvent that binds both specifically or non-specifically, in a screening assay. There is a 
real possibility that low affinity ligands/fragments might appear as false negatives.  
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(A) Ligand Kd = 0.7 μM (high affinity),                   Total [FKBP12]  = 10 μM ,                Total [Ligand]  = 250 μM 
% DMSO Total [DMSO] (mM) Eq. [FKBP-L] (μM) Eq. [FKBP12-DMSO] (μM) Eq. [FKBP12] (μM) 
0 0 9.97 0 0.03 
0.1 14  9.96 0.01 0.03 
1  141 9.84 0.13 0.03 
2  282 9.72 0.25 0.03 
5 715 9.36 0.61 0.03 
 
(B) Ligand Kd = 7 μM (medium affinity),                   Total [FKBP12]  = 10 μM ,                Total [Ligand]  = 250 μM 
% DMSO Total [DMSO] (mM) Eq. [FKBP-L] (μM) Eq. [FKBP12-DMSO] (μM) Eq. [FKBP12] (μM) 
0 0 9.72 0 0.28 
0.1 14  9.60 0.12 0.28 
1  141 8.65 1.10 0.25 
2  282 7.80 1.98 0.25 
5 715 5.99 3.83 0.18 
 
(C)  Ligand Kd = 70 μM (low affinity),                   Total [FKBP12]  = 10 μM ,                Total [Ligand]  = 250 μM 
% DMSO Total [DMSO] (mM) Eq. [FKBP-L] (μM) Eq. [FKBP12-DMSO] (μM) Eq. [FKBP12] (μM) 
0 0 7.76 0 2.24 
0.1 14  7.07 0.9 2.03 
1  141 3.94 4.94 1.12 
2  282 2.65 6.60 0.75 
5 715 1.32 8.31 0.37 
 
Table 6-1 DMSO as a competing ligand 
The concentrations of the species at equilibrium were calculated for three hypothetical ligands:  
(A) Kd = 0.7 μM, (B) Kd = 7 μM and (C) Kd =70 μM ; [ligand] = 250 μM, [FKBP12] = 10 μM and 
DMSO between 0 and 5 %. The program Berkeley Madonna (V.8.3.11) was used to solve the 
equations for two competing ligands (Appendix 1). The concentrations of the protein complexes and 
free protein were calculated at equilibrium (Eq.). Including DMSO in a screening experiment with a 
tight binding ligand, Kd = 0.7 μM (A) had little effect on the proportion of protein in complex with the 
ligand. For a weaker inhibiter, Kd = 70 μM (C), there was significant competition at 1 % DMSO.  
  
It is also interesting to note that for the 70 μM ligand although there is significant 
competition with DMSO at < 5 %;  the ratio of [FKBP-ligand]/[FKBP] remains remarkably 
consistent (FKBP12-DMSO complex is the dominant species in solution).  
 
The screening ratio was biased for the detection of low affinity ligands. This reduced 
discrimination between nanomolar affinity ligands. In the unlikely eventuality that a large 
number of tight binding ligands were discovered in a single screen, more detailed 
thermodynamic characterisation would discriminate between them. 
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6.3 Biochemical and biophysical methods 
6.3.1 Peptidyl-prolyl isomerase assay  
In this study the Kd for inhibitors of FKBP12 was determined from the competitive 
inhibition of the isomerisation of the substrate Succ-Ala-Leu-Pro-Phe-p-nitroaniline.  
 
An assay was developed by Fischer to measure peptidyl-prolyl isomerase (PPIase) activity in 
immunophilins (Fischer et al., 1984a; Fischer et al., 1984b). This assay relies on the 
conformationally selective hydrolysis of substrates of the form Xaa-Pro-Phe-p-nitroaniline 
by α-chymotrypsin. Hydrolysis of the C-terminal p-nitroaniline ester bond occurs for Xaa-
Pro is in the trans conformation. FKBP12 catalyses the conversion between the cis to trans 
conformation of the peptidyl-prolyl bond in the substrate. FKBP12 shows substrate 
specificity for peptides with a hydrophobic, bulky residue next to the proline (Harrison and 
Stein, 1990). The progress of the ester hydrolysis may be followed spechrophotometrically 
by measuring the absorbance of the bright yellow p-nitroaniline product (λabs = 400 nm). 
Although theoretically sound, the reaction was found to be hard to quantify because of 
uncertainty in the initial ratios of cis/trans isomers. The trans form of the substrate was 
hydrolysed very rapidly by α-chymotrypsin in the so called “burst” reaction. Moreover, there 
was a high thermal turnover between cis to trans conformers at room temperature. The assay 
was improved by Kofron et al., (1991) who introduced a new solvent for the substrate that 
shifted the conformational equilibrium in favour of the cis isomer (Kofron et al., 1991).  
 
A possible disadvantage of this assay is the dependence on a colour change; this can require 
careful use of controls for coloured or fluorescent compounds. In addition, the reaction 
occurs over a short time course. The cis/trans ratio of the substrate is reduced in the presence 
of water. The substrate must be kept as dry as possible prior to and during experimentation. 
The experimental method required considerable manual dexterity.  
 
Materials and Methods 





 α-chymotrypsin (CalBiotech) in 10 mM hydrochloric acid was prepared and kept 
on ice. Buffered FKBP12 was incubated with each inhibitor for at least 30 minutes at 0 
o
C. 
100 μl of α-chymotrypsin was added to the protein/ inhibitor solution, gently mixed and very 
rapidly pipetted into a spectrometer cuvette containing 30 μl, 4 mM substrate (Bachem,UK) 
in 2,2,2-trifluoroethanol, 47 mM lithium chloride (placed in the instrument). The substrate 
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solution was pipetted immediately before the rapid pipetting step. This ensured that the 
substrate remained dry and cis/trans ratio was as high as possible. Final solution: 100 nM 




 α-chymotrypsin; 120 μM Succ-Ala-Leu-Pro-Phe-p-
nitroaniline; 14 mM lithium chloride; 1 % methanol (v/v); 3 % 2,2,2-trifluoroethanol (v/v), 
PBS, pH 8; final volume 1 ml. The initial equilibrium ratio of cis/trans Xaa-Pro-Phe-p-
nitroaniline was found to be ~ 1.5. This allowed a measurable time course for the isomerase 
reaction and a reduction in the initial burst reaction when α-chymotrypsin rapidly hydrolysed 
the trans conformer. Thermal turnover was reduced by conducting the assay at 4
o
C (Peltier 
cooling of cuvette). It was not possible to cool below 4 
o
C due to problems with 
condensation on the cuvette during the course of the reaction. Absorbance at 400 nM was 
record every 0.01s for 120s on a Perkin-Elmer Lambda 20 spectrometer (Perkin- Elmer). The 
rate of the reaction was determined between 0.5 and 1.5 s and rates determined using UV 





From 0-2 s the substrate was assumed to be in excess and the rate of isomerisation 
independent of the substrate concentration. This was seen as a linear portion of the graph of 
absorbance of product plotted against time. The reaction reached completion within 120 s. 
 
Without the use of stop-flow equipment there was still considerable variance in the 
experimental data; each data point was repeated 9 times and the standard error calculated. 
The random errors in data; are believed to be due to variability in the start of data recording, 
incomplete mixing and bubbles in the cuvette because of over vigorous pipetting. The 
activity of α-chymotrypsin is pH dependent; maximum activity occurs at pH 8.0 (Blow et al., 
1969). Solution pH was confirmed for each test compound and a control was included to 
check for the possible effect of the inhibitor (no protein) on background turnover of the 
substrate. This control also accounted for coloured or fluorescent compounds. It was not 
possible to test some potential inhibitors due to their intense yellow colour. 
 
Screening the test set by PPIase assay 
The PPIase assay was used to screen members of the inhibitor test set to assess the threshold 
affinity of the assay for a specific compound screening concentration. The experiment was 
also designed to assess the variance in a reading and the suitability of the assay to rank order 
a series of compounds by affinity. A concentration of 300 μM was selected; most 
compounds were soluble to this point. Ligands were dissolved in methanol (no DMSO) and 
solvent concentrations kept constant in every experiment. The % inhibition was calculated at 
the screening concentration.  
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Determining the apparent equilibrium dissociation constant, Ki 
The concentration of the inhibitor was varied from zero (0 % inhibition) to 100 % inhibition 
of the PPIase activity of FKBP12. 100 % inhibition was not attainable for lower affinity 
ligands of poor solubility and restricted the general applicability of the method.  
 
The Ki, for an inhibitor was determined by the non-linear least squares fit of equation 20 to 
the rate of turn-over of the substrate, corrected for the background turnover at 4 
o
C, plotted 
against the concentration of an inhibitor (Morrison, 1969; Kofron et al., 1991). Non-linear 
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    Equation 20 
 
 
Where; Vi is the rate of the reaction at a specific concentration of inhibitor, Vo the rate of reaction with 
no inhibitor present, [P] is the concentration of FKBP12 and [I] the concentration of the inhibitor.  
 
The equilibrium dissociation constant, Kd, for each inhibitor, was determined by correcting 











    Equation 21 
 
Where: [sub]cis is the concentration of the cis isomer of the substrate and Km is the Michaelis constant 
for substrate . Km = 301 μM for the 6H-FKBP12 construct used in this study (Wear et al., 2007b). 
 
The concentration of the substrate was taken as the concentration of the cis isomer. This was 
calculated from the total concentration of the substrate corrected for the proportion of the 
substrate in the trans form. This was determined from the absorbance at close to zero, after 
the “burst” reaction, as a fraction of the total absorbance after completion of the reaction.  
 126 
6.3.2 Isothermal titration calorimetry 
A defining feature of isothermal titration calorimetry (ITC) is the direct measurement of the 
enthalpy of binding, ΔH, for a protein-ligand complex. ITC also provides information on 
stoichiometry, the free energy change, ΔG, and the entropic change, ΔS (Cooper and 
Johnson, 1994; Holdgate, 2001; Freyer and Lewis, 2008; Bouchemal, 2008). The Kd for the 
interaction can be calculated from ΔG using equation 2. It is possible to perform experiments 
at a range of temperatures, examine changes in the thermodynamic profile with temperature 
and calculate the difference in specific heat capacity, ΔCp, for a complex.  
 
In a typical ITC experiment the ligand is injected into a solution of protein and the heat 
change measured. The heat change comes from formation of the complex, the heat of 
dilution of the ligand and protein and a small effect due to mixing (the injection syringe 
constantly rotates in the reaction cell). It was necessary to perform controls and correct for 
dilution and mixing effects in ITC experiments, Table 6-2. The heat of dilution of the ligand 
was typically the largest correction necessary in this study. An exception to this rule, were 
the experiments using ammonium acetate as a buffer and injecting a concentrated solution of 
protein into a ligand solution. There was a significant heat of dilution for the protein in 
buffer.  
 
ITC was principally used for secondary screening; the Kd for a given complex was estimated 
from primary screen prior to the ITC experiment. The purpose of the ITC experiments was to 
improve the estimation of Kd and to determine other thermodynamic parameters.  
 
Materials and Methods 
Concentrated solutions of ligand were added to a solution of protein in a series of small 
injections and the heat change for each injection measured by comparison to a reference cell 
containing the experimental buffer. The law of mass action and an estimated Kd were used to 
model the complex formed for each proposed injection (Microsoft Office Excel, 2003). 
Analyte concentrations and injection volumes were adjusted so that the initial injections had 
similar integrated heats of injection and that the binding sites of the protein sample were 
saturated for the final few injections. Sigmoid curves were achieved for a plot of integrated 
heats of dilution against the molar ratio of ligand/protein (after correction for heats of 
dilution/mixing) for the high affinity ligands. Integrated heat curves for lower affinity 
ligands show less steep sigmoid curves for the same analyte concentrations. Beyond the 
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obvious influence of affinity on the shape of the curve there were usually experimental 
constraints from ligand solubility and quantity of available protein. The test set was a useful 
tool to assess the discrimination between different ligands in experiments designed with a 
low c value. c = (concentration of macromolecule x stoichiometry)/Kd and is a useful 
dimensionless quantity used to assess the sensitivity of the ITC thermogram to subtle 
changes in Kd (Holdgate, 2001)). Increasing the c value has an obviously detrimental effect 
on protein requirement in an already protein hungry assay. 
 
ITC experiments were carried out on a MicroCal auto-VPITC instrument (GE Healthcare). 
Reagents were dissolved in 50 mM sodium phosphate, pH 6.8; 50 mM sodium chloride. 
Ammonium acetate was initially tested as a buffer as it is used in ESI-MS experiments. An 
advantage of ammonium acetate is that the pKa does not vary much with temperature 
between 5 and 60 
o
C.  However, it was found that the heats of dilution for the protein was 
large compared to enthalpy of ligand binding. The majority of the experiments were 
performed with a sodium phosphate buffer (Ferguson et al., 1980). In a screening experiment 
300 μM ligand (in the syringe) was injected into 15 μM FKBP12 (in the reaction cell). For 
insoluble ligands it was possible to inject a concentrated solution of protein into a ligand 
solution. Rapamycin and FK506 were tested by injecting solutions of 35 μM FKBP12 
(syringe) into 1 μM ligand (reaction cell). The default experimental protocol was: 28 x 10 μl 
injections (0.5 μl 1
st
 injection), 20 s injection duration, 180 s injection delay, syringe spin 






The auto-VPITC allowed samples of protein and ligand to be stored at 4 
o
C prior to 
experimentation. Analyte solutions are degassed as part of the automated filling of the 




Table 6-2 shows the control experiments necessary for each ligand examined. Each 
experiment was repeated in triplicate. DMSO and methanol are often chosen as the solvent 
for ligand stock solutions. It was important to match solvent concentration in the reaction 
cell, syringe and reference cell to reduce unnecessary solvent dependent effects on the heats 




Heats of reaction were determined by integration of heat of injection peaks and baseline 
corrected for heats of dilution. In most cases, it was possible to fit the heats of dilution to a 
linear model. This was then used to correct the data. This method meant that unnecessary 
noise was not added to the heat of formation of the complex. Integrated heat data was fit to a 








Information from experiment 
protein  ligand  enthalpy of  complex formation  combined with heats of dilution/mixing 
protein buffer heat of dilution of protein  
buffer ligand heat of dilution of ligand  
buffer buffer heat of mixing, possible buffer mismatches, poor cell rinsing 
 
Table 6-2 Typical control experiments for ITC  
 
Errors in analyte concentration 
Data analysis in ITC experiments is very sensitive to errors in analyte concentrations. The 
deviation of the “chemical” stoichiometry, N, from 1 (or a known real number) is an 
indication of the systematic error in the experiment. These errors tend to be dominated by 
errors in the protein and ligand concentrations. It is worth noting that fixing N to 1 does not 
lead to improvements in the estimation of ΔH and ΔS due to the correlation of the 
parameters and must be avoided (Tellinghuisen, 2003). Determining the concentration of the 
protein is described in section 2.3.2. The concentration of rapamycin was determined from 




 (Wear et al., 2007b). 
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6.3.3 Differential scanning calorimetry 
The temperature induced unfolding (denaturation) of a protein can be investigated by 
differential scanning calorimetry (DSC). The heat energy required to raise the temperature of 
a protein sample is compared to that required for a similar protein free solution in a reference 
cell. Most proteins are only marginally stable under physiological conditions. Heating, a 
solution of a folded protein, increases the internal energy of the molecule and leads to 
disruption of non-covalent bonds holding the amino acid chain in the folded state (Jelesarov 
and Bosshard, 1999). Investigation of the folding and unfolding pathways of FKBP12 
showed that wild-type protein folds and unfolds according to a two-state model (Egan et al., 
1993; Main et al., 1999). The protein also auto catalyses refolding after denaturation with 
urea (Scholz et al., 1996). 
 
The unfolding temperature is characteristic of the protein and is defined by the mid-point of 
the melting process, Tm, when 50 % of the molecules are denatured. This can be thought of 
as the point when the free energy of the folded and un-folded forms are equivalent (Munoz 
and Sanchez-Ruiz, 2004). The end point of the melting process is more difficult to determine 
as unfolded protein has a tendency to aggregate and precipitate. Tm is dependent on buffer 
composition, pH and the presence of bound ligand (Cooper, 1999a). Unfolding of proteins is 
generally an endothermic process; the enthalpy required to break non-covalent interactions is 
the dominant term. Conversely, aggregation of unfolded molecules can be an exothermic 
process and can lead to noise in high temperature data.  
 
DSC can be used as a screening technique for ligands. If a ligand preferentially binds to the 
folded or native form of a protein, the folded form of the protein is stabilised and Tm is 
increased, +ΔTm. If the ligand preferentially binds to the denatured form of the protein the 
protein is destabilised and Tm is reduced, -ΔTm (Brandts and Lin, 1990; Matulis et al., 2005; 
Cimmperman et al., 2008). A disadvantage of DSC as a screening technique is the relatively 
high consumption of protein; in the case of FKBP12 700 μl of 80 µM (0.7 mg) is required. 
This was an important consideration with regard to both protein production and ligand 
solubility. Many ligands tested had maximum solubility in the order of 300 µM. The meant 
that the maximum protein ligand screening ratio was reduced to around 1:4 for this 
technique. This limited the possibility of detecting medium to low affinity ligands. 
Moreover, the instrument available did not have the capacity to test more than one sample at 
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a time or automate sample change over. Each sample took around 2 hours. DSC experiments 
were carried out to determine Tm for FKBP12, but not to screen ligands. 
 
Materials and Methods 
Differential scanning calorimetry (DSC) was used to determine Tm from changes in the 
specific heat capacity of the protein system with respect to temperature, relative to a buffer 
control. 79.7 μM FKBP12 in 50 mM ammonium acetate at pH 7 was heated from 30 to 80 
o
C 
with an increment of 0.1 
o
C in a Nano differential scanning calorimeter (TA Instruments – 




The DSC thermogram is a plot of partial molar heat capacity at constant pressure (Cp) 
against temperature, Figure 6-4. The DSC thermogram takes the form of a bell-shaped curve; 
Tm is determined from the maximum value of Cp. The enthalpy of unfolding, ΔHu can be 
calculated from the area under the thermogram. ΔCpu, the specific heat capacity change on 
unfolding, can be calculated from the difference in partial molar heat capacity before and 
after the melting transition. The magnitude of ΔCpu is indicative of the relative increase in 
exposure of hydrophobic groups to solvent in the unfolded form of the protein. Data was 
processed using software supplied with the instrument and was normalised for protein 
concentration and corrected for buffer effects using a buffer baseline (CpCalc, TA 
Instruments). 
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6.3.4 Thermal denaturation fluorescence assay 
The thermal denaturation fluorescence assay (TDF) uses an environmentally sensitive 
fluorescent dye to follow temperature induced protein unfolding (denaturation). SYPRO 
orange (Invitrogen) was used to monitor the unfolding of a 50 μl of 10 μM FKBP12 (6 μg) in 
a 96-well format (Steinberg et al., 1996). This represented a reduction in protein 
consumption of around 100 fold when compared to DSC. This method relies on the quantum 
yield of the dye being different in a hydrophobic or aqueous environment. Hydrophobic 
residues are largely buried within a folded protein; exposure of these residues on 
denaturation changes the quantum yield of the SYPRO dye in the environment of the 
exposed hydrophobic groups. Use of a real time PCR machine facilitated the excitation (λex = 
490 nm) of SYPRO dye and the detection of changes in fluorescent emission (λem = 590 nm) 
with temperature in a tightly controlled heat cycle (Pantoliano et al., 2001; Epps et al., 2001; 
Lo et al., 2004). The TDF thermogram consists of a plot of fluorescent emission against 
absolute temperature. The midpoint melting temperature, Tm, can be estimated from the 
thermogram. As Tm is dependent on buffer stability, additives and pH, it was necessary to 
optimise conditions for screening. The aim was to choose a buffer system that had little pH 
dependence with temperature and control the use of additives that influenced Tm. As the 
background fluorescence of the SYPRO dye is influenced by the dielectric constant of the 
bulk solvent; it was important to control the % of solvent in all samples and use appropriate 
controls (Hawe et al., 2008). 
 
Materials and Methods 
Standard screening conditions were 10 μM FKBP12 in 50 mM ammonium acetate, pH 7, 
10x SYPRO on a 96-well PCR plate sealed with iCycler IQ
TM
 optical tape (Bio-Rad). 
Ligands were screened at a concentration of 250 μM (unless otherwise stated). The total 
analyte volume was 50 μl. The SYPRO concentration is relative to the stock solution 
supplied by the manufacturer at 5000x in DMSO (equivalent to ~ 0.2 % DMSO final 
analyte). Experiments were carried out on a Bio-Rad iCycler IQ
TM
 instrument with an iQ5 
Real Time Detection System (V2.0 software, Bio-Rad). Protein melting was examined 
between 20 
o
C and 80 
o
C, using 0.5 
o
C temperature increment and 30 s hold at each 
temperature. In all screening experiments controls were included to measure Tm for an 
inhibitor free well (negative control) and for a known inhibitor SD1 (Kd = 7 μM, positive 
control) under identical buffering conditions. The negative and positive controls were always 
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performed in at least triplicate. The fluorescence of each compound was also investigated 
using a protein free control.  
 
Estimating Tm by non-linear regression 
The midpoint melting temperature, Tm, the enthalpy of unfolding, ΔHu and the specific heat 
capacity of unfolding, ΔCpu were calculated by fitting fluorescent emission thermal 
denaturation data to equation 22 by non-linear regression using the program Kaleidagraph 
(V4.03, Synergy Software). This equation describes the melting curve for the two-state 
reversible thermal denaturation of a protein (Pantoliano et al., 2001). It is believed that the 
folding of FKBP12 is not unusual (Fulton et al., 1999). It is one of the largest globular 
proteins thought to undergo reversible two-stage unfolding. FKBP12 was confirmed as a 
monomer in solution in this study (section 2.3.4). Floating a large number of unreliably 
estimated parameters can make non-linear regression algorithms non-convergent. There is 
also correlation between ΔHu and ΔCpu in the fitting and it is necessary to constrain one if a 
reliable estimate of the other is required. To minimise problems, an initial value for ΔHu was 
entered from DSC data, ΔCpu was selected for typical low molecular weight globular 
proteins (Cooper, 2005). It was necessary to truncate data soon after the protein had reached 
its maximum fluorescence, this is standard practice for this method of analysis (Lo et al., 
2004). The decrease in fluorescence is probably due to a number of reasons, including; 









CH 1 1 T T
1 exp ln 1
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      Equation 22 
 
Where: F(T) is the fluorescent emission at a given temperature, T; F(fold) is the baseline fluorescent 
emission before the melting-transition; F(melt) the fluorescent emission after the transition; o
T
uH  
the enthalpy of unfolding of the protein without the presence of the ligand (initial value for fitting was 
entered from DSC data, 6.3.3), 0
T





), T the temperature for a specific fluorescent emission, Tm the mid-point melting 
temperature and R the universal gas constant. All temperatures were absolute temperatures in Kelvin. 
 
The experimental values for DSC and TDF are discussed in the TDF results section. 
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Estimating Tm from the thermal denaturation thermogram 
The mid-point melting temperature, Tm, can also be estimated from the gradient of the 
denaturation thermogram. The maximum value of the first derivative of the fluorescent 
emission with respect to temperature was found to be a good approximation to Tm derived by 
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Figure 6-1 Estimation of Tm from a protein denaturation thermogram 
(A) Typical raw fluorescent emission plotted as a function of absolute temperature. 10 μM FKBP12 in 
10 mM sodium phosphate, pH 7; 10x SYPRO orange. Curve is the best fit of data to equation 22 using 
the non-linear regression program Kaleidagraph (V4.03, Synergy software). o
T









 (B) First derivative of the fluorescent emission in (A) 
with respect to temperature, dF/dT, plotted as a function of absolute temperature. 
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Estimating ligand affinity from shift in Tm 
Tm was calculated with and without the presence of a ligand (Tm = T0 with no ligand present) 
and the apparent equilibrium dissociation constant (Kd) of the ligand estimated at the melting 
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K  is the apparent equilibrium dissociation constant for the ligand at the melting 
temperature Tm; To the melting temperature of the apo protein; 
oT
uH  the enthalpy of unfolding for 
the apo protein; 0
T
puC the heat capacity change on unfolding; mTL  the concentration of the free 
ligand and R the universal gas constant. 
 
Equation 23 makes the assumption that the concentration of the free ligand approximates to 
the total concentration of ligand, 
m mT Tfree total
L L , when the ratio of ligand to protein 
is high. 
 
It was possible to extrapolate the Kd of the ligand to an alternative temperature if 
thermodynamic data of the protein-ligand interaction was known from an ITC or SPR 
experiments. Knowledge of the enthalpy of binding of the ligand, ΔHL, allows an estimation 
of the effect of temperature on Kd, equation 24. ΔHL is only known if a detailed ITC or SPR 
study has been carried out. If this parameter was not available a bracketing approach was 













K is the is the apparent equilibrium dissociation constant for the ligand at temperature T; 
mdL T
K  is the apparent equilibrium dissociation constant for the ligand at the melting temperature 
Tm; T the temperature of interest; Tm the melting temperature with the presence of ligand and R the 
universal gas constant. 
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A better estimation is possible if the change in specific heat capacity on ligand binding, 




dL T dL T
m m m
H 1 1 C T T
K K exp ln 1
R T T R T T
   Equation 25 
 
Where: Variables are as defined for equation 22 and PLC  is the specific heat capacity change on 
ligand binding. 
 
The requirement of thermodynamic data to correct Kd for temperature is obviously a 
potential disadvantage for this method. A rank order of affinity can be creation at the protein 
melting temperature. The use of bracketing allowed the calculation of Kd at  
25 
o
C for a range of putative ΔHL. This approach was used in the screening experiments 
described in chapter 8. The Kd was extrapolated to 25 
o







 and equation 24. PLC was not 
included in the analysis unless known (stated in the text). Another consideration is that a 
+ΔT can indicate binding at any site on the protein surface and not necessarily the site of 
interest. 
 
The term apparent equilibrium dissociation constant, Ki, is particularly appropriate in the 
TDF studies. The magnitude of the equilibrium dissociation constant estimated by this 
method is conditional upon the % of DMSO and any pH change caused by addition of 
ligand. All experiments were carried out with a minimum concentration of 0.2 % DMSO.  
 
Screening the test set by TDF assay 
The TDF assay was used to screen members of the inhibitor test set to assess the threshold 
affinity of the assay. A ligand screening compound concentration of 300 μM was chosen and 
the experiment repeated 6 times (method was as described above). The Kd was calculated at 
the screening concentration using equation 24 and the bracketing technique described above. 
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6.3.5 Surface plasmon resonance  
Surface plasmon resonance (SPR) can be used to investigate the affinity of a ligand for a 
protein and provide kinetic information (Cooper, 2002; Navratilova et al., 2007). The SPR 
phenomenon allows for the indirect measurement of the proportion of protein in complex 
with a ligand in real-time. The sensor “chip” has two faces; a thin gold film backed by glass. 
Light is incident on the inner surface of the gold through the glass, analyte solutions are 
passed over the exposed gold surface. The exposed surface of the gold film is coated to 
enable protein to be immobilised by means of a coupling reaction. The choice of coupling 
chemistry is dependent on the protein under investigation. It is important that the coupling 
reaction does not lead to occlusion of the protein binding site and that the macromolecule 
retains its native affinity.  
 
Ligand/reference solutions are passed over the immobilised protein by means of a flow cell. 
When a light is incident on the gold film there is a resonance energy transfer between the 
incident light and free electrons in the metal. Energy transfer is dependent on the refractive 
index of the media in close proximity to the surface. Refractive index, a function of density, 
is dependent on ligand occupancy of the immobilised protein. If the reflected intensity is 
measured as a function of the reflected angle, the SPR effect manifests as a dip in the 
intensity of the reflected light at a specific angle, the resonant angle. Energy transfer is 
measured by changes in the reflected light and is output as response units (RU). Ligand 
passing over the immobilised protein binds, and attains equilibrium with the protein at a 
measurable rate. This rate can be correlated to the rate of association of the ligand with the 
protein. The rate of dissociation of the ligand can be determined by monitoring rate of 
reduction in the response units as a ligand free solution is passed over the complex. It is 
possible to calculate the affinity of the ligand from the magnitude of the steady-state 
response over a ligand concentration series. This was the method used in this study. It is 
usual to compare the SPR of the immobilised protein of interest with a surface prepared in an 
identical fashion minus the protein component, the reference surface. Identical fluids are 
passed over each surface during the experiment. 
 
FKBP12 was found to be inactive following coupling via primary amines (CM5 chip). 
Coupling via lysine amines was thought to lead to occlusion of the binding site. FKBP12 has 
been successfully coupled by Ni
2+
-nitrilotriacetic acid (NTA)/His-tag capture (NTA chip) 
and streptavidin-biotin-X-NTA (streptavidin chip, X is a 10-carbon spacer) in this laboratory 
 137 
(Wear and Walkinshaw, 2007).  The study by Wear describes how kinetics and affinity data 
were acquired for the FKBP12-rapamycin complex. Thermodynamic parameters are in 
agreement with ITC studies. 
 
Materials and Methods 
Data was collected for FKBP12 immobilised on an NTA chip on a Biacore T100 instrument 
(GE Healthcare). Protein was captured on the Ni
2+
-NTA surface followed by brief covalent 
stabilisation using the method described by Wear et al. (2007). This method has been shown 
to produce surfaces of between 65 and 90 % activity with minimal baseline drift. Ligand was 
passed over the chip at concentrations in the range 0 to 50 μM ligand (SD1, SD12, SD2 and 
SD3); 137 mM sodium chloride; 2.7 mM potassium chloridel; 0.005 % P20 surfactant;  
10 mM sodium phosphate, pH 7.3 at a flow rate of 30 μl∙min
-1
. The experiment was carried 
out at 25 
o




C intervals) for SD1. 
Experiments were repeated in triplicate. Data was corrected for bulk buffer effects by 
subtracting the response from the reference cell and the baseline was set to zero. 
 
Estimating affinity from steady state affinity data 
The steady-state response (Req) was plotted against the concentration of ligand. Data was 
fitted to a Langmuir 1:1 binding model, equation 26, using the software supplied with the 










    Equation 26 
 
Where: Req the response units after baseline correction at steady-state for a specific ligand 
concentration, Rmax the maximum response at protein saturation, Kd the equilibrium dissociation 
constant and [L] the concentration of the ligand. 
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Van’t Hoff analysis 
The van’t Hoff method was used to measure ΔH from the dependence of Kd on temperature, 






    Equation 27 
 
Where: Kd is the equilibrium dissociation constant, ΔH the enthalpy change on binding, ΔS the 
entropic change on binding, T the absolute temperature and R the universal gas constant. 
 
For data exhibiting a linear van’t Hoff relationship; the gradient of the graph is equal to 
H
R
and the intercept with the y-axis, 
S
R
. Curvature in the graph suggests that ΔH is 
temperature dependent (Naghibi et al., 1995). Including an additional term in the equation 
accounts for the specific heat capacity change on ligand binding at constant pressure, ΔCp, 
this is described by equation 28 (an integrated form of the van’t Hoff equation considering a 
reference temperature). 
 
Non- linear van’t Hoff  plot – including  ΔCp 
Equation 28 was fitted to non-linear van’t Hoff plots using least squares non-linear 
regression (Kaleidagraph V4. 03, Synergy Software). It is often difficult to detect non-
linearity in a van’t Hoff plot, due to uncertainty in the data, particularly at high temperatures, 
and the narrow temperature range explored in the experiments (Chaires, 1997). Equations 27 
and equations 28 were both fitted to data to determine the most appropriate methodology for 
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  Equation 28 
 
Where: variables and constants are those described for equation 27 at the reference temperature; ΔCp 
is the specific heat capacity change on ligand binding at constant pressure and  





6.4 Screening the ligand test set - results and discussion 
6.4.1 Peptidyl-prolyl isomerase assay 
Determining threshold affinity using the ligand test set 
Estimating the affinity of a ligand for FKBP12 using the PPIase method and fitting data to 
inhibition curve described by equation 20 was extremely low throughput; taking ~ 1 week 
per ligand. This was useful as a final characterisation step for a specific FKBP12-ligand 
complex, but too slow for use as a screening strategy for virtual hits.  
 
A single point assay was tested as a method to rank a ligand series by affinity. It was well 
known that there is considerable variability in PPIase results for identical solutions for the 
reasons described in the methods section. A threshold affinity was determined for the PPIase 
assay for the ligand test set at a compound screening concentration of 300 μM repeated 9 
times. This approach increased throughput to 3 compounds/day. Figure 6-2 shows the results 
for a single point assay of 300 μM ligand (SD1, SD2, SD12 and SD3) at 4 
o
C . FK506 (Kd = 
0.4 nM) was used as the positive control. Results are presented as the relative rate of 
turnover of substrate relative to the turnover of the enzyme under identical conditions with 
no inhibitor present. The positive control, FK506, gave 98 % inhibition at a concentration of 
0.5 μM. FK506 is not particularly soluble in aqueous buffer and could not be tested at the 
same concentration as the test set compounds. Inhibition was seen for compounds with Kd ≤ 
157 μM (SD3, 6 % inhibition), lower affinity ligands were not seen to inhibit the turnover of 
the enzyme at this screening ratio. Even with nine repeats the standard deviation in the % 
inhibition was ±10 %. Compound SD12 appeared above SD2 in the rank order by this 
method. However, the difference in mean rate of substrate turnover between the two ligands 
was in the same order as the standard deviation of 9 repeats. The ligands did not significantly 










































Figure 6-2 The ligand test set and PPIase inhibition  
Screening the ligand test set at a single concentration, error bars show standard errors (n=9). Rates 
were corrected for background turnover of the substrate at 4 
o
C. 100 nM FKBP12, 300 μM ligand 




 α-chymotrypsin, 120 μM Succ-Ala-Leu-Pro-Phe-p-
nitroaniline, 14 mM lithium chloride, 1 % methanol (v/v), 3 % 2,2,2-trifluoroethanol, PBS, pH 8,  
4 
o
C. FK506 was used as the positive control at 0.5 μM. Structures are shown for interest for the SD 
series of ligands. 
 
It is worth noting that this method is not tolerant of precipitation in the analyte. Even low 
levels of precipitate reduce the A400nm and can lead to false positives.  
6.4.2 Isothermal titration calorimetry 
Figure 6-3 shows representative ITC data for the FKBP12-SD1 complex. 300 μM SD1 was 
injected into 13.7 μM FKBP12 at 25 
o
C; 50 mM sodium chloride; 50 mM sodium phosphate, 
pH 6.8.  Heats of ligand dilution were relatively large for SD1. This was apparent in the raw 
data and was accounted for in the data analysis.  SD1 was the lowest affinity ligand in the 




















(0.4  nM, 
pos. cont.) 
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Figure 6-3 Determining Kd of the FKBP12-SD1 complex by SD1 
 (Top panel) Raw ITC data. 0. 3 mM SD1 was injected into 1.47 ml, 13.7 μM FKBP12 in 28 x 10 μl 
injections (0.5 μl 1st injection), 180 s apart at 25 
o
C. All reagents were dissolved in 50 mM sodium 
chloride; 50 mM sodium phosphate, pH 6.8. 
(Bottom panel) Integrated heat data was corrected for heat of ligand dilution and fit to a standard 1:1 
binding model, red curves (MicroCal Origin software, V4.0). The inset show the structure of SD1, the 
thermodynamic profile and the stoichiometry of the interaction, N. Results are in triplicate (black, 
green blue), standard errors are shown between repeats (over 3 days) rather than the error in the fit to 
the data. 
 
It is interesting to note that although the data shown for the 3 repeats appears to be very 
reproducible, fits the model well and gives a stoichiometry (N) close to 1, there was still a 
reasonable degree of uncertainty in the thermodynamic parameters. The uncertainty is 
calculated for repeats on three different days rather that the fit of the model to the data. 
These results are typical for ITC where ΔG is estimated with the greatest precision, followed 
by ΔH. TΔS has the highest uncertainty as it is calculated arithmetically from ΔG and ΔH 
(Holdgate, 2001).  For SD1, a relatively low affinity ligand, the curve of integrated heats 
plotted as a function of protein/ligand molar ratio is not sigmoid. Increasing the protein 
 
 
Kd = 6.8 ± 1.2 μM 
ΔG = -7.1 ± 0.1 kcal∙mol
-1
 
ΔH = -6.1± 0.6 kcal∙mol
-1 
TΔS = 1.0± 0.7 kcal∙mol
-1 

















concentration would address this issue to some degree and “steepen” the curve, although this 
would make the assay more protein hungry. Raising the concentration of the ligand is not 
possible because of solubility issues. These results indicate that the interaction between 
FKBP12 and SD1 is both enthalpically and entropically driven (this is discussed further in 
Chapter 4). 
 
Results for members of the test set are shown in the combined results Table 6-6. The lowest 
Kd detected with these screening conditions was 6.8 μM (SD1). Compounds SD12, SD2 and 
SD3 all showed measurable heats of dilution. Enthalpies of binding were too small and too 
linear to process at these analyte concentrations. The closest affinity ligand in the test set to 
SD1 is SD12 with a predicted Kd = 56 μM. ESI-MS suggests that this compound unfolds 
FKBP12 rather than forming a non-covalent interaction.  SD2, Kd = 95 μM is of much lower 
affinity than SD1. 
 
The activity of the protein was tested after 1.5 weeks storage in the ITC hotel (4 
o
C) and was 
found to be > 95 % of the starting activity by PPIase assay. FKBP12 was therefore 
considered to be a suitable protein for auto-ITC experiments over a long timescale. 
 
6.4.3 Differential scanning calorimetry 
The thermal denaturation of FKBP12 
FKBP12 is a single domain protein and the DSC thermogram showed a simple bell-shaped 
curve. Tm for FKBP12 was estimated to be 53 
o
C; Figure 6-4. The enthalpy of unfolding, 
ΔHu of FKBP12 was determined from the area under the DSC thermogram curve. Data was 
processed using software supplied with the instrument and was normalised for protein 
concentration and corrected for buffer effects using a buffer baseline (CpCalc, TA 
Instruments). Ammonium acetate showed good thermal stability at the temperatures 
employed. The pKa of ammonium acetate changes from 4.7 to 4.8 between 20 and 80 
o
C 
respectively (TA instruments data table). The unfolding of FKBP12 was an endothermic 
process with an enthalpy of unfolding, ΔHu = 42.7 kcal∙mol
-1
 and an associated entropic 




. The value for ΔHu is considerably lower than that obtained 
in the analysis of TDF data (ΔHu = 73.2 ± 2.3 kcal∙mol
-1
). Cooper gives a typical value for a 




) (Cooper, 1999b). The entropic change 













 calculated in the TDF 
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DSC was only available for a short time. It would be interesting to repeat these experiments.  
 
Addition of 2 % DMSO (286 mM) increased the melting temperature to 53.8 
o
C,  
ΔTm = 0.8 
o
C. This increased thermal stability of the protein was consistent with the findings 
that DMSO binds to the active site of FKBP12 with an affinity in the tens of millimolar 
range (Burkhard et al., 2000). 
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Figure 6-4 DSC thermogram of FKBP12 
DSC thermogram for 79.7 μM FKBP12 in 50 mM ammonium acetate, pH 7. The protein had a mid-
point melting temperature of 53 
o
C. Nano DSC (TA Instruments – Waters LLC). Data was normalised 
for protein concentration and corrected for buffer effects by using the buffer baseline.  Tm and the 
enthalpy and entropy of unfolding included on the figure. Dr Daphne Kan from TA Instruments 
assisted in processing the data. 
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6.4.4 Thermal denaturation fluorescence assay  
Optimising screening conditions for FKP12 
Figure 6-5 shows the influence of pH, protein and solvent concentration on Tm. Figure 6-5 
(A) shows that pH had a significant effect on Tm. All screening experiments were carried out 
at pH 7. These results are in agreement with experimental data from ESI-MS experiments 
where low pH was found to give a spectrum consistent with a denatured protein (section 
2.3.3). A reduction in Tm with more acidic conditions is typical for small globular proteins 
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Figure 6-5 Optimising screening conditions 
(A) Tm showed a correlation with pH. 18 μM FKBP12. (B) Tm does not show a dependence on protein 
concentration. However, the variance in Tm was correlated to protein concentration, PBS, pH 7. (C) 
Increasing the % of DMSO increased Tm. 18 μM FKBP12, 0 - 5 % DMSO, PBS, pH 7. (D) Low 
concentrations of methanol had no significant effect on Tm. 18 μM FKBP12, 0 - 5 % methanol, PBS, 
pH 7. Error bars are standard deviations for n = 3. “Straight line” curves are best fit to the data (y = 
mx + c); the curve shown on part (A) is to aid visualisation. 
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The estimation of Tm. was not dependent on protein concentration. The lack of correlation of 
Tm with concentration suggests that FKBP12 is not influencing folding/unfolding in its 
capacity as a peptidyl-prolyl isomerase, in this concentration range. Figure 6-5 (B) shows 
how the variance of 3 repeats reduced as the protein concentration was increased above  
5 μM. 10 μM FKBP12 was used in all screening experiments; this gave a large enough 
change in fluorescence between folded and unfolded states. Fitting data to thermograms gave 
smaller, more random residuals when the difference between the F(fold), the baseline 
fluorescent emission before the melting-transition, and the F(melt), the fluorescent emission 
after the transition, was greater than 1500 fluorescence units. Observations from within our 
group suggest there is inverse relationship between the molecular weight of the protein 
investigated and minimum molarity required for the protein in the analyte solution.  
 
Solvents were kept to a minimum by preparing solvent stock solutions of ligand at high 
concentration. DMSO was found to stabilise the protein at low concentrations, Figure 6-5 
(C). This is consistent with previous studies; where DMSO was found to inhibit the active 
site of FKBP12 with a Kd of  ~20 mM (Burkhard et al., 2000). Jackson et al. found that 
trifluoroethanol (3.6 - 9.6 % (v/v)) stabilised the native state of FKBP12 to urea-induced 
denaturation (Main et al., 1999). Methanol did not significantly influence Tm between 0 and 
5 %.  Compounds were routinely dissolved in methanol, unless obtained as stock solutions in 
DMSO. DMSO was incompatible with ESI-MS and was also avoided for this reason. 
 
SD1 as a positive control for FKBP12 
Compound SD1, Kd = 6.8 μM, was used as a positive control in thermal denaturation 
experiments at a concentration of 250 μM. SD1 binds to FKBP12 with 1:1 stoichiometry and 
competes with a preferred substrate for the active site of the enzyme. The ligand is soluble to 











Figure 6-6 TDF FKBP12-SD1 
(A) Typical raw TDF data. Melting curves are shown for 10 μM FKBP12 at 0 (black), 100 (green), 
200 (blue) and 400 μM (red) SD1 respectively, 50 mM ammonium acetate, pH 7; 10x SYPRO, 1% 
methanol. Thermal denaturation occurs  between 30 and 60 
o
C. The decrease in fluorescence after 
melting is thought to be due to aggregation/thermal bleaching. (B) –dF/dT for graph (A). The melting 
temperature Tm increases with increasing concentration of ligand. Tm is labelled for SD1 between 0 
and 400 μM. 
(A) Raw TDF data: FKBP12-SD1  
0 μM SD1 
100 μM SD1 
200 μM SD1 
400 μM SD1 
Thermal denaturation Aggregation/thermal bleaching 
of SYPRO? 
400 μM Tm 
(B) - dF/dT: FKBP12-SD1  
unfolding 
finished 
0 μM Tm 
100 μM Tm 
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Figure 6-7 SD1 as a positive control  
Tm as a function of the concentration of SD1; error bars show standard deviations for results in 
triplicate. 10 μM FKBP12 at 0, 100, 200 and 400 μM SD1 respectively, 50 mM ammonium acetate, 
pH 7.0; 10x SYPRO, 1% methanol. 
 
 
Kd estimated by thermal denaturation fluorescence were similar to values obtained from ITC 
(section 6.4.2), Table 6-3. The value quoted has been extrapolated to 25 
o
C using equation 25 
as thermodynamic parameters are known for the FKBP12-SD1 complex (ITC 6.4.2, SPR 
6.4.5). Data for DMSO is included in the table for interest. For this compound the data has 
been extrapolated to 25 
o
C using thermodynamic data estimated from buried surface area 
calculated from x-ray crystallographic data (Burkhard et al., 2000). Buried surface area = 
41.7 Å
2






 (Wear et al., 2007a) 








 (Connelly and Thomson, 1992). For these reasons the 
result for DMSO must be treated with some caution. However, it is in general agreement 











SD1 7.2±2.6 6.8±1.2 29.8±0.8 
DMSO 37000±14000 - 49000±19000 
 
Table 6-3 Comparison of Kd estimated by TDF with other biophysical techniques 
Table shows Kd calculated from TDF, ITC and SPR assays. Standard deviations are shown for at least 
n=3 (Affinity measured by TDF has been transformed to 25 
o
C using equation 25 (For SD1 ΔHL(ITC) = 
-6.09 kcal∙mol
-1




. For DMSO ΔHL(calc) = -7.09 kcal∙mol
-1







Influence of inhibitor on pre-transition fluorescence, F(fold) 
FKBP12 has large shallow hydrophobic pocket, containing many aromatic residues. This 
forms the binding site for the immunosuppressants FK506 and rapamycin, and proline in 
peptide substrates. It is interesting to note that F(fold) is reduced on addition of an inhibitor 
in a dose dependent manner, to a value close to zero at saturation (Figure 6-7).. The data can 
be rationalised by SYPRO orange having an increased quantum yield in the environment of 
the active site. The presence of an inhibitor in the active site, with a higher affinity to 
FKBP12 than that of SYPRO, displaced SYPRO into the bulk solvent and fluorescence 
decreased. SYPRO orange has a commercially sensitive structure and MW; it was not 
possible to quantify binding. Similar effects were obtained in a series of experiments using 
the environmentally sensitive dye 1-anilinonaphthalene-8-sulfonate (ANS), (Cardamone and 
Puri, 1992). It was not possible to reach saturation when ANS was titrated with FKBP12 
(results not presented).  
 
Determining threshold affinity using the ligand test set 
Figure 6-8 shows ΔTm for a screen of the ligand test set: 300 μM ligand (SD1, SD2, SD12 
and SD3), 2 μM ligand (rapamycin and FK506), pH 7, repeated 6 times. The bar graphs were 
divided into (A) and (B) to distinguish the nanomolar affinity ligand (rapamycin and FK506) 
protein/ligand screening ratio (0.2) from the micromolar affinity ligand (SD1, SD12, SD2 
and SD3) screening ratio (25). Experiments were carried out with the same batch of protein 
on the same 96-well plate. The same negative control is shown on both bar charts labelled 
protein mean. The ligand test set was particularly useful for this assay as the compounds are 
not fluorescent at the excitation/emission wavelengths of SYPRO orange. 
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FK506 and rapamycin are only soluble to 2 μM in aqueous buffer. At this protein/ligand 
ratio (0.2), ΔTm was small compared to the standard error (n = 6) and was felt to be too small 
to use these compounds as a positive control. Rapamycin appears to stabilise FKBP12 more 
than FK506, although the difference is small compared to the standard error and cannot be 
considered significant. The estimated Kd for rapamycin were 80 ± 40 nM and 130 ± 40 nM 
respectively when extrapolated to 25 
o
C ,Table 6-4. These estimates are over a factor of 10 
higher than published Kd. This in part due to the estimation of Kd from the model described 
in equation 22. This model is only a good approximation if 
m mT Tfree total
L L ; this is 
not the case for FK506 and rapamycin.  
 
In the micromolar affinity group, shown in Figure 6-8 (B), the assay discriminated between 
SD1 (Kd = 7 μM), the only low micromolar affinity ligand and the other members of the 
group; SD12 (Kd = 56 μM), SD2 (Kd = 95 μM) and SD3 (Kd = 157 μM). SD1 gave a ΔTm = 
4.7 ± 0.6 
o
C at 300 μM. SD3 showed the second largest ΔTm in this set, leading to an over 
estimation of Kd, Table 6-4. SD3 was not confirmed as an inhibitor by ITC and appeared as 
only a weak inhibitor in the PPIase assay. Interestingly SD12 produced a positive ΔTm, this 
is usually interpreted as a compound preferentially binding to the folded form of the protein 
(Cimmperman et al., 2008). The ligand can of course bind to different conformations present 
in the assembly with varying affinity. The melting curve only shows the global change in 
fluorescence. ESI-MS showed that SD12 appeared to destabilise FKBP12 in a time-
dependent manner and give a spectrum consistent with an unfolded protein. There was no 
evidence in ESI-MS that SD12 bound to the unfolded or folded form.  
 
SD1 was chosen as the positive control for the TDF assay due to its good solubility and the 
large ΔTm at the screening concentration (250 μM). Extrapolating to 25 
o
C requires an 
estimation of the enthalpy of binding of the compound. The enthalpy of SD1, ΔH = -6 kcal 
mol
-1
, this was thought to be more representative of the small molecule inhibitors from the 






















































Figure 6-8 TDF for the ligand test set 
The bar graphs show the shift in melting temperature for the ligand test set at a single concentration. 
10 μM FKBP12, 50 mM ammonium acetate, pH 7; 1 % methanol (v/v). (A) 2 μM (rapamycin, 





2 μM ligand 
300 μM ligand 
(0.2 nM) (0.4 nM) 
 (7 μM)  (56 μM)  (95 μM) (157 μM) 
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rapa. 1.2±0.6 0.08±0.05 0.9 0.6 0.5 0.0005ITC -16.4 -0.30 (Connelly and 
Thomson, 1992) 
FK506 1.3±0.6 0.13±0.04 1.0 0.7 0.5 0.001ITC -14.2 -0.26 (Connelly and 
Thomson, 1992) 
SD1 50±28 4.42±3.48 37.2 23.7 17.5 6.8ITC -6.09 -0.71 EAB, section 6.4.2 
SD12 133±68 - 101.3 66.8 50.7 56nmr - - (Stebbins et al., 
2007) 
SD2 151±93 - 115.2 76.4 58.1 95nmr - - (Stebbins et al., 
2007) 
SD3 103±49 - 78.0 51.0 38.4 15 7nmr - - (Stebbins et al., 
2007) 
 
Table 6-4 Estimating Kd(app) from TDF results 
The Kd for the ligand complex was estimated at Tm (equation 23); 
oT









. If thermodynamic information was available Kd was extrapolated to 25 
o
C 
(equation 25). For screening, when thermodynamic parameters were not available, Kd were calculated 








 (results in italics).  
Standard errors are for values on separate days/plates.  
  
Table 6-4 illustrates how the extrapolation of Kd at Tm to 25 
o
C is influenced by 
LH and pLC . For compound SD1, where thermodynamic parameters had been recently 
measured and the constraints of the biophysical model are met, TDF gives a good estimation 
of affinity. This was also true for compound KB2_61D (7 μM screening hit) and is discussed 
in Chapter 8. Use of Kd at Tm (~ 55 
o
C) and a single point assay is probably sufficient to 
distinguish nanomolar (rapamycin, FK506), low micromolar (SD1, KB2_61D) and medium 
micromolar affinity ligands (SD12, SD2, SD3). For the nanomolar ligands the three putative 
binding enthalpies are much smaller than those measured by ITC and extrapolations using 




The assay in this form provides a medium through-put screen. It would be possible to screen 
96 compounds and controls (positive/negative and controls for screening compound 
fluorescence) in 12 hours.  
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[FKBP12] = 10 M
[ligand] = 250 M
 
 
Figure 6-9 Uncertainty in estimated Kd is correlated to both estimated binding enthalpy and the 
magnitude of ΔTm 
The effect of using an incorrect binding enthalpy is more pronounced for lower affinity ligands, 
showing small ΔTm. The figure shows the effect of extrapolating raw TDF data (black curve) for a 
series of putative enthalpies (dashed curves: -2 to -10 kcal∙mol
-1
) to 25 
o
C. The extrapolation was 
simulated using the model described by equation 24; as would be the case for a screening experiment. 
This model does not consider a temperature dependence on enthalpy. Considering ΔCp would further 
increase the uncertainty in the estimation for Kd. The blue and green bars define areas of uncertainty 
for ΔTm = 2 ± 0.5 
o
C and 8 ± 0.5 
o
C respectively for enthalpy variable between -2 and -10 kcal∙mol
-1
. 
The red star represents the extrapolation of the raw estimate of Kd from the mid-point melting 
temperature to 25 
o
C for SD1, the positive control for the TDF experiments. The simulation considers 
[FKBP12] = 10 μM and [ligand] = 250 μM. 
 
The effect of using an incorrect binding enthalpy in the extrapolation to 25 
o
C must be 
viewed in the context of the experimental error in Tm (~ 0.5 
o
C) and the magnitude of ΔTm , 
Figure 6-9. Low affinity ligands have a small value of ΔTm compared to high affinity ligands 
for a given screening ratio. Due to the non-linear nature of the relationship between ΔTm and 
SD1, + control 
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Kd it is clear that that ranking compounds with small shifts in the melting temperature is 
open to considerable uncertainty even without considering the possibility that the ligand has 
some degree of affinity for partially folded forms of the protein or competition with solvents 
present in the buffer.  
 
The inherent uncertainty associated with small ΔTm could be addressed by increasing the 
ratio of ligand to protein. However, ligand solubility prevents this as a general solution. In 
this study the TDF assay was used as a first screen to group compounds into activity bands. 
It can be seen from Figure 6-9 that if ΔTm > 4 
o
C it is likely to equate to a ligand with Kd < 
50 μM and for ΔTm >  2 
o




6.4.5 Surface plasmon resonance 
SD1 was the lowest affinity ligand that was reliably detectable from the ligand test set. 
Figure 6-10 SPR data for FKBP12 and SD1. Figure 6-10 (A) shows very fast association and 




) for SD1 at 25 
o
C at all ligand concentrations. The 







































































 = 29.8 +/- 0.8 M, 25 
o
C




























Figure 6-10 SPR FKBP12-SD1 
(A) Representative SPR sensorgram showing response units for FKBP12 and SD1 from 0 to 50 μM at 
25 
o
C. SD1 has a high association constant and a steady state was reached within the timescale of the 
experiment (shaded area). (B) Response units plotted against [SD1]M for representative data at 25 
o
C. 
Curve is the least-squared fit to the Langmuir model for 1:1, equation 26. (C) Kd determined from a 
1:1 binding model, 10 to 40 
o
C (283 to 313 K , n = 3, standard errors, curve is added to aid 
visualisation. (D) Van’t Hoff analysis of SPR data. Data was fit to equation 27 (straight line), the 
curved fit is the non-linear least squares fit to equation 28 that considers an enthalpic change with T 






It was not possible to derive kinetic data from the sensorgrams. The fast association rates at 
the high ligand concentrations meant that steady-state response levels were used for 
evaluating the affinity of the interaction, Figure 6-10 (B). Rmax is not large for this system, ~ 
13 RU. For comparison, 1.28 μM rapamycin (0.2 nM, 914 Da) gave Rmax ~ 25 RU 
(saturating concentration). SD1 has affinity in the low micromolar range (6.8±1.2 μM, 25 
o
C, 
ITC) and a small mass, MW = 251.1 Da. Figure 6-10 (C) shows how Kd was varied with 
temperature; 10 to 40 
o
C in 5 
o
C intervals. There was a rapid dependence of Kd on T above 
298 K (25 
o
C), there was also more variability in the data above this temperature.  
 











 -14.5±1.5 -8.5±1.5 - 
Non-linear van’t Hoff
b




 equation 28 
Table 6-5 van’t Hoff analysis – SPR data FKBP12-SD1 
SPR data from 10 to 40 
o
C was fit to a linear van’t Hoff model (
a 
equation 27) and a non-linear model 
(
b
 equation 28) to examine the temperature dependence of the enthalpic change on ligand binding. 
Points plotted are mean values for n = 3, errors are from the fitting program.  
 
  
Van’t Hoff analysis was carried on the data first using a model where there was no 
dependence of the enthalpy of binding, ΔH, on temperature, equation 27. Non-linear van’t 
Hoff analysis was also carried out considering temperature dependence for ΔH. Data was fit 
to equation 28 using least squares non-linear regression (Kaleidagraph V4. 03, Synergy 
Software). Due to the small temperature range and the considerable variability of the data 
above 300 K it is probably not sensible to put too much weight on the dissection of the free 
energy change into enthalpic and entropic components, Table 6-5. ITC predicted a small 
positive entropic contribution to binding at 25 
o
C (6.4.2). The modelling studies on SD1 in 
complex with FKBP12 (4.4.3) would suggest that the large negative ΔH on ligand binding as 
predicted by the van’t Hoff analysis of the SPR data is unlikely, due to the small size of the 
ligand, limiting the possibility of van der Waals, contacts and the single putative hydrogen 
bond. The large negative ΔS is also unlikely as SD1 is a relatively hydrophobic molecule. It 
is thought that there is a favourable entropic change when two ordered waters are displaced 
from hydrogen bonding interaction with Tyr82 of FKBP12 (Connelly et al., 1993; Burkhard 
et al., 2000). The model described in 4.4.3 predicts a hydrogen bond between the carbonyl 
oxygen of SD1 and Tyr82 replacing the hydrogen bonds with water. A negative value for 
ΔCp can be indicative of a hydrophobic interaction (Homans, 2007).This model gave a 




. A large negative value 
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for ΔCp is more indicative of a hydrophobic interaction than the relative contributions of ΔH 
and ΔS to ΔG from van’t Hoff analysis. When this value is used to extrapolate TDF data 
from Tm to 25 
o
C (6.4.4); calculated affinities are close to values measured by ITC for SD1. 
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% in complex  
 (8+) cV = 15 V 
Literature 
 Kd (μM) 
Reference 




1 97.6±0.9 1 0.0002radio 
to 0.008ITC 
(Bierer et al., 
1990; Connelly 
and Thomson, 
1992; Wear and 
Walkinshaw, 
2007) 
FK506 97.8±8.5  2 - 2 1.3±0.6 
 




KB2_61D 90.8 ±18.0  3 6.6±0.7 v 3 18±3.5 3 74.5±9.5 3  section 
SD1 69.7±9.3  4 6.8±1.2 w 4 50±28 
 
4 32.3±15.2 4 ~9NMR (Stebbins et al., 
2007) 
SD12 27.2 ±9.7  6 - - 133±68 
 
6 protein unfolds  - 56NMR (Stebbins et al., 
2007) 
SD2 40.8±9.9  5 - - 151±93 7 18.7±4.0 5 95NMR (Stebbins et al., 
2007) 
SD3 5.7±13.2  7 - - 103±49 5 12.3±7.7 6 157NMR (Stebbins et al., 
2007) 
SD4 - - - - - - No complex - 221NMR (Stebbins et al., 
2007) 
SD5 - - - - - - No complex - 270NMR (Stebbins et al., 
2007) 
Key:   - experiment performed, no affinity data 
 a data kindly provided by Dr. Martin Wear (Edinburgh University). 
Table 6-6 Biochemical and biophysical characterisation studies - screening the ligand test set 
The ligand test set provided a useful series of compounds to compare screening assays. The results 
presented in the table are for screening at a single ligand concentration for the PPIase, TDF and ESI-
MS assays. ITC data is included as a benchmark affinity measurement. Standard errors are shown for 
n=3 for all assays except the PPIase assay where n=9. The rank order is shown to the right of the 
affinity data. The solid red bar indicates the threshold affinity for the technique. Note assay 
protein/ligand screening ratios are similar but not identical in the different assays. The maximum 
ligand concentration for screening in PPIase, ITC and TDF is limited by solubility. High ligand 
concentrations are generally desirable for these assays to improve signal to noise ratio. For the ESI-
MS assay ligand concentration is also limited by solubility but less so due to the methanol added to 
the analyte to improve desolvation. However, a high ligand concentration can lead to suppression of 
the protein signal and reduce signal to noise ratios for the species of interest or produce false positive 





chymotrypsin, 120 μM Succ-Ala-Leu-Pro-Phe-p-nitroaniline, 14 mM LiCl, 1 % methanol (v/v), 3 % 




 ITC: (FKBP12-rapamycin): 34.9 μM FKBP12 




 ITC: (FKBP12-KB2_61D): 15 μM FKBP12 (cell), 300 μM KB2_61D (syringe), 50 mM sodium 




 ITC: (FKBP12-SD1): 13.74 μM FKBP12 (cell), 
300 μM SD1 (syringe), 50 mM sodium phosphate, 50 mM sodium chloride, pH 7, 25 
o
C. TDF: 10  
μM FKBP12, 300 μM ligand, 10x SYPRO, 50 mM ammonium acetate, 0.2 % DMSO
final
 , 1 % 
methanol
final
. ESI-MS: 10 μM FKBP12, 100 μM ligand, 19 mM ammonium acetate, pH 6.8.  
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Screening results need to be considered in the context of the time for the assay, reagent 
consumption and cost. This information is presented in Table 6-7. For the purposes of 























9 Coupled assay  
(100 nM FKBP12, 
120 µM substrate) 









iQ5 real time 
detection)  
3 10 μM FKBP12 
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3 15 μM FKBP12 




0.5 mg 12 weeks 6.8 
 
 
Table 6-7 Comparison of Biochemical and Biophysical screening techniques – reagent 
consumption and timing 
The table summarises the general screening conditions and the protein consumption and time to assay 
96 compounds. The ligand consumption is calculated per ligand, a typical MW of 350 Da was chosen 
for the calculation. The use of standard controls has been included and repeats as detailed for each 
assay. 
w
 indicates that the assay is not automated for a 96 plate and can only be carried out over the 





6.5  Discussion and conclusions  
Choice of screening approach required balancing throughput, sensitivity and the richness of 
thermodynamic data. A general comparison of advantages and disadvantages of each method 
are listed in Table 6-8. It is useful to consider these in tandem with Table 6-7 which details 
assay times, reagent consumption and results for the ligand test set. It is clear that no one 
method can provide all the information required within in a reasonable time scale or cost. 
Each method delivers an apparent Kd that must be considered with the inherent assumptions 
made in the model and the possibility of false positives. Compounds from the ligand test set 
were used to compare different methods and lead to screening strategy that could be used to 





Figure 6-11 Screening strategy 
 
The strategy divides the assays into 3 tiers based on throughput and information. TDF and 
SPR provide the highest throughput assays (~2 days for 96 compounds). TDF was chosen as 
the first step due to the considerably lower cost of consumables and the increased sensitivity 
for low affinity ligands in the protocols tested. ESI-MS and SPR form the second tier in the 
























4  Rank compounds by affinity 
 Determines specificity for the active 
site 
 
 Low throughput: ~3 compounds/day, many 
repeats required 
 Coloured  and fluorescent compounds a problem 
 Coupled assay 
 Manual dexterity needed 





iQ5 real time 
detection)  
~55  Rank compounds by affinity 
 High throughput (parellised) 
 Low DMSO concentrations can be 
accounted for 
 Automated data capture 
 Ligand solubility a problem 
 Coloured  and fluorescent compounds a problem 
 Extrapolating Kd to 25 
oC requires knowledge of 






 Rank compounds by affinity 
 Monitors protein 
folding/contamination 
 Confirms mass of protein/ligand  
 Fluorescent and coloured compounds 
ok 
 10 % methanol in analyte aids 
compound solubility 
 Possibility of compound mixtures 
 Does ESI-MS estimate ΔH not ΔG? 
 No DMSO 
 Are hydrophobic ligands poorly represented in 
ranked lists? 





4-45  Rank compounds by affinity 
 High throughput 
 Kinetic data 
 Automated data capture 
 Low reagent consumption 
 Expensive chips 
 Solvents can cause noise in data 
 No real parallisation on T100 





2-80  Highest quality thermodynamic data, 
direct measurement of ΔH 
 Dissection of ΔH and ΔS from ΔG in a 
single experiment   
 Automated data capture 
 Low throughput: ~6 compounds/day 
 Fitting v. sensitive to reagent concentration  
 Correction for heats of dilution 
 Reagent consumption 
 High capital outlay for instrument 
 
Table 6-8 Comparison of Biochemical and Biophysical screening techniques – general 
considerations. 
The table summarises the advantages and disadvantages for each assay for screening a single ligand 
concentration against FKBP12. The temperature range of each instrument is also included. In the case 
of ESI-MS, temperature can be increased and decreased but values are hard to quantify.   
 
Estimating Kd from TDF is limited by the need to extrapolate data to 25 
o
C using ΔHL and 
ΔCp. Information that is not available before a detailed ITC study. The enthalpic contribution 
to binding can be quite variable for structurally diverse ligands of similar size. This means 
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that the ranking position of a ligand at the protein melting temperature can be quite different 
from that at 25 
o
C. This study suggests that the best approach is to use TDF to select a subset 
of the virtual screening hits to be tested by the other methods. A cut-off ΔTm of ~2 
o
C should 
pick up ligands of Kd < 150 μM. Chapter 4 describes how ESI-MS can be used to dissect the 
enthalpic contribution to binding. SPR has the potential to be carried out at different 
temperatures and also to provide kinetic information. ESI-MS and SPR can provide richer 
information for a SAR study than TDF. In addition, these methods provide information on 
the stoichiometry of the interaction. Useful information, particularly in fragment screens 
where ligands might be non-specifically “sticky”.  
 
The throughput of the PPIase assay was not high enough for the assay to be selected as the 
first stage in a medium throughput screening strategy. This was in part due to the need for a 
high number of repeats to gain a meaningful rank of ligand by affinity. The principle benefit 
of the technique is that it confirms specificity for the active site of FKBP12 by a biochemical 
method. We would propose that it is used as an element of the final tier of screening, 
alongside ITC. 
 
ITC measures the enthalpy of complex formation. Most other techniques rely upon 
calculation of Kd from the measurement of a correlated physical parameter by use of a model 
with varying degrees of complexity. The rich thermodynamic data needs to be taken in the 
context of the greater demand for protein and ligand and a longer experimental time. The 
experiments designed to increase the throughput of ITC by reducing the c-value of the 
experiment were disappointing. The method performed well for ligands with a Kd < 10 μM 
but failed to pick up the low affinity ligands. In the screening strategy proposed, ITC is 
placed in the final tier providing “gold standard” thermodynamic information. 
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7 Chapter 7 Screening for Inhibitors of FKBP12  
7.1 Introduction  
Compounds from four libraries were screened against FKBP12; EDULISS 2  
(3.8 M unique compounds from commercial and academic sources (Hsin, 2009) ; a subset of 
the Specs catalogue (15000 compounds. www.specs.net; Jan 2009); a fragment library (96 
compounds selected from The Maybridge Ro3 collection, UK) and the KB series (a library 
designed to target immunophilins). 
 
Figure 7-1 Screening space 
Compounds followed two paths to “wet” laboratory testing: from virtual collections via screening 
programs and from two in-house “real” compound collections. The “drum” library icons are labelled 
with the number of compounds in the library. The horizontal arrows link to the structural data input. 
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Figure 7-1 shows an overview of the path of compounds from a library through screening 
techniques from virtual to experimental. It is useful to make a distinction between the virtual 
libraries and the “real” in-house compound collections. Screening assays are discussed in 
detail in Chapter 6. 
 
The large libraries of virtual compounds were initially screened with in silico or virtual 
screening approaches. The aim was to score the compounds in such a way that the highest 
ranking compounds in a list had a higher percentage of active compounds than a random 
selection. The final number selected was dependent on both the cost of compounds and the 
throughput/cost of the assay. Compounds from the virtual libraries were all passed through 
filters to select for drug-likeness and one or more virtual screening programs. The virtual 
screening strategies all had an input of structural data specific to the protein target. Each 
method took the structural information in a different form and then applied it in a unique 
way. The virtual screening methods are described in more detail in the following sections. 
UFSRAT (Steven Shave, Edinburgh University) and the Bayesian clustering algorithm 
(Angelopoulos et al., 2009) are ligand based methods. LIDAEUS (Wu et al., 2003) and 
FlexX (Rarey et al., 1996) are well established macromolecular docking programs that use 
protein and ligand structure to make binding energy predictions.  
 
UFSRAT compared the 3D-structure and electrostatic properties of a library compound to a 
ligand of known activity and gave it a score based on similarity. The Bayesian clustering 
algorithm used physicochemical/structural descriptors and experimental activity data from a 
training set (known actives and inactives of FKBP12) to assign an activity probability for a 
specific library compound. The docking programs LIDAEUS and FlexX used an x-ray 
structure of FKBP12 to predict the enthalpy of binding of a putative ligand.  
 
The selection of the in-house compounds collections were also guided by structural 
considerations. However, the principles of compound selection were very different. The 
fragment library was not specifically designed to target FKBP12. The aim was find novel 
scaffolds (chemotypes) that bound to FKBP12 (Schuffenhauer et al., 2006; Ertl et al., 2006). 
The fragment based approach to drug design has two central tenets. Firstly, that is more 
efficient to probe chemical space by using fragment-like compounds. Secondly, that the free-
energy contribution to binding per atom, the ligand efficiency, is greater for a weakly 
binding fragment than for the larger molecule typically seen in a HT-screen (Kuntz et al., 
1999; Hesterkamp and Whittaker, 2008). It is implicit that low affinity fragments are more 
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tractable to lead optimisation than low affinity larger molecules (Ciulli and Abell, 2007; 
Reynolds et al., 2008). In contrast, the KB series of compounds was designed and 
synthesised by Dr. Kevin Bailey as a library to specifically target two structurally different 
immunophilins; FKBP12 and human cyclophilin A (section 1.11.1 describes the 
immunophilin proteins). Structure activity relationships were derived from a literature 
review of known FKBP12 and cyclophilin inhibitors, section 1.11.6.  This method was not 
designed to select novel scaffolds but to further the understanding of these enzymes. 
7.2 LIDAEUS 
7.2.1 Ligands discovered using the program LIDAEUS 
The bulk of virtual screening employed Edinburgh University’s in-house docking program 
LIDAEUS (LIgand Design At Edinburgh University). LIDAEUS has found novel inhibitors 
for 3 protein targets: cyclin dependent kinase 2 (CDK2), polo-like kinase (PLK1) and 
cyclophilin A (hcypA). The best in series compound inhibiting CDK2 was CYC3, with an 
IC50 of 2.2 μΜ (Wu et al., 2003). Cyclapolin 9 binds in the ATP-binding site of Polo-like 
kinase (PLK1) with an IC50 of 20 nM (McInnes et al., 2006). The inhibitor series for hcypA 
are interesting because they are built upon the small fragment-like molecule dimedone (Yang 
et al., 2007). Dimedone was picked up as hit in a virtual screen and subsequently crystallised 
in complex with hcypA. SANDOCK, a precursor to the program LIDAEUS written by the 
same principle authors (Taylor and Walkinshaw), discovered a diverse set of ligands for the 
protein FKBP12 (Burkhard et al., 1999).  The structure of the steroid found to bind to 
FKBP12 is shown in Table 1-4. 
7.2.2 Docking and scoring using the LIDAEUS pipeline  
Docking using the program LIDAEUS is divided into a series of discrete steps or modules. 




Figure 7-2 The LIDAEUS docking pipeline 
 
7.2.3 Site-point generation with MAPGEN 
LIDAEUS uses high quality crystallolographic data, of a protein in complex with a ligand, to 
generate a 3D cubic grid of site-points in the binding pocket of the target protein. The 
binding pocket is defined by inputting the coordinates of a molecule in the active site of the 
protein in the form of a SDF file. This molecule is used as series of reference points to define 
the dimensions and placement of the grid; it need have no physiological relevance and it is 
possible to define the volume around the ligand to explore (for example, 4 Å beyond ligand 
coordinates). The program MAPGEN was used to generate a set of energy maps to guide the 
program in the assignment of the classification (type) of site-points to the each position in 
the grid and to score ligand poses. Site-points are classified hydrogen-bond donor (blue in 
visualisations), hydrogen-bond acceptor (red) and hydrophobic (white). Energy maps are 
calculated that describe hydrophobic, extremely hydrophobic, hydrogen bond donor and 
hydrogen bond acceptor potentials for each grid point. Each grid point may have only one 
type of site-point assigned. There is a user definable energy cut-off value for the minimum 
energy required to assign a site-point to a particular type (colour). If a more than one site-
point criterion is met the potential energy for each map is compared and a series of rules 
used to assign the colour of the site-point.  
 
Library of virtual compounds 
3D SDF files 
PREEN 
POSE 
Assigns atom types and adds H-atoms  
LIDAEUS PIPELINE 
SCORE 
Ligand atoms of the correct atom type are 
fitted to site-points to generate poses 
Poses are scored against energy maps 
SORT Poses are ranked by score 
MAPGEN  
OUTPUT 3D SDF file of scored and ranked poses 
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The site points generated for FKBP12 were clustered in regions of the binding pocket where 
non-covalent interactions were most likely. For example in the FKBP12 binding pocket there 
were hydrophobic site-points assigned near the Trp59 residue that forms the base of the 
pocket (Figure 1-5 and Figure 7-3). Similarly, hydrogen bond acceptor site-points were 
assigned near the main chain N of Ile56 that donates an H atom in an H-bond interaction 
with rapamycin (ligand atoms that act as H-bond acceptors are docked onto acceptor site-
points). 
 
    
 
Figure 7-3 Site-points for FKBP12 
(A) Shows site points in the active site of FKBP12. Blue: hydrogen bond donor (HBD); Red: 
hydrogen bond acceptor (HBA); white: hydrophobic. A Connelly surface has been added to FKBP12 
to aid visualisation of the active site using the program PyMOL (V1.0r2, DeLano Scientific). (B) The 
structure of rapamycin in complex with FKBP12 in the same frame of reference as the site-points. 
 
7.2.4 PREEN 
The PREEN module assigns atom types and charges to each atom of the molecules (ligands) 
to be docked, using the coordinates and connectivity information in the input SDF file. For 
example a sp3 hybridised carbon atom is distinguished from a sp2 and an atom that can act 
as a hydrogen bond donor from one that can act as a hydrogen bond acceptor. This is 
necessary for fitting atoms of the correct type onto site-points during posing of the ligands in 
the active site. Hydrogen atoms are added to the SDF file.  
 
(A) (B) HBA (red) site-points are 
key to successful docking 
White hydrophobic 
site-points   






POSE geometrically matches pairs of ligand atoms to pairs of site points to generate poses. 
The user may define what types of atoms are fitted to a particular type of site-point. For 
example, under standard operating parameters ligand atoms that act as H-bond acceptors are 
docked onto acceptor site-points and atoms that act as donors onto donor site-points. The 
user may also define the number of matches between ligand atoms and site points. The 
greater the number of matches the longer the run time and the fewer poses generated. The 
resolution setting in LIDAEUS determines the allowable difference in distances between 
ligand atoms and site points. For each subsequent match this requirement is relaxed. The 
higher the resolution set the greater the number of poses generated and the longer the run 
time. A resolution of 0.04 Å was the default setting in this study. Default settings were used 
for atom typing, matching and energy cut-offs. Alternative values for energy cut-offs were 
tested using crystallographic data as a reference structure to compare with docking results. 
These alternative cut-offs did not improve RMSD between docking results and 
crystallographic poses and were rejected. 
7.2.6 SCORE and SORT 
The SCORE function in LIDAEUS calculates an approximation to the free energy of binding 
for each pose. Ligands then undergo a rigid body force field energy minimisation to optimise 
the pose and predicted binding affinity, ligands are then are sorted by SCORE. The more 
negative the score the more favourable the interaction. LIDAEUS uses an empirical scoring 
function that combines the energy scores for each atom in a ligand pose from the energy 
maps generated in MAPGEN.  A separate score is outputted for each map and also a 
combined score which may be a simple summation or weighted (user defined) in favour of a 
particular map. It is possible to define the number of poses outputted and/or use a score cut-
off to reject poorly scoring poses. 
 
The program has been adapted to run on the Blue Gene/l (IBM, 2005) supercomputer (Shave 
et al., 2008). This allows the program to run on up to 2048 parallel processors and vastly 
reduces the run time for docking. This has increased the potential for docking large, diverse 
sets of compounds and also analysing hits after changes to docking template or program 
parameters. Using the LIDAEUS suite of programs the experimenter can influence site-point 
generation, and therefore docking near to key residues (“hot spots” identified from x-ray 
structures of known tight binders). 
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7.2.7 Choice of docking template influences LIDAEUS docking  
When structures of FKBP12 in complex with inhibitors were compared with the apo 
structure it is clear that there are small changes on ligand binding, principally in the regions 
of the 80s and 40s loops (Figure 1-8 shows an alignment of 12 x-ray structures). For this 
reason a structure of FKBP12 in complex with a ligand was considered the most suitable 
conformation (template) for docking experiments. Waters were not included in the docking 
template as all the x-ray structures deposited in the PDB show the 3 waters, seen in the 
active site of the apo structure, to be displaced on ligand binding (Figure 1-9). A test set of 
ligands identified in crystallographic studies were docked to compare performance between 
templates. The RMS deviation of the docked pose from the crystallographic pose was used 
as the metric for docking success. Enrichment rates were also compared by plotting ROC 
(receiver operating characteristic) curves (Verdonk et al., 2004; Konstantinou-Kirtay et al., 
2007). The most successful template proved to be 2DG3.pdb (FKBP12 in complex with 
rapamycin, (Fulton et al., 2003)). LIDAEUS docks rapamycin (x-ray conformation 
minimised in TRIPOS) with an RMSD of 1.02Å using the 2DG3.pdb template. Examining 
the docking results and the site-points generated for the different templates showed key 
differences that were important for good enrichment and low RMSD. Hydrogen-bond 
acceptor site-points associated with the main chain N of Ile56 are the key to successful 
docking. H-bonding interactions between Ile56 and the ligand are seen in all known x-ray 
structures of FKBP12 small molecule complexes (Table 1-3). Some templates have subtle 
differences in structure that mean that Tyr82 (a possible H-bond donor) dominated 
calculated potential energy contributions at grid points between Ile56 and Tyr82 and 
MAPGEN assigned site-points as hydrogen bond donor in these positions. 2DG3.pdb was 
used as the docking template in subsequent docking experiments. 2DG3.pdb was also used 
as the template for docking with FlexX. 
7.3 FlexX 
FlexX uses a fragment-based approach to docking (Rarey et al., 1996). The initial step in 
docking is to break the ligand up into fragments; the principle fragment is known as the base 
fragment. A relatively rigid base fragment is chosen with fewer low energy conformations 
than alternative deconstructions of the molecule. Weight is also given to selecting base 
fragments that make more non-covalent interactions with the protein surface. In the same 
way that relaxing the resolution setting in LIDAEUS increases the possible number of poses 
and therefore docking time, small base fragments in FlexX extend computational time. Once 
chosen, the base fragment is considered a rigid body and triangles of atoms in the molecule 
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are geometrically fitted to a description of the protein surface. Potential ligand poses are 
clustered by considering the root mean squared deviation between poses. Members of a close 
cluster are mathematically combined into a single solution. Solutions are then compared and 
ranked in terms of the possible interaction energy of the fragment with the protein. The 
ligand is then incrementally grown from the best solution at each stage of incremental 
growth. The program makes use of tables of low energy torsion angles derived from the 
Cambridge structural database.  
 
Docking in FlexX was performed using the crystal structure of rapamycin in complex with 
FKBP12 (2DG3.pdb) as the template. 6.5 Å was explored around the template ligand and 
default charges used for ligand and protein. 3D SDF files of ligands were converted to mol2 
files prior to docking using the facility in the FlexX suite of programs. The top scoring pose 
was saved for each ligand using the standard FlexX scoring function. This is an empirical 
scoring function based on the work of Boehm and a test set of experimental data of binding 
constants for 82 protein ligand complexes (Klebe and Boehm, 1997; Boehm, 1998). 
7.4 Validating docking results 
It is widely acknowledged that fast empirical scoring functions in docking programs such as 
FlexX and LIDAEUS do not predict the free energy of binding of a ligand with a high degree 
of accuracy (Perola et al., 2004; Feher, 2006; Konstantinou-Kirtay et al., 2007; 
Waszkowycz, 2008). Docking results are generally validated by two metrics. Firstly, the 
ability of the algorithm to pick (score most highly) the correct pose of the ligand in the active 
site. Secondly, a metric that measure enrichment as a function of ranked score. Root mean 
square deviation (RMSD) is routinely used to compare the highest scoring docking pose of a 
ligand with the crystallographic pose. A cut-off of 2 Å is often used to define a “good” 
docking pose (Perola et al., 2004). Receiver operating characteristic curves (ROC curves) 
can be used to graphically illustrate the proportion of hits as a function of score 
(Konstantinou-Kirtay et al., 2007). 
7.5 Ligand-based virtual screening 
7.5.1 Chemical similarity 
The concept of chemical similarity is useful but also one which is hard to define. The central 
assumption of the similarity principle is that molecules with a similar structure have similar 
physicochemical properties and similar biological activity (Bender and Glen, 2004). There is 
no such thing as absolute similarity; rather molecule A can be considered similar to molecule 
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B relative to some measurable or definable element. This element could be a specific 
functional group, an atom path/graph within a molecule or a descriptor defining some global 
property of the molecule. It is also hard to define similar biological activity. For example, 
when conducting a similarity search in EDULISS 2 compound SD1 is retrieved as a close 
neighbour of compound SD2 by the program UFSRAT (top 0.1 % in 5.3 million 
compounds). SD1 has a Tanimoto similarity coefficient > 0. 9 when compared to SD2 using 
a fingerprint based method. The difference in structure between SD1 and SD2 is a 
substitution of –S– for –SO2–; this resulted in a 10 fold loss of activity. Replacing –S– with –
O– reduced activity 50 fold (Stebbins et al., 2007). This result could rightly be considered a 
triumph of the program UFSRAT and the similarity principle in purely structural terms. 
However, in most experimental assays it is extremely difficult to pick up an inhibitor in the 
100s of μM range at standard screening concentrations. Where does similarity in biological 
activity end? Is an 8 μM inhibitor similar to a 100 μM inhibitor or a 400 μM one?  
 
Whatever the complexities in comparing the structural features of one molecule with 
another, the concept of chemical similarity is frequently utilised in drug discovery. The 
ability to assess the diversity of a large chemical library (real or virtual) is very useful, 
particularly when deciding on the compounds to include in an HTS assay. In the context of 
virtual screening it is very useful to assess chemical similarity in the “post processing” stage 
of docking experiments. “Post processing” is the slightly ambiguous term that is used to 
describe the analysis of docking results. At an early stage of this project it became apparent 
that when the top 1000 hits of a LIDAEUS run were visually inspected there were chemical 
series in the hits. Tools were used to cluster the hits from a docking run by chemical 
similarity. This method allowed the experimenter to sample the chemical space of the hits 
more efficiently when only a small number of compounds could be purchased and tested. 
Clustering compounds by chemical similarity places less emphasis on the detailed ranking 
provided by a scoring function. This tool was also very useful when looking at SAR in 
experimental data.  
 
Chemoinformatic techniques that are used in similarity studies to define a molecule in terms 
of a 2D fingerprint can also be used to relate the complexity of molecules to bioactivity 
(Schuffenhauer et al., 2006). Similar techniques have been used to compare the variety of 
ring scaffolds in screening collections and known drugs (Ertl et al., 2006). 
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7.5.2 Clustering compounds by chemical similarity 
7.5.3 Molecular fingerprints and similarity metrics 
Molecular fingerprints (2D string representations of a molecule) were used to make pair wise 
comparisons of molecules in a compound collection. A binary fingerprint is a string of 1s 
and 0s describing the features of a molecule. If a feature is present the bit is set to 1 and if it 
is absent to 0. The feature may be a chemical functional group; an atom count; a substructure 
within the molecule; or a path length between a specific pair of atoms/functional groups/ring 
systems/pharmacophores Commonly used fingerprints are those from MDL Information 
Systems Inc. (Durant et al., 2002) and Barnard Chemical Information Ltd. (BCI fingerprints, 
(Barnard and Downs, 1997)). 2D hashed fingerprints are also commonly used; they differ 
from binary fingerprints in they do not use a predefined dictionary of fragments. Common 
commercially available hashed fingerprint algorithms are Daylight fingerprints 
(www.daylight.com; Jan 2009) and the Unity fingerprint. When comparing two fingerprints 
it has been found that some methods are more sensitive to changes in chemical linkers than 
other methods and this must be borne in mind when viewing results (Stahl et al., 2005). 2D 
fingerprints can be calculated from the  coordinates and connectivity table in a 2D structure 
file or from SMILES strings (Weininger, 1988). In this study fingerprints were encoded 
using a proprietary method in the program Accord for Excel (Accelrys). 
 
Two molecules can be assessed for similarity by comparing their fingerprints using a 
distance or similarity coefficient. In this study the Tanimoto coefficient similarity coefficient 
was used. The Tanimoto coefficient has been shown to perform well with chemical 
fingerprints (Willett, 2006). Two identical molecules have a Tanimoto similarity coefficient 
of 1 and two completely different molecules a coefficient of 0. The Tanimoto coefficient for 







(N N ) N
                   Equation 29 
 
Where: NA is the number of bits set (1) in string A, NB is the number of bits set to 1 in string 
B and NAB the number of common bits set to 1. 
 
Defining rules for cut-offs of Tanimoto coefficients depends on the fingerprint employed and 
is rather open to the interpretation of an individual chemist. As a rule of thumb, the Accord 
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fingerprint gives a Tanimoto coefficient > 0.7 for two very similar molecules and > 0.5 for 
two broadly similar molecules. For a given molecule of interest, ordering the remaining 
molecules in a set by Tanimoto coefficient can be a useful tool to pick close analogues in a 
large library. Fingerprints may be pre-generated and stored in a relational database. It is 
worth noting that the Accord fingerprints are generated from 2D SDF and two molecules 
deemed very similar by this method could have quite different 3D shape due to the 
replacement of a linker. 
 
If a pair wise comparison is made of all the molecules in a set, it is possible to generate a 
symmetrical similarity matrix of dimensions NxN. (where N is the number of molecules in 
the set). The diagonal of this matrix is made up of 1s for matrix using the Tanimoto 
similarity coefficient (the diagonal represents the molecule being compared with itself). The 
similarity matrix was used as the input to a clustering algorithm to group the molecules into 
clusters and produce a dendrogram displaying chemical similarity. 
7.5.4 Clustering algorithms 
In this study the simple hierarchical agglomerative clustering algorithm UPGMA 
(unweighted pair-group method with arithmetic mean) was used to cluster the molecules in a 
set (MVSP V3.13, Kovach Computing Services). Data was input in the form of a similarity 
matrix. Using this methodology the output in the form of a dendrogram was useful for a 
visual overview of the diversity of a set of 100 compounds or fewer. Above this number the 
diagram was difficult to interpret visually. Figure 7-18 shows the UPGMA clustering of the 
KB2 series of compounds. 
 
7.5.5 UFSRAT 
UFSRAT (Ultra Fast Shape Recognition and Atom Typing) is a virtual screening program 
developed by Steven Shave (Edinburgh University) that utilises molecular similarity. It is a 
database mining program that selects compounds based on a comparison of shape and 
electrostatic properties. UFSRAT was used to select compounds from the EDULISS 2 
database with similarity to known inhibitors of FKBP12. Data is input in the form of 3D 
SDF files and output in the form of a list of compounds ranked by similarity score. The 
similarity scores from UFSRAT are normalised so that two identical molecules received a 
similarity score of 1 and two completely unlike molecules a score of 0. 
 
 174 
UFSRAT encodes the shape of a molecule using metrics that describe the statistical 
distribution of Euclidean distance of individual atoms from a reference point. There are 16 
points of reference in total: 4 for each atom type (hydrogen bond donor, hydrogen bond 
acceptor and hydrophobic) and 4 for all the atoms in the molecule. This method of 
describing molecular shape is an extension of the work of Ballester and Richards (Ballester 
and Richards, 2007). UFSRAT can be distinguished from Ballester and Richard’s program 
as it considers atom types and therefore encodes a description of both overall shape and 
electrostatic properties. Atoms are classified as hydrogen bond donor, hydrogen bond 
acceptor or hydrophobic using similar criteria to those applied in the PREEN module of 
LIDAEUS. Each of the set of four points of reference comprises: the geometric molecular 
center (centroid), the closest atom and farthest atom to the centroid and the farthest atom 
from the farthest atom. Each distribution of distances is described using the standard 
statistical moments of mean, variance and skew. Each point of the 16 reference points has 3 
descriptors giving 48 in total.  
 
The reductionist approach of UFSRAT, in which 3D information is encoded in a 1D vector, 
allows for fast computational comparison of compounds. The program can compare 1million 
compounds per hour with a query molecule using pre-generated 3D SDF files. In this mode 
descriptors are generated on the fly. Using precalculated descriptors 1 million compounds 
can be compared to the query in 3 s. 
 
UFSRAT has several features that distinguish it from the many similarity searches based on 
2D molecular fingerprints. Fingerprints such as MDL and DAYLIGHT encode specific 
features within a molecule. A Tanimoto coefficient compares binary fingerprints by 
comparison of specific bits/features within a molecule. To state the obvious, a similarity 
search using this method retrieves molecules with similar features. As UFSRAT is not 
prescriptive of bond order or functionality the program has the potential to “scaffold hop”. 
“Scaffold hopping” is the retrieval of molecules with similar shape and properties but with a 
different carbon skeleton (Boehm et al., 2004). The emphasis of the algorithm on shape is of 
particular note. An inhibitor must have a complimentary shape to the binding pocket of the 
protein. A change to a linker between, for example, two ring systems can profoundly alter 
the overall shape of a molecule but might not be given weight in a 2D fingerprint. Such a 
change might make the molecule unable to exploit a binding pocket (the van der Waals 
potential describes the strong repulsive force when atoms come too close to one another). 
The emphasis of shape is perhaps both the strength and the weakness of UFSRAT. 
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Comparison by UFSRAT is sensitive to the conformation of the molecules in question. This 
is not immediately apparent when a known active is retrieved from a database, as the 
biological conformation of the molecule need not be known. In this case it is only important 
that the two conformations are consistent. In this study a minimum energy conformation in a 
vacuum generated by the program CONCORD (TRIPOS) was used for each molecule in the 
database. One could argue that set of active compounds retrieved using this algorithm might 
be richer when searching for more rigid molecules (fewer rotatable bonds). This would mean 
that the search compound had a higher probability of being the correct conformer. 
 
UFSRAT was used to select two series of compounds in this study.  
7.5.6 Using Bayesian machine learning to predict affinity 
The virtual screening technique described (very briefly) in this section was developed by Dr. 
Nicos Angelopoulos (Angelopoulos et al., 2009). Dr. Angelopoulos applied a Bayesian 
averaging technique to learn classification trees from high-dimensionality descriptors and 
affinity data and used these to predict relative ligand binding affinities. Compounds 
predicted to have a high probability of activity against FKBP12 were selected for testing.  
 
Experimental affinity data was taken from the San Diego NMR high throughput screen of 
small molecules against FKBP12 (http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=608, 
PubChem BioAssay database: SDCCG-A014-FKBP12-NMR). This data is referred to as 
“the training set”. For the purpose of the model, training set molecules were classified as 
active or inactive. Molecules were considered active if they had an estimated Kd ≤ 500 μM. 
Long vectors of descriptor values were built for each molecule in “the test set” and the 
screening collection of molecules from the descriptors deposited in the EDULISS 2 database. 
A Markov chain Monte Carlo (MCMC) algorithm was used to construct a long chain of 
possible classification trees for the screening collection. In a classification tree, a specific 
magnitude of a descriptor determines the partitioning of the molecules at each internal node 
(forking of a branch). Molecules with a descriptor value smaller than a certain magnitude 
follow one edge (branch) and those larger the other edge (branch), Figure 7-4 Example of an 




Figure 7-4 Example of an internal node in a classification tree  
The partitioning of molecules at this node is determined by a value of MlogP smaller or larger than 
4.123. 
 
The tree ends in terminal nodes (leaves), each one representing a specific molecule in the 
library. Each leaf in the model gives a probability value of activity (0-1) to the molecule. 
This probability is derived from the proportion of actives to inactives in "the training set". 
The whole chain of trees is used to give an average probability of activity for each molecule 
in the screening collection. The average probabilities of activity for each molecule are used 
to create a ranked list. 
 
The Specs green collection was screened using the Bayesian machine learning method 
(7.7.4). 
 
7.6 Choosing drug-like compounds 
A question that arose in this study was whether it was better to pass compounds through a 
drug-likeness filter prior to virtual screening and immediately exclude compounds that failed 
or, to filter compounds after virtual screening. The approach taken depended on the time 
taken in the individual screening steps. The majority of the compounds in EDULISS 2 pass 
Lipinski’s criteria. LIDAEUS is an extremely fast docking program; the parellel version of 
LIDAEUS running on BlueGene (IBM) can dock 5 million compounds in a matter of hours 
(Shave et al., 2008). In contrast docking 15,000 compounds with FlexX took over a week on 
a multiprocessor server. Therefore more stringent filtering was necessary before a FlexX run. 
When docking with LIDAEUS it was quicker to dock a very large database, filter the top 
scoring hits, and manually examine compounds that failed a specific parameter. The 
workflow for each library examined is described in section 7.7. 
7.6.1 Excluding compounds with undesirable functional groups 
The physicochemical parameters used in the rules described in section 1.4 focuses on a few 
global parameters for each molecule. The functional groups within the molecule can inform 
MlogP 
≤ 4.123 ≥ 4.123 
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the prediction of metabolism, excretion and toxicity (Dearden, 2003). Databases, such as 
EDULISS 2, contain compounds with undesirable reactive groups; these compounds are 
often building blocks for chemical synthesis. Other fuctional groups have been implicated as 
causing toxicity or mutagenicity. The pharmaceutical industry keeps detailed records and 
monitors the literature for functionality that has caused problems in past drug development 
programs. The program DEREK (Deductive Estimation of Risk from Existing Knowledge) 
employed as part of EDULISS 2 is an expert system derived from the knowledge of human 
experts. As part of my CASE Studentship it was possible to filter virtual libraries and 
remove compounds with undesirable functionality. A proprietary algorithm was used to flag 
compounds green, amber or red depending on the presence of certain functional groups. 
7.6.2 Predicting solubility 
A low value of logP is indicative of a compound having reasonable aqueous solubility. 
Algorithms for predicting aqueous solubility from structure almost universally rely on a 
directly proportional relationship between logP and solubility (Jorgensen and Duffy, 2002; 
Delaney, 2005). The general solubility equation (described by equation 30) is a simple 
empirical relationship that predicts aqueous solubility from logP and melting point.  
 
w mlogS 0.5 0.01 T 25 log P    Equation 30 
 
Where: Sw is the aqueous solubility in units of mol.L
-1
, Tm the melting temperature in 
o
C and 
logP the log of the octanol/water partition coefficient P. 
 
Unfortunately, experimentally measured values for Tm and logP are rarely available. This 
significantly reduces the usefulness of this equation! It was not used in this study. In this 
study MlogP was used to guide compound selection. The general cut-off value for MlogP 
was set at 4.5. Compounds with MlogP ≤ 2 were usually soluble (~90 %). 2 ≤ MlogP ≤ 4.5 
was less predictive (50 – 60 %). 
 
7.7 The 4 screening collections 
7.7.1 The Fragment library  
The Maybridge Ro3 fragment library 
The Maybrige Ro3 (www.maybridge.com/images/pdfs/ro3frag.pdf, November 2008) 
fragment library is a commercial fragment library of 1000 high purity (≥ 95 %) compounds. 
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The compounds all satisfy the “rule of 3”, a refined version of Lipinski’s “rule of 5”. 
Satisfying the “rule of 3” should increase the probability of good ADMET properties 
(Lipinski et al., 1997; Carr et al., 2005). Compounds were selected to show good chemical 
diversity and to exclude functional groups that could lead to unsuitable reactivity or lack 
stability in aqueous solution. The fragments do however exhibit functionality that can be 
useful to link fragments to other chemical moieties during lead optimisation. The aqueous 
solubility of compounds was computed using the ALogGPS  algorithm (Tetko and Tanchuk, 
2002) was > 1 mM. The computed octanol:water partition ClogP (calculated logP) was 
provided for each compound using a proprietary algorithm (Chemomine Consultancy 
Limited). 
 
It was not possible to purchase the whole Maybridge Ro3 library for reasons of cost. 96 
compounds were selected from the 1000 compounds by Dr. Matt Nowicki (Edinburgh 
University) based on diversity. The structures of the 96 compounds are shown in Appendix 



























































































































Figure 7-5 Distribution of calculated properties in the fragment library 
Histograms showing the physicochemical properties for the fragment library. Properties were 
calculated by the supplier using commercial packages (Daylight, Chemical Information Systems Inc. 
and Chemomine Consultancy Limited). 
 
The fragment library provided a very useful series of compounds to assess the thermal 
denaturation fluorescence assay (TDF). 
 
Materials and Methods 
The fragments were screened by TDF assay. Compounds were dissolved in 50 % double 
deionised water: 50 % DMSO mixture to a concentration of 50 mM in the well of the plate 
supplied by the manufacturer. 94 of the 96 compounds dissolved to 50 mM, two compounds 
dissolved after diluting with water to 25 mM. The plate was sealed with aluminium film and 
stored at -80 
o
C (Adhesive aluminium foil seals rated to -80 
o
C, Thermo scientific). 
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Screening sub-plates (ABgene PCR plates, rated to -80 
o
C, Thermo scientific) were made up 
with 100 mM bis-tris buffer at pH 7 with a fragment concentration of 625 μM (300 μl/well). 
The TDF assay was performed at a ligand concentration of 250 μM. The 625 μM plate 
provided the aliquots of 20 μl necessary for 3 repeats and 1 fluorescence control. The 
arrangement of the plate was designed to facilitate the use of an 8-tip multi-channel pipette. 
This reduced random error during pipetting into the main screening plate. For the same 
reason, solutions of protein and SYPRO orange were pre-diluted in bulk with buffer to 
ensure that pipetted volume was always ≥ 10 μL. The final well volume was 50 μL. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A                         
B   F41 F42 F43 F44 F45 F46 F47 F48 SD1_6 Neg_6   
C   F33 F34 F35 F36 F37 F38 F39 F40 SD1_5 Neg_5   
D   F25 F26 F27 F28 F29 F30 F31 F32 SD1_4 Neg_4   
E   F17 F18 F19 F20 F21 F22 F23 F24 SD1_3 Neg_3   
F   F9 F10 F11 F12 F13 F14 F15 F16 SD1_2 Neg_2   
G   F1 F2 F3 F4 F5 F6 F7 F8 SD1_1 Neg_1   
H                          
Figure 7-6 Fragment plate for the TDF assay 
48 compounds and controls were tested in parallel on a TDF plate. A similar plate array was set for 
compounds 49-96.  
 
The TDF screening plate is shown in Figure 7-6. 48 fragments (250 μM), were tested in 
parallel on a single plate. The fragments are labelled F1 to F48 in Figure 7-6; fragments 49-
96 were tested on a similar array. 6 positive controls (SD_1-6) and 6 negative controls 
(Neg_1-6) were included on each plate. The final solution contained 10 μM FKBP12,  
250 μM Ligand/SD1(+ control); 30 mM Bis-Tris and 40 mM ammonium acetate at pH 7; 0.25 % 
DMSO, 0.25 % methanol and 10x SYPRO orange (SYPRO orange has a proprietary 
structure and is supplied as a 5000x solution in DMSO). The edge wells were kept empty. 
There was no evidence in this project that wells close to the edge gave less good results. 
Each plate was repeated in triplicate. A fluorescence control plate was also carried out. 
Conditions for the fluorescent control were similar to the fragment screening plates; protein 
solution was replaced with the appropriate buffer. Plates were incubated at room temperature 
for 15 minutes prior to the start of every assay. 
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7.7.2 The KB series  
The KB series of 20 ligands were synthesised by Dr. Kevin Bailey (University of 
Manchester). The aim of the project was to design a series of ligands that would target both 


















































Bis-Oxamide Series  
Figure 7-7 Synthesis of the KB series 
The KB series were synthesised by Dr. Kevin Bailey from piperidine or an analogue of piperidine. 
Ethylpiperidine glycoxylate (KB2_68C) is circled in red, this compound has been found to inhibit 
cyclophilin A with a Kd = 25 mM (Kontopidis et al., 2004). The blue inset box shows a binding 
moiety common to many FKBP12 inhibitors (Figure 1-10 Core binding motif of many FKBP12 
inhibitors). The green inset shows proline. FKBP12 and hcypA both act as peptidyl-prolyl isomerases. 
 
The starting point for the synthetic strategy was guided by the following observations from 
the literature. In an x-ray crystallographic and biochemical study by Kontopidis et al, 
ethylpiperidine glycoxylate inhibited hcypA with a Kd = 25 mM (KB2_86C in this study, the 
compound circled in red in Figure 7-7. (Kontopidis et al., 2004)). hcypA is the binding 
common binding moiety of 
inhibitors of FKBP12 








KB2_68C: Inhibitor of 
human cyclophilin A, 







partner of the immunosuppressant drug cyclosporin (Handschumacher et al., 1984). The role 
of cyclophilin in vivo is not fully understood. However, like FKBP12, it’s function as a 
peptidyl-prolyl isomerase is thought to be important in processes where protein 
folding/unfolding is a rate-limiting step in cell biology and when the cell is under stress 
(Galat, 2003). Both proteins have been shown to bind to di-peptides containing proline or 
small molecule ligands with a motif  that mimics proline (Dornan et al., 2003).  
 
 
Figure 7-8 Ethylpiperidine glycoxylate in the active site of human cyclophilin A 
(A) X-ray structure of the hCypA-KB2_68C complex (1W8M.pdb, Kontopidis et al (2004)). Two 
orientations of the ligand are shown: purple C-atoms 65 % occupancy, green C-atoms 35 % 
occupancy. An electrostatic surface was generated to illustrate the geometry of the active site; PyMol 
V1.02 (DeLano Scientific). The hydrogen bond between C=O and the main chain nitrogen of Asn102 
is labelled with a black dashed line, 2.9 Å (B) The symmetrical bis-oxamide ligands were synthesised 
in an aim to increase the potency of KB2_68C, towards cyclophilin A, by simultaneously making the 
interactions of both orientations of KB2_68C seen in the active site.   
 
The second observation was that the common binding moiety of many inhibitors of FKBP12 
is a pipecolate ring with a diketo linker from the nitrogen on ring and an ester linker in the 
ortho position (blue inset box in Figure 7-7); this is structurally similar to KB2_68C (Dornan 
et al., 2003; Wang and Etzkorn, 2006). The binding mode of this moiety for FKBP12 is 
discussed in detail in section 1.11.6. The aim of the KB series of compounds was to test if it 
were possible to design inhibitors to inhibit both hcypA and FKBP12. Examining the 
structures of known actives of FKBP12 would suggest that modifying KB2_68C by making 
substitution at the ortho/meta positions of the piperidine ring might lead to a compound that 
would target FKBP12. Substitutions at the ortho/meta positions might however have positive 































FKBP12 are generally larger than those of hcypA; a direct consequence of the dimensions of 
the active site. hcypA has a narrow trench-like binding groove (Figure 7-8) compared to that 
of FKBP12 which is a wide hydrophobic pocket. The crystal structure of KB2_68C in 
complex with hcypA is particularly interesting; the ligand is seen in two positions in the 
active site (Figure 7-8 (A)). In both poses the ligand makes a hydrogen bond with the main 
chain nitrogen of Asn102; this is seen in all peptide-hcypA structures (Ke et al., 1991; 
Kallen et al., 1998). The occupancy of the ligand shown with purple C-atoms was 65 %, the 
ligand shown with green C-atoms, 35 %. This is interesting as the purple C-atom ligand is 
the least buried of the ligands. This crystal structure suggested that a symmetrical bis-
oxamide might be more active than KB2_68C. Figure 7-8 (B) illustrates how a symmetrical 
bis-oxamide might simultaneously make the interactions seen in the two poses of KB2_68C 
observed in the active site. It is worth noting that the piperidine ring of the green KB2_68C 
fits into a fairly small pocket adjacent to Phe113 and modifications to the piperidine ring 
might lead to changes to the amino acid side-chain conformations lining the pocket (Arg55, 
Met61, Phe113, and His126). The aim was to increase the potential for non-covalent 
interactions between ligand and protein and improve ligand affinity. 
 
An additional aim was to design soluble compounds. The law of mass action dictates that 
ligand solubility is of paramount importance when characterising the binding of low affinity 
ligands. The KB series of molecules range in mass from 185.2 to 292.4 Da.  
 
Synthetic strategy 
Figure 7-7 shows the synthetic strategy which is based on the reaction of piperidine with 
various acid chlorides. These reactions lead directly to symmetrical bis-sulfonamides, 
symmetrical bis-oxamides, an asymmetric oxamide or an acid chloride that was converted to 
an asymmetric bis-oxamide or sulphonamide by reaction with an imine. Replacing the 
piperidine with a piperidine substituted at one or more positions on the ring, morpholine, 1,4-
oxathiane or pyrrolidine expanded each series. The oxamide, bis-oxamide and bis-
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KB2_60 KB2_61F KB2_66A KB2_61D
KB2_61A KB2_61E KB2_61B KB2_61C  
 




























KB2_64C KB2_63 KB2_64B KB2_67A  
 
Figure 7-11 KB bis-sulphonamides 
 
Materials and Methods 
Initial Screen -TDF 
The initial screen for the KB series was by TDF assay. Stock solutions were made by 
dissolving the compounds in HPLC grade methanol (BDH) to 100 mM. Compound 
KB2_61B was the least soluble compound and a stock solution of 25 mM was made. 
Solutions were divided into 100 μl aliquots and stored at -80 
o
C in cryogenic vials (Nunc). 
96-well plates were made up of the compounds in 100 mM bis-tris buffer at pH 7 at a 
concentration of 625 μM following similar protocols to those described for the fragment 




The 20 compounds were tested in parallel on a single plate. 3 positive controls (SD1) and 3 
negative controls were included on each plate. The final solution contained 10 μM FKBP12, 
250 μM Ligand/SD1 (+ control); 30 mM Bis-Tris and 40 mM ammonium acetate at pH 7; 
0.25 % methanol and 10x SYPRO orange (SYPRO orange has a proprietary structure and is 
supplied as a 5000x solution in DMSO). The experiment was repeated in triplicate in 
separate experiments. A fluorescence control was also included for each compound on the 
plate. Plates were incubated at room temperature for 15 minutes prior to the start of the 
assay. 
 
Confirming the specificity of KB2_61D for the active site of FKBP12 - PPIase 
A peptidyl-prolyl isomerase assay (PPIase) was performed to determine the specificity and 
the Kd of KB2_61D (most active member of the series) by competitive inhibition of the 
isomerisation of the substrate Succ-Ala-Leu-Pro-Phe-p-nitroaniline by FKBP12. A titration 
was carried out using compound KB2_61D at concentrations between 0 and 500 μM using 
the protocol described in section 6.3.1. The apparent equilibrium dissociation constant was 
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estimated from the best fit of equation 20 to the rate of turn-over of the substrate, corrected 
for the background turnover at 4 
o
C between 0.5 and 1.5 s after addition of the substrate, 
plotted against the concentration of the inhibitor as described in section 6.4.1. The 
equilibrium dissociation constant, Kd, for each inhibitor, was determined by correcting the Ki 
for competition with the substrate using equation 21. 
 
Thermodynamic characterisation of the FKBP12-KB2_61D complex 
An isothermal titration calorimetry (ITC) was carried out to characterise the thermodynamic 
parameters for the FKBP12-KB2_61D complex (ITC is described in section 6.3.2). ITC 
experiments were carried out on a MicroCal auto-VPITC instrument (GE Healthcare). 
Reagents were dissolved in 50 mM sodium phosphate, 50 mM sodium chloride at pH 7; 0.25 
% methanol. 300 μM KB2_61D (syringe) was injected into 22 μM FKBP12 (reaction cell). 
The experimental protocol was 28 x 10 μl injections (0.5 μl 1
st
 injection), 20 s injection 





experiment was repeated in triplicate including standard controls to account for the heat of 
dilution of the ligand and protein and the heat of mixing. Data analysis was as described in 
section 6.3.2). 
 
Determining the Kd of the FKBP12-KB2_61D by ESI-MS 
An ESI-MS titration was performed with 10 μM FKBP12 and 0 to 300 μM KB2_61D in  
10 mM ammonium acetate at pH 6.8 on the LCQ
TM
DECA (ThermoQuest) instrument using 
the protocol described in section 3.5.6. 
 
Clustering the KB series by chemical similarity 
The KB series was clustered by chemical similarity; the resulting dendrogram was used as a 
tool to examine the activity data provided by the TDF assay. Fingerprints were calculated 
from 2D representations of the molecules using the program Accord for excel (Accelrys). A 
pair-wise comparison was made of the bit strings for each molecule using a Tanimoto 
coefficient (Haranczyk and Holliday, 2008). The resulting symmetrical similarity matrix 
(20x20 for 20 compounds) was used as the input for a UPGMA clustering algorithm (MVSP 
V3.13, Kovach Computing Services).  
 
 187 
Effect of KB2_61D on two strains of C.elegans 
Sexually mature wild type (N2) and FKB3 triple mutant (TP83) C.elegans were exposed to 
10 to 500 μM KB2_61D for 6 days; worm growth was compared to negative controls. KB2-
KB2_61D was dissolved in ethanol; the final ethanol concentration was less than 3 % (v/v). 
These experiments were carried out by Dr. Victoria Butler (Faculty of Veterinary Medicine, 
University of Glasgow). 
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7.7.3  The SL series 





Figure 7-12 Selecting the SL series by virtual screening 
The SL series of compounds were selected from the EDULISS 2 database using two virtual screening 
approaches in series; an algorithm that calculated 3D similarity coefficients for test compounds 
compared to a known active (UFSRAT) and a protein-ligand docking algorithm (LIDAEUS). 
Compounds were filtered for drug-likeness using Lipinski’s criteria. This strategy reduced the 
compound set to 0.02 % of the original EDULISS 2 database. Docking poses were manually inspected 
for potential interactions with key residues in the active site. 
 
The selection of the SL series was based on the premise that structurally similar compounds 
are likely to exhibit similar physiological effects (Crum Brown and Fraser, 1869; Bender and 
Glen, 2004). The choice of query structure for UFSRAT was based on activity and size. Poor 
ligand solubility is often a limiting factor in estimating affinity by biophysical methods for 
ligands with Kd > 10 μM. This has been a problem throughout this study. The activity of a 
compound relative to size is worthy of particular consideration. The aim was to pick a 
structure with high ligand efficiency. It was felt that use of a ligand with pendant groups that 
3.8 million 
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made few non-covalent interactions with FKBP12 would lead to poorer enrichment by 
UFSRAT.  
 
Three structures were used to query the EDULISS 2 data base, SD1, SD2 and the core 
binding motif of rapamycin. SD1 and SD2 are known ligands of FKBP12 that bind 
specifically to the active site (Stebbins et al., 2007). The nanomolar affinity 
immunosuppressant ligands of FKBP12; rapamycin and FK506 are macrocyclic lactones; 
~50 % of the ligand binds not to FKBP12, but to a second protein (mTor and calcineurin 
respectively). It is the inhibition of this partner protein that leads to their immunosuppressive 
action. Our aim was to inhibit FKBP12 without immunosuppression. For these reasons 
rapamycin and FK506 are unsuitable query structures for a similarity search.  However, both 
share the same FKBP12 binding motif (Figure 1-7). This motif occupies the majority of the 
active site making 4 hydrogen bonds with key residues. The first approach was to select the 
fragment of rapamycin that contained atoms within 3.5 Å of FKBP12 (PyMol V1.02, Delano 
Scientific). The rationale being to create a “shape” made up of atoms of the correct type 
(atoms with the potential to make non-covalent interactions) and spatial distribution 
matching hot spots in the active site. This is analogous to the generation of site-points for a 
docking experiment. This approach was refined when docking experiments showed that the 
compounds selected by UFSRAT were generally too massive to dock deeply into the active 
site of FKBP12. During manual inspection of the docked ligands, very few made hydrogen 
bonding interactions with residues identified as being hot spots in the active site (hydroxyl of 
Tyr82 or main chain N of Ile56). The rapamycin query structure was pruned to include only 
the most buried atoms (rapa_core, Figure 7-12). Pruning retained atoms making hydrogen 
bonds with FKBP12. 
 
The 3D coordinates of SD1, SD2 and those in EDULISS 2 were generated using the program 
CONCORD (TRIPOS). The conformation of the query structure is clearly of considerable 
importance. One might argue that this should be that of the ligand in complex with the 
protein. Alternatively, one could argue that the 3D structures from EDULISS 2 generated by 
CONCORD are minimised low energy conformations in vacuo and that it is this 
conformation of the ligand that should be used. The former approach should favour the 
retrieval of more rigid scaffolds that closely match the shape of the active site. The latter 
approach has been shown to give the query compound the highest similarity score (Shave 
and Blackburn, unpublished results). Care was taken to make sure that the two chiral centers 
in rapa_core matched those in rapamycin and FK506. These atoms are labelled C1 and C2 in 
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Figure 7-12. This was done by taking the conformation of rapamycin from an x-ray structure 
of a complex with FKBP12 (2DG3.pdb). There are no x-ray structures available for SD1 or 
SD2 in complex with rapamycin and a low energy conformer was generated using the 
program CONCORD (TRIPOS).  
 
The top 500 hits from UFSRAT were saved for each query structure (1500 total) and docked 
using the programs LIDAEUS. The generation of the site-points defining the active site of 
FKBP12 is described in section 7.2.3 (grid of spacing of 0.09 Å for the site-points). The 
docking resolution parameter was set at 0.04 Å. This parameter setting was arrived at by re-
docking a minimised conformation of rapa_core at 0.02, 0.04 and 0.06 Å. Setting the 
resolution to less than 0.04 Å meant that the program failed to rank the pose most similar 
(low RMSD) to that seen in the crystal structure (2DG3.pdb) as the highest in a series of 
solutions. The highest ranked pose of a complete structure of rapamycin has an RMSD of  
1.2 Å when compared to the crystal structure. Setting a more relaxed docking resolution 
(larger) is a fast method of accounting for a small amount of conformational flexibility in the 
ligand. Ligands matching the shape and atom types of the site-points were ranked according 
to the enthalpy of the interaction and buriedness. The top 500 poses were saved from each 
query. These poses were analysed for duplicates and the highest scoring pose saved, when 
more than one solution were available. The set of unique compounds was filtered for drug-
likeness using Lipinski’s rule of 5 criteria (Lipinski et al., 1997). The compounds were also 
docked using the program FlexX. These series of in silico experiments reduced the 3.8 
million unique compounds in EDULISS 2 to 802 compounds (0.02 % of the database). The 
poses were then visually examined for buriedness and putative interactions with important 
residues in the active site. Ligands were only selected if they occupied the base of the pocket 
and made at least one hydrogen bond with Tyr82 (hydroxyl) or Ile56 (main chain N). 
Compounds that met these criteria were grouped by supplier and their availability and cost 
determined. When a compound was not available the search engines in PubChem 
http://pubchem.ncbi.nlm.nih.gov, December 2008, Chembase (Seiler et al., 2008) and ZINC 
(Irwin and Shoichet, 2005) were used to source an alternative supplier. 10 compounds were 
purchased. 
 
To conclude, the aim in the selection of the SL series was to use shape similarity to select a 
similar, but “not too similar compound”. UFSRAT has a greater potential to scaffold hop 
than the use of a 2D binary fingerprint that encodes specific structural elements in the query 
structure (Boehm et al., 2004; Ballester and Richards, 2007). 
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Materials and Methods 
Initial Screen -TDF 
The SL series were tested using the thermal denaturation fluorescence assay, as described in 
sections 6.3.4 and 7.8.1. The compounds were supplied as a solid, they were dissolved to a 
concentration of 30 mM in methanol (SL1, SL2, SL3, SL7 and SL9) or DMSO (SL5, SL6, 
SL8), and stored at -80 
o
C. 8 of the 10 compounds purchased dissolved. No suitable solvents 
were found for SL4 or SL10. Compounds were screened at 10 μM FKBP12 and 250 μM 
screening compound. Compound SD1 250 μM was used as the positive control;  
Kd = 6.8 μM. All wells contained equal concentrations of DMSO (0.8 %) and methanol  
(1 %) The assay was repeated in triplicate on separate plates. 
 
ESI-MS 
SL1, SL2, SL3, SL7, SL9 were tested at 100 μM ligand, 10 μM FKBP12 in 10 % methanol 
(v/v), 10 mM ammonium acetate, pH 6.8 on the LCQ
TM
DECA (ThermoQuest) instrument 
using the protocol described in section 3.5.1. It was not possible to test SL5, SL6 and SL8 by 
ESI-MS due to the presence of DMSO. 
 
Clustering the SL series by chemical similarity 
The KB series was clustered by chemical similarity; the resulting dendrogram was used as a 
tool to examine the activity data provided by the TDF assay. 
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7.7.4 The Specs library 
Compound selection 
In this study a subset of 15000 compounds from the Specs catalogue (www.specs.net) were 
screened against FKBP12. 2D representations of 25 000 compounds from the supplier were 
processed using proprietary software when on placement with my CASE Studentship 
sponsor Organon (Part of the Schering-Plough Corporation, www.schering-plough.com, Jan 
2009). SDF files of 25000 compounds were computationally cleaned; this process involved 
the removal of metal ions, fragments and the assignment of charge appropriate to pH 7.4. 
Compounds were compared to remove duplicates and than assessed for drug likeness. The 
term drug-likeness refers to passing Lipinski’s Ro5 (Lipinski et al., 1997) and absence of 
undesirable functional groups. 14894 compounds passed the most stringent set of criteria; 
these are referred to as the Specs green subset. Figure 7-13  shows the distribution of MW, 
ClogP, number of hydrogen bond donors and hydrogen bond acceptors. 3D SDF files were 
created using the program CONCORD (TRIPOS).  
 
The 14894 compounds were docked using the programs LIDAEUS and FlexX using the 
crystal structure of FKBP12 in complex with rapamycin as a template (2DG3.pdb). 
UFSRAT was used to select compounds most similar to 3 known actives as described in 
section 7.7.3. The Bayesian algorithm of Dr Nicos Angelopoulos (Angelopoulos et al., 2009) 
was used to assign a probability of activity against FKBP12 for each of the compounds    
(The San Diego Data Set was used as the training set; 
http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=608, January 2009). The 40 top 
scoring hits were selected from each program and those that had a good score in LIDAEUS 
and FlexX (ranked by the arithmetic addition of scores from each program). 10 of the 
compounds were selected by more than one program. Compounds were also selected from 
the Organon compound collection (all purchasable compounds) that contained fragments that 
were known to bind to FKBP12 (crystallographic data, Appendix 3). This was carried out by 
means of a BCI fingerprint.   
 
Materials and Methods 
In total 162 compounds were tested using the thermal denaturation assay, as described in 
section 6.3.4. The compounds were supplied at 10 mM in DMSO and screened with 15 μM 
FKBP12 and 250 μM test compound. Compound 250 μM KB2_61D was used as the positive 
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control; Kd = 6.6 μM. 40 compounds were tested on each plate with 5 repeats for positive 




Figure 7-13 The Specs green subset 
Distribution of MW, ClogP, number of hydrogen bond donors and hydrogen bond acceptors 
for the Specs green subset. Histograms were created using the program Topcat 
(www.star.bris.ac.uk/~mbt/topcat/; January 2009). 
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7.8 Results 
7.8.1 The Fragment library  




Figure 7-14 TDF screen of the fragment library 
TDF screen of the fragment library. The y-axis shows the shift in mid-point melting temperature  
(ΔTm
  o
C). 10 μM FKBP12; 250 μM fragment; 10x SYPRO orange, 0.25 % DMSO, 0.25 % methanol, 
30 mM ammonium acetate; 40 mM Bis-Tris, pH 7. Positive control contained 250 μM SD1 in place of 
a fragment. The negative control contained no ligand. (A) Fragments 1-48. (B) Fragments 49-96. Two 
compounds reduced the mid-point melting temperature by a significant amount: F3 and F59, these are 
highlighted in the figure. F65 gave a small positive melting point shift; this compound is boxed in red. 
 
One compound gave a +ΔTm > 0.5 
o
C, 1,3-diazepane-2-thione (Fragment F65,   
ΔTm = 1.3 
o






















C for ΔHL using equation 24, ΔCp was not included). Two simple cyclic compounds, 
cyclohexanone and cycloheptanone, were identified in Burkhard’s study of ligands binding 
to FKBP12 with Kd of 50 μM and 30 μM respectively (Burkhard, PhD Thesis, Basel 
University, 1995). Burkhard’s study measured binding by the quenching of Trp59 
fluorescence as function of ligand concentration (Park et al., 1992). In a study by 
Kontopidis, cyclooctanone was crystallised in complex with FKBP12 (Kontopidis, PhD 
Thesis, Edinburgh University, 1999). Cyclootanone occupied a position close to Trp59 in the 
active site in a similar location and orientation to DMSO (1d7h.pdb, (Burkhard et al., 2000)).  
 
Two fragments: F3 ((S)-(-)-alpha-amino-gamma-butyrolactone hydriodide) and F59 ((5-
morpholinothien-2-yl)methanol) gave negative ΔTm of -13.1 
o
C and -4.6 
o
C respectively. It is 
interesting to note, fragment F3 also reduced the mid-point melting temperature of pyruvate 
kinase from Leishmania mexicana (ΔTm ~ -5 
o
C) and reduced the activity of the protein in an 
activity assay. The effect of the compound was also tested in a crystallisation trial for 
pyruvate kinase where crystallisation conditions for the protein were well established. On 
addition of F3 there was rapid production of an amorphous precipitate (unpublished results; 
Dr. Hugh Morgan, Edinburgh University). For a small molecule F3 has good potential for 
making hydrogen bonds; protein destabilising effects may be explained by the compound 
acting as a chemical denaturant. 
 
Trends in activity were investigated by examining relationships between ΔTm and descriptor 
values. ΔTm was plotted against MW, ClogP, number of hydrogen bond acceptors, number 
of hydrogen bond donors and polar surface area (Chemical Information Systems). No trends 
in activity were observed for any of the descriptors (results not presented).  
 
Figure 7-14 shows the fragments that gave a small consistent positive ΔTm; (these results are 
not statistically significant). The three compounds highlighted in grey show some structural 
similarity to known inhibitors of FKBP12. F62, F79 and F80 all contain a heteroaromatic 
ring linked by a sulfonyl group to a heterocycle. It is interesting to note that this substructure 
is seen to be the most deeply buried fragment in the ligand in complex with FKBP12 in the 
crystal structure 1J4I.pdb, (Sun et al., 2003). Figure 7-16 shows the orientation of 308 in the 
active site of FKBP12. Appendix 3 shows the structures of ligands crystallised in complex 
with FKBP12.  
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Figure 7-15 Positive ΔTm in the fragment screen with FKBP12 
The majority of the compounds in the TDF screen gave a small – ΔTm with FKBP12. The compounds 
shown above gave very small + ΔTm. A ΔTm  = 0.2 
o
C would equate to a Kd apparent > 200 μM at the 
melting temperature; theses results are not statistically significant and are only included for the record. 
Fragment F65, ΔTm = 1.29 
o
C, is the most interesting compound in the set, this equates to a Kd 
apparent of ~160 μM at Tm. This would extrapolate to between 40 – 70 μM at 25 
o
C (extrapolating to 
25 
o






























Figure 7-16 Compound 308 in complex with FKBP12. 
Representation of the x-ray structure of compound 308 in complex with FKBP12 (1J4I.pdb, (Sun et 
al., 2003)). (B) 2D schematic representation of the non-covalent interactions between the protein and 
ligand from the x-ray structure using the Poseview server: http://poseview.zbh.uni-
hamburg.de/~poseview/poseview.php (Stierand et al., 2006). Hydrogen bonds are represented as 
dashed lines and hydrophobic interactions as green arcs. The shaded ellipsoid highlights the moiety in 
compound 308 that is structurally similar to the compounds in the fragment screen that showed a 
positive shift in mid-point melting temperature (F62, F79 and F80). 
(A) (B) 
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7.8.2 The KB series 
The results of the TDF assay on the KB series are shown in Figure 7-18. Results are grouped 
by chemical similarity. The most active compounds were KB2_61D and KB2_62D; these 
compounds gave a shift in mid-point melting temperature, ΔTm > 1.5 
o
C. Table 7-1 shows 
ΔTm and Kd estimated at the melting temperature, Tm, (calculated with using equation 23, 
section 6.3.4). Kd were extrapolated to 25 
o



















ΔHc  = -7.0 kcal∙mol-1 
(25 oC) 
KB2_61D 6.8 ± 0.3 22.2 16 10 7 
KB2_62D 1.8 ± 0.3 131 99 65 49 
 
Table 7-1 The most active compound cluster in the KB series (FKBP12) 
The apparent equilibrium dissociation constant are shown at the melting temperature and at 3 putative 
values of ΔHL. 
 
Compound KB2_62D is a sub-structure of compound KB2_61D. Figure 7-17 is a plot of  
–dF/dT against temperature for KB2_61D and KB2_62D plus controls.  
 
   
Figure 7-17 TDF data for compounds KB2_61D and KB2_ 62D and FKBP12 
Tm is the minimum value of –dF/dT in the plot of –dF/dT against temperature. 10 μM FKBP12, 250 
μM ligand, KB2_62D (purple), SD1 (red) and KB2_61D (blue). There is no ligand present for the 





10 μM FKBP12 















































































































































































































































































Figure 7-18 TDF assay results for the KB series of compounds 
Compound KB2_61D stabilises FKBP12 to a greater degree than the 6.8 μM positive control SD1.  
10 μM FKBP12, 250 μM ligand/SD1; 10x SYPRO orange, 0.25 % methanol, 30 mM ammonium 
acetate; 40 mM Bis-Tris, pH 7. Standard deviation is shown for n = 3 (three separate experiments). 
The structures of the heterocyclic ring are shown to illustrate the effect of changes to the ring (colour 
coded by atom type at position 4). The shaded bars represent symmetrical molecules with two 
identical rings. The cluster dendrogram is shown to illustrate similar compounds. The algorithm 
makes a primary classification by distinguishing between a sulphonamide or oxamide linker. See 
Figure 7-9, Figure 7-10 and Figure 7-11 for full ligand structures. 
 
Structure activity relationships 
In contrast to the screening of the fragment library, which provided only one compound with 
a ΔTm of ~1 
o
C, the KB series gave 9 hits where ΔTm was ≥ 1
 o
C. The most active cluster of 
compounds has the substituent -COOEt in the ortho position on the heterocyclic ring.  
KB2_61D and KB2_62D are the closest analogues of the core binding motif of known 
FKBP12 inhibitors. The modelling of compound KB2_61D into the active site of FKBP12 
was discussed in some detail in section 4.4.4; Figure 7-19 shows a 2D schematic diagram of 
predicted interactions between ligand and protein. These compounds have the potential to 










with the ester carbonyl on the closest ring and the main chain nitrogen of Ile56. In this 
binding mode the pipecolate moiety mimics proline in preferred substrates of FKBP12. 
 
 
Figure 7-19 Model of KB2_61D in the active site of FKBP12 
2D schematic diagram of electrostatic interactions predicted by the model of KB2_61D in the active 
site of FKBP12. Protein-ligand electrostatic interactions are represented by dashed lines and 
hydrophobic interactions by solid green arcs. Not all hydrogen atoms are shown for clarity. FlexX 
V3.0.2 (Rarey et al., 1996). The docking is described in section 4.4.4. 
 
The symmetrical compounds containing two heterocycles are more active than those with 
one heterocyclic ring. Changes to the atom in position 4 on the heterocycle from C to S or O 
does not seem to have a significant effect on activity. The general trend in activity with 
substitution in the ortho/meta position on the heterocyclic ring is: –COOEt > CH3 > H. There 
are examples in the series with a methyl group in the ortho positions and in the meta 
positions. It is not clear which position is more favourable.  Replacing the six membered ring 
with a five membered pyrrolidine ring does not increase activity. Only 4 compounds contain 
the sulphonamide linker, it is therefore difficult to come to a firm conclusion; these 
preliminary results suggest that replacing the di-keto linker of the oxamide series has little 
effect on activity. 
 
The affinity of compound KB2_61D for FKBP12 was further investigated by a variety of 
biochemical and biophysical techniques. 
  
Determining the specificity of KB2_61D for FKBP12 
 A PPIase assay showed that compound KB2_61D competes with a preferred substrate for 
the active site of FKBP12; Kd = 2.1 ± 0.8 μM at 4 
o
C. This is in general agreement with the 
result of the TDF assay. The graph of the background corrected rate of turnover of substrate 
(0.5 – 1.5 s after addition of substrate) as a function of concentration of inhibitor is shown in 






































































































Figure 7-20 Estimating the Kd for KB2_61D and FKBP12 
(A) Inhibition of PPIase activity of FKBP12 by KB2_61D. The initial velocity, V0 (μM s
-1
), of 
FKBP12 catalysed cis–trans isomerisation of the tetrapeptide substrate sALPF-pNA is plotted against 
increasing concentrations of the inhibitor, standard errors for six repeats. The solid line is a best fit to 
equation 20. (B) ITC thermogram for the interaction between KB2_61D and FKBP12. The 
experiment was repeated in triplicate (blue, green and black points), error is the standard deviation for 
3 separate experiments. Integrated heat data was corrected for heat of ligand dilution and fit to a 
standard 1:1 binding model, red curves (MicroCal Origin software, V4.0) (C) ESI-MS titration data 
for KB2_61D and FKBP12. The experiment was repeated in triplicate, error bars are the standard 
deviation for 3 separate experiments. The solid lines are least squares fit to equation 12. (D) Table of 
Kd estimated by the different biochemical and biophysical methods. 
































The analysis of the ITC data is complicated because the sample of KB2_61D is a 
diastereotopic mixture. The ITC thermogram for the titration of KB2_61D is shown in 
Figure 7-20 (B). Kd was estimated to be 6.6  ± 0.7 μM at 25 
o
C making the assumption that 
all of the ligand in the sample is the active isomer. Modelling studies suggest that not all 
forms are equally active (section 4.4.4). If the racemic pipecolate reagent consisted of a 1:1 
mix of S and R forms and the synthesis did not occur by an steriospecific mechanism the 
product would be composed of 3 diasteromers: SR (50 %), RR (25 %) and SS (25 %). The 
activity of each diasteromer is open to conjecture. The modelling study described in 4.4.4 
inferred that the activity is likely to decrease in the order: SR > SS >> RR. This would 
suggest that 50 % of the ligand sample was the most active form with 25 % being a slightly 
less active. Table 7-2 examines the effect on the ITC model if the compound is considered to 
be 100 % active and 50 % active. These calculations do not contradict this hypothesis that 
the sample is less than 100 % active. The activity of the protein sample was determined to be 











(μM) (25 oC) 
500 μM (100 % active) 1.68 ± 0.05  -4.58 ± 0.18 8.0 ± 0.8  7.7 ± 0.8  
250 μM (50 % active) 0.89 ± 0.06  -11.66 ± 1.12 -15.4 ± 4.1  6.6 ± 0.7  
 
Table 7-2 ITC for the FKBP12-KB2_61D complex 
ITC is sensitive to the concentration of active ligand. Integrated heat data was corrected for heat of 




The complex of FKBP12 and KB2-KB2_61D had an apparent mass of 13650.4 ± 1.89 Da, 
this was an addition of 368.7 Da. KB2-KB2_61D has a mass of 368.4 Da, from this one can  
infer that the complex is a 1:1 ratio of protein to ligand. Figure 7-20 (C) shows the calculated 
concentration of complex is plotted against the concentration of inhibitor (10 μM FKBP12,  
0 – 40 μM KB2_61D). The least squares fit of the data to equation 12 gave a Kd = 26 ± 13 
μM, this is in general agreement with the data from ITC and TDF assay. The experiment was 
performed with a capillary temperature of 50 
o
C. KB2_61D ionised well in electrospray and 
caused suppression of the protein signal at high ligand concentration. It was not possible to 
collect data for a concentration of ligand above 40 μM as the protein signal to noise ratio was 
too low. 
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Effect of KB2-KB2_61D on the growth of C.elegans 
Compound KB2_61D (500 μM) was included in the growth media for two strains of 
C.elegans; N2 and TP83. N2 is a wild type worm and TP83 an fkb-3 triple mutant. Fkb-3 is 
PPIase homologous to mammalian FKBP9 and falls in the secretory pathway class of fkbs 
(Bell et al., 2006). Treated and untreated worms were compared after 6 days growth, Figure 
7-21. Adult worms are typically 1 mm in length. The N2 wild-type worms treated with KB2-
KB2_61D showed reduced growth and small vacuoles in the tail region at concentrations 
above 100 μM. The TP83 worms were more affected; treated worms had vacuoles in the tail 
and head regions. Organ development was less pronounced in the treated worms. These 
experiments were carried out by Dr. Victoria Butler (Glasgow University). 
 
18 cyclophilins and 8 FKBPs were identified in the genome of C. elegans (C.Elegans 
sequencing consortium, 1998). There is believed to be a high degree of functional 
redundancy among PPIases in C. elegans. Cyclosporin A and FK506 have been shown to 
have anti-nematode effects at high concentrations. This is thought to be the result of the 
compounds inhibiting an endogenous PPIase, rather than through a mechanism involving 
inhibition of calcineurin. The high concentrations required are thought to be the result of the 
large number of immunophilin isoforms (Page et al., 1995). The effect of KB2_61D on the 
phenotype of C. elegans was similar to that seen with cyclosporin A or a dimedone 
derivative (compound 7) (Yang et al., 2007). KB2_61D does not contain a domain that binds 
to calcineurin; the effect of KB2_61D cannot be a result of calcineurin inhibition and may be 
due to PPIase inhibition.  
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Figure 7-21 The effect of KB2_61D on two strains of C.elegans 
Representative light micrographs of sexually mature worms treated with 100 μM KB2-KB2_61D for 
6 days. The worms exhibited growth defects that were consistent with the inhibition of peptidyl-prolyl 
isomerase activity. The FKB3 triple mutant worms showed more effects than the wild type. The 
treated worms show poor organ development, reduced size and vacuoles in the tail region (TP83 
worms also show vacuoles in the head region). These experiments were carried out by Dr. Victoria 




7.8.3 The SL series 
The results of the TDF assay on the SL series are shown in Figure 7-22 Results are grouped 
by chemical similarity (the clustering method is described in section 7.8.2). The most active 
compounds were SL6 and SL8; these compounds gave a shift in mid-point melting 
temperature, ΔTm > 1.5 
o
C. Table 7-3 shows ΔTm and Kd estimated at the melting 
temperature, Tm, (calculated using equation 23, section 6.3.4). Kd were extrapolated to 25 
o
C 











































































Figure 7-22 TDF assay results for the SL series 
TDF assay results for the SL series. 10 μM FKBP12, 250 μM ligand/SD1; 10x SYPRO orange, 1 % 
methanol, 0.83 % DMSO, 30 mM ammonium acetate; 40 mM Bis-Tris, pH 7. Standard deviation is 























ΔHc  = -7.0 kcal∙mol-1 
(25 oC) 
SL8 1.85 ± 0.53 127 97 65 49 
SL6 2.53 ± 0.32 98 74 49 37 
 
Table 7-3 Kd apparent for the two most active members of the SL series 
The apparent equilibrium dissociation constant is shown at the melting temperature and at 3 putative 
values of ΔHL. 
 
SL1, SL2, SL3 and SL7 were seen to fly in complex with FKBP12 under standard screening 
conditions on the LCQ
TM
DECA (ThermoQuest), Figure 7-23. It is hard to discriminate 
between the ligands from this data or estimate affinity. Only SL1 was seen to fly in complex 
with FKBP12 on the ZMD (Waters). Ratios of complexed and uncomplexed protein are 
indicative of ligands in the 100s of μM range. There is no evidence for SL9 binding to 
FKBP12; this result is consistent with the data from the TDF assay. The TDF was repeated 
for compounds that dissolved in methanol without the addition of DMSO. This gave a 
similar trend but larger Tm shifts. This was consistent with DMSO competing for the active 




Figure 7-23  ESI-MS spectra for FKBP12 and selected members of the SL series 
Representative ESI-MS spectra for FKBP12 and SL1, SL2, SL3, SL7, SL9 (1000 to 2000 m/z). A 
spectrum of free FKBP12 is shown for comparative purposes. 10 μM FKBP12, 100 μM ligand 
dissolved in 10 mM ammonium acetate, pH 6.8; 10 % methanol (v/v). Blue diamonds mark peaks 
corresponding to FKBP12 in complex with ligand. 
 
7.8.4 The Specs library 
It has only been possible to test the 162 compounds in the specs set twice. The results 
presented here are of a preliminary nature as it has not been possible to confirm hits by an 
alternative assay. Of the 162 compounds 43 (~26 %) compounds show a + ΔTm > 2 
o
C. This 
would equate to a Kd < 120 μM (equation 23). If time had allowed the compounds would 
have been tested a third time and a blank run to test for fluorescence. Melt curves were 
visually examined to see if there was evidence of a characteristic protein melt in the presence 
of an inhibitor. Fluorescent compounds typically show high fluorescence at 20 
o
C that often 
shows thermal quenching as the assay progresses. The positive controls used in the TDF 
assay gave an extremely consistent ΔTm; fluorescence compounds or those with solubility 
problems show much less consistency. A typical Tm for 5 repeats of 250 μM KB2_61D and 
15 μM FKBP12 is 55.6±0.3 
o




































































































compounds do not show significant evidence of fluorescence or insolubility and are worth 
further investigation. Of these 28 compounds, 7 contain a fragment with two rings linked by 
a sulfonyl group. Compounds containing this pharmacophore were selected from the 
Organon collection using a BCI fingerprint, the pharmacophore was known to be present in 
FKBP12 inhibitors reported in the literature. The virtual screening program that showed the 
highest hit rate was UFSRAT at 26 %. Selecting compounds using a BCI fingerprint (queries 
were fragments present in a known inhibitor) gave a hit rate of 18 %. The unavoidable 
presence of 2.5 % DMSO in the TDF screen for this compound collection would have 
reduced the capacity of the assay to detect low affinity ligands. DMSO binds to the active 
site of FKBP12 and there would always have been a degree of competition between an 
inhibitor and DMSO at 2.5 % DMSO. 
 
If time had allowed the next screening step for the hits in the TDF assay would have been 
purchase the top 30 compounds in solid form and dissolve them in methanol. Methanol is the 
preferred solvent for ESI-MS and SPR. Compounds with a Kd of less than  
30 μM in an ESI-MS or SPR titration would have been tested using ITC as the next step in 
determining the affinity for FKBP12.   
7.9 Discussion and conclusions 
The TDF assay has proved a useful assay to test 100s of compounds in a reasonable 
timescale. It is limited in its ability to discriminate between ligands with a Kd > 100 μM. 
This is in large part due to the assay estimating Kd at the melting temperature (> 50 
o
C) and 
the requirement for thermodynamic data to transform the affinity estimation to 25 
o
C (see 
Figure 6-9). However, lack of sensitivity in the high micromolar affinity range does not 
distinguish it from most biophysical techniques. To date, only NMR and x-ray 
crystallography routinely pick up ligands in the high micromolar to millimolar affinity range 
at moderate screening concentrations. TDF does however have the advantage of being 
tolerant to low concentration of DMSO. This feature was invaluable for testing the 
compounds of poor aqueous solubility selected by the docking programs. Low affinity 
compounds might however be missed due to competition with DMSO. 
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 Virtual Screening Program Methodology Hit rate (%)
1
 
UFSRAT Ligand based  25 
Σ(LIDAEUS score + FlexX score) Docking 17 
Bayesian Bayesian machine learning 17 
LIDEUS score Docking 7 
FlexX score Docking 7 
Table 7-4 Hit rates for different docking programs 
1
 A hit was defined as having a predicted Kd < 120 μM at Tm in the TDF assay. 
 
Within the time constraints of a PhD it is difficult to acquire enough experimental data to 
make meaningful comparisons of the enrichment rates for different virtual screening 
programs. A preliminary analysis would suggest that UFSRAT performed well and that a 
good score from an arithmetic addition of scores from LIDAEUS and FlexX was a better 
predictor of activity than a good score in a single program, Table 7-4. In the TDF screen of 
the Specs green collection 28 compounds had an estimated Kd  < 120 μM at Tm. 
 
This study suggests that the sensitivity of the TDF assay is a limiting factor in fragment 
screening. Nonetheless, a fragment with micromolar affinity was discovered with chemical 
similarity to small molecules known to bind to FKBP12 (F65).  
 







Figure 7-24 Common pharmacophore seen in fragment screening experiments 
A common sub-structure in screening hits was a heteroaromatic ring linked by a sulfonyl group to a 
heterocycle. This is a sub-structure seen in nanomolar affinity ligand in the literature and occupies the 
most buried region of the active site (section 1.11.6 and Appendix 3). 
 
The 3 fragments contained a substructure consisting of a heteroaromatic ring linked by a 
sulfonyl group to a heterocycle, Figure 7-24. This sub-structure was also seen to have a small 
+ΔTm in KB series (3 compounds in the bis-sulphonamide subset; Figure 7-11). In the Specs 
green collection 7 of the 28 compounds that gave a +ΔTm > 2
o
C contained this sub-structure 
(best hit Kd ~5 μM). Although it is worth noting that these particular Specs or KB series 
compounds were synthesised or selected from a compound collection using knowledge 
derived from the literature search for this project. They can perhaps be considered 
confirmation of the similarity principle rather than novel inhibitors. 
 
 210 
The KB series of compounds confirmed the observation from the literature that a substitution 
of –CO-R in the ortho position on a heterocyclic ring (that takes the place of proline of the 
natural substrate) is important to affinity. This group is present in the majority of nanomolar 
inhibitors of FKBP12 (Figure 1-10). The active site of FKBP12 is a broad, shallow pocket 
and a hydrogen bond between a carbonyl group and the main chain N of Ile56 is a common 
feature of inhibitors. The best inhibitor in the KB series, KB2_61D, had an affinity of  
6.6 μM (25 
o
C by ITC); it inhibited the turnover of the preferred substrate for FKBP12 in the 
PPIase assay. This compound was a diastereotopic mixture, the modelling data suggests that 
one of the 3 diastereomers is more active and that it is probable that the single (S),(R) form 
may have an affinity for FKBP12 in the high nanomolar range. 
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8 Chapter 8 Human Cyclophilin A – Testing the 
KB Series 
8.1 Introduction  
The major part of this study investigated protein-ligand interactions for FKBP12. The KB 
series were designed to target two immunophilins; FKBP12 and hcypA (section 7.7.2 
describes the design of the series). Experimental studies on hcypA were only carried out for 
the KB series. The full KB series was screened against hcypA using the TDF assay. Selected 
compounds were examined by x-ray crystallography (co-crystallisation and crystal soaking). 
The crystallisation conditions for hcypA are well established. The aim of the crystallisation 
experiments was to detect binding for low affinity ligands (Kd in the mM range). 
8.2 Materials and Methods 
8.2.1 Protein Production 
Recombinant untagged human cyclophilin A (hcypa) was expressed in E.coli (BL21 Star 
(DE3), Figure 8-1) and purified under native conditions following the protocol described by 
Wear (Wear et al., 2005). Pure protein yields were in the order of 5 mg∙L
-1
 culture. hcypA 
was judged to be greater than 95 % purity by SDS-PAGE, Figure 8-2.  
 
Figure 8-1 Expression of hcypA 
15 % acrylamide SDS-PAGE gel under reducing conditions showing overexpression of hcypA in 
E.coli (recombinant strain BL21star
TM
) grown in 2xTY media at 37 
o
C with 260 rpm shaking. Cells 
were induced after reaching an optical density of A600nm ~ 0.6 with 1 mM IPTG. Lanes TO and T4 
show the soluble fraction from before and after 4 hours induction with IPTG. Italic lanes are a 2x 
dilution. Molecular weight marker (MW) Sigma wide range. Molecular weight markers are annotated 





Figure 8-2 hcypA after purification by gel filtration 
15 % acrylamide SDS-PAGE gel under reducing conditions showing hcypA after the final step of 
purification. The cell extract (pH adjusted to 6.8 in the buffer used for the cation exchange column) 
was applied to an HiPrep 16/10 SP FF (GE Healthcare) cation exchange column pre-equilibrated with 
50 mM HEPES, pH 6.8; 1mM DTT, 2.5 mM EDTA, 1 mM sodium azide. The column was eluted 
with a gradient of 0 to 400 mM sodium chloride. The pooled fractions were concentrated to 1.5 ml 
and passed over a HiPrep 16/60 s200 gel filtration column (GE Healthcare) pre-equilibrated with 10 
mM sodium phosphate (pH 7), 100mM sodium chloride, 0.5 mM DTT, 0.5mM EDTA and 1 mM 



















8.2.2 Protein characterisation (hcypA) 
The concentration of hcypA was measured by absorption at 280 nm using an extinction 




 on a nanovue instrument (GE Healthcare). The molecular 
weight of hcypA is 18012 Da. This was confirmed by ESI-MS performed under denaturing 
conditions following the protocol described in section 3.5.1, Figure 8-3. The protein flew 
with an apparent mass of 18147 Da and was the dominant species in the sample; this is 
consistent with other studies. 
 
Figure 8-3 ESI-MS spectrum of hcypA 
20 μM hcypa was flown in 20 mM ammonium acetate, pH 2.5; 2 % Formic acid; 10 % methanol 
(v/v) flown under default conditions. The inset diagram shows the transformed spectrum labelled with 
the mass of hcypA, the dominant species. The spectra were background corrected smoothed and 
transformed using MassLynx V4.1 (Waters). 
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8.2.3 Screening the KB series by TDF assay 
The TDF assay was performed as described in sections 6.3.4 and 7.7.2. The only significant 
differences to the method were the concentration of hcypA and the positive control. hcypA 
(18 kDa) is a larger protein than FKBP12 (13 kDa). Scouting experiments (described for 
FKBP12 in section 6.4.4) showed that 5 μM hcypA was sufficient to give a large enough 
fluorescent change on thermal denaturation of the protein. Cyclosporin A (CsA) was used as 
a positive control at a concentration of 8 μM. CsA was not soluble beyond 10 μM in aqueous 
buffer.  
 
The 20 compounds in the KB series were tested in parallel on a single plate. 3 positive 
controls (CsA) and 3 negative controls were included on each plate. The final solution 
contained 5 μM hcypA, 250 μM Ligand/8 μM cyclosporin (positive control); 30 mM bis-tris, 
pH 7; and 40 mM ammonium acetate; 0.25 % methanol and 10x SYPRO orange. The 
experiment was repeated in triplicate in separate experiments. A fluorescence control was 
also included for each compound on the plate. Plates were incubated at room temperature for 
15 minutes prior to the start of the assay. Data was processed using the methods described in 
section 6.3.4. 
8.2.4 Crystallisation of hcypA 
The crystallisation and crystal soaking protocol was modified from the method described by 
(Yang et al., 2007). hcypA was exchanged into 20 mM HEPES, pH 8; 100 mM sodium 
chloride; by PD10 rapid desalt column (GE Healthcare) and concentrated to ~ 26 mg∙ml
-1
 by 
spin concentration (Vivaspin 500, MW cut-off 5 kDa). Crystals were grown by vapour 
diffusion in 24 well Linbro plates (Molecular dimensions) by the hanging drop method at 
277 K. The initial 5 μl drop consisted of 13 mg∙ml
-1
 hcypA, 10 mM HEPES, 50 mM Tris,  
pH 8; 100 mM sodium chloride, 14 to 16 % PEG8000 (v/v). The well solution consisted of 
100 mM Tris, pH 8, 100 mM sodium chloride, 28 to 32 % PEG8000 (v/v). Crystals grew 
within a few hours and reached a maximum size after ~3 days. Crystals formed with and 
without the presence of 5 % DMSO (Kontopidis et al. (2004) added 5 % DMSO to aid 
crystallisation which they then soaked out).  
 
The crystals were soaked by transferring them into pre-equilibrated drops (14 hours) 
containing increasing concentrations of ligand dissolved in the well solution (25 %, 50 %, 75 
%, 100 % (v/v) saturated solution of ligand; otherwise similar to the well solution). The 
crystal was soaked in the final solution for 3 hours. The success rate for the soaking 
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experiments was variable; some ligands caused the crystal to crack at a low concentration. 
DMSO was not included after it was found to be unnecessary for crystallisation. Co-
crystallisation was tried for ligand KB2_61D by adding 10 mM ligand to the drop ([ligand] > 
10x [protein]). Crystals formed in drops containing 16 to 18 % PEG8000 in this series of 
experiments.  
 
The crystals were flash frozen in liquid nitrogen after soaking in a cryoprotectant solution 
similar to the final soaking/co-crystallisation solution with the addition of 22 % glycerol 
(step-wise soaking in increasing concentrations of glycerol). 
 
Data was collected at SRS, Daresbury (λ = 0.95 Å)  or SRS, Diamond (λ = 0.97 Å) and 
processed with the CCP4 suite of programs V6.0.2 (CCP4, 1994). Frames were read and 
integrated with MOSFLM (Powell, 1999) and scaled using SCALA (CCP4, 1994). 
Molecular replacement was performed using MOLREP (Lebedev et al., 2008). An x-ray 
structure of hcypA from a complex containing the di-peptide ligand Ala-Pro (2CYH.pdb, 
(Zhao and Ke, 1996)) was used as the model for molecular replacement. This structure has 
100 % sequence identity with the recombinant hcypA used in this study. Structural 
refinement was carried out using Refmac5 (Murshudov et al., 1997). Output from the 
programs were viewed and structural models altered for rounds of structural refinement 
using the model building program COOT (Emsley and Cowtan, 2004). 
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8.3 Results 
8.3.1 Affinity of hcypA for cyclosporin A  
The immunosuppressant CsA, was used as the positive control for binding studies with 
hcypA. CsA is an undecapeptide that binds to hcypA with 1:1 stoiciometry with low 
nanomolar affinity. hcypA exhibited an affinity for CsA in general agreement with the 
literature. The Kd of CsA for hcypA has been reported from 1.6 to 46 nM by a variety of 
different assays at a range of temperatures (Wear et al., 2005; Wear and Walkinshaw, 2006). 
Wear et al. (2005) compare Kd from the literature. 
 
Equation 22 was fitted to the raw fluorescence data using the method described in section 











Figure 8-4 (B) shows the change in mid-point melting temperature on addition of 10 μM 
CsA to 5 μM hcypA (+ΔTm = 5.7 ± 0.3 
o
C). It was interesting to note that the background 
fluorescence for native hcypA was much lower than that of FKBP12. This could be 
rationalised by hcypA having fewer hydrophobic surface residues than FKBP12.  
 
The affinity of CsA was calculated at the mid-point melting temperature (Tm) using equation 
23. Kd was extrapolated to 25 
o
C using thermodynamic parameters calculated by Wear and 








(Extrapolated to 25 
o
C) 
Literature Kd  
(nM) 
 
CsA 240 ± 50 7.9 ± 2.0 1.6 – 46 (Wear et al., 2005) 
 
Table 8-1 Affinity of CsA for hcypA measured in the TDF assay 
Affinity measured by TDF was transformed to 25 
o











 were taken from the literature (Wear and Walkinshaw, 2006). Standard 




     
     
 
Figure 8-4 TDF thermograms for hcypA and cyclosporin 
(A) Typical raw TDF data. Melting curves are shown for 5 μM hcypA; 10 μM (red) cyclosporin; 10x 
SYPRO; 1% methanol; 50 mM ammonium acetate, pH 7.0. Thermal denaturation occurs between 30 
and 60 
o
C. Inset curve in blue is the best fit of data to equation 22 using the non-linear regression 
program Kaleidagraph (V4.03, Synergy software) (B) –dF/dT for graph (A). Tm is labelled for the 
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Figure 8-5 Screening the KB series by TDF assay (hcypA) 
5 μM FKBP12; 8 μM (red) cyclosporin/500 μM test compound, 10x SYPRO; 0.25 % methanol, 
30mM ammonium acetate; 40 mM Bis-Tris, pH 7.  The red bar represents the positive control CsA. 
Blue diamonds indicate that the ligands were tested in the crystallographic study. 
 
None of the KB series was found to bind to hcypA. Results of the TDF assay are shown in 






Figure 8-6 hcypA crystal grown in 16 % PEG8000, pH 8 
The maximum dimension of this crystal was 0.8 mm. 
 
X-ray crystallisation has the potential to detect the binding of ligands in the mM range if 
they are sufficiently soluble under crystallisation conditions (Hartshorn et al., 2005). The 
crystallisation of hcypA proved to be relatively straightforward. Data was collected for 
hcypA in the presence of saturating concentrations of 5 of the KB series. These were solved 
to a resolution between 1.8 and 2.7 Å in space group P212121. None of the ligands tested in 
the soaking and cocrystallisation experiments were found in the active site of hcypA. Results 
are summarised in Table 8-2. A typical hcypA crystal is shown in Figure 8-6. 
 
 
Summary of soaking/co-crystallisation experiments – hcypA and the KB series 
 
Compound  Method Diffraction Results 
KB2_61D  Co-crystallisation 
1:12 protein:ligand ratio 
YES no ligand in active site 
KB2_62D  3 hour soak in sat sol
n YES no ligand in active site 
KB2_61A 3 hour soak in sat sol
n YES no ligand in active site 
KB2_61B 3 hour soak in sat sol
n YES no ligand in active site 
KB2_66A 15 minute soak in sat sol
n YES no ligand in active site 
KB2_64C 15 minute soak in sat sol
n YES Crystal diffracted, damage to crystal on soaking, no data set 
taken 




8.4 Discussion and conclusions 
In the study of Kontipidis et al. KB2_68C was crystallised in complex with hcypA (Figure 
7-8, (Kontopidis et al., 2004)). There was no evidence that this bound in the TDF assay 
performed in this study. This probably not a surprising result as the affinity of this compound 
for hcypA was in the order of 25 mM and this is beyond the sensitivity of the TDF assay. 
Unfortunately the soaking experiments were not successful for this ligand and results were 
not reproduced. No other members of the KB series were found to bind to hcypA with TDF 
or x-ray studies. The region of the active site that binds KB2_68C is a small pocket adjacent 
to Phe113; these results would suggest that substitutions to the piperidine ring ortho to the 
di-keto linker make the ligands tested too bulky to occupy this site. A substitution of –CO-R 
in the ortho position on a heterocyclic ring is present in all most inhibitors of FKBP12 
(Figure 1-10). The active site of FKBP12 is a much broader pocket and a hydrogen bond 
between a carbonyl group and the main chain N of Ile56 is a common feature of inhibitors.  
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9 Chapter 9  Summary and Future Work 
The study explored a series of biophysical assays to determine the best screening 
methodology to test hits from high-throughput virtual screening programs. The aim was to 
inhibit the human immunophilin FKBP12, a target for the treatment of neurodegenerative 
diseases.  The conclusions from this study can be divided into four main areas. 
  
1. Studying protein-ligand interactions by ESI-MS.  
A detailed evaluation was carried out to test the suitability of ESI-MS for estimating 
ligand affinity in FKBP12-ligand complexes. There was good correlation between 
the rank order of affinity in ESI-MS and in solution phase experiments. Collision 
induced dissociation experiments, with protein-ligand complexes, showed that there 
was a correlation between the cone voltage that gave 50 % dissociation of the 
complex (VC50) and the enthalpic contribution to the Gibbs free energy of binding 
in three  different protein systems (Chapters 3 and 4). 
 
2. Extending the sensitivity of ESI-MS – The charge-state ghost  
A novel method was investigated that extended the sensitivity of ESI-MS to detect 
very weak inhibitors of FKBP12 by examining changes to the charge-state 
distribution of protein molecular ions (Chapter 5). 
 
3. A comparison of different biophysical methods to characterise protein-ligand 
binding affinity 
A test set of inhibitors of FKBP12; with diverse structure and a wide range of 
affinity was complied to assess the sensitivity and throughput of a series of 
established biophysical assays. These assays were compared to results from the ESI-
MS; there was good agreement between the different biophysical techniques 
(Chapter 6). 
 
4. Screening for FKBP12 inhibitors  
Hits from virtual screening, a fragment library and compounds designed to target 
multiple immunophilins were tested in the laboratory using biophysical methods 
Over 300 compounds were screened in the laboratory and 34 inhibitors identified in 
preliminary screens. (Chapter 7 and 8). 
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9.1 Studying protein-ligand interactions by ESI-MS 
9.1.1 Aims 
The first aim of this section of the study was to fly the six-histidine construct of FKBP12 in 
ESI-MS. The second aim was to estimate the equilibrium dissociation constant for a complex 
from a comparison of signal intensity between free protein (protein ion) and protein in 
complex with a ligand (complex ion).  
9.1.2 Major results and conclusions 
The six-histidine construct of FKBP12 flew well on all instruments tested; the protein 
exhibited a narrow charge-state distribution dominated by the 8+ charge-state. Between 5 
and 10 µM protein in 10 mM ammonium acetate, pH 6.8; 10 % methanol (v/v) gave a 
reproducible spectrum and good signal to noise ratio.  
 
Single point screening experiments in ESI-MS were information rich. Experiments carried 
out at a single ligand concentration gave data on the mass of a ligand, its relative binding 
affinity/stoichiometry and also screened for protein stability. Ligand or pH conditions that 
induced protein unfolding in solution gave a much broader charge-state distribution than 
correctly folded protein.  
 
A method was developed for calculating Kd from an ESI-MS titration experiment. These 
experiments gave an estimate of Kd close to the value measured in solution for ligands with 
low nanomolar affinity for FKBP12. The lowest affinity ligand in the test set seen to fly in 
complex with FKBP12 had a solution Kd of 157 μM. Kd were consistently over estimated by 
the titration method. This was attributed to collision induced dissociation of the complex. 
Nonetheless, rank order of affinity was similar to that measured in solution. Setting cone 
voltage in ESI-MS was always a compromise between sensitivity and good signal to noise 
ratio. Cone voltage dissociation experiments established 15V to be the minimum cone 
voltage required to screen a series of compounds on the ZQ instrument using standards 
screening concentrations. 
 
Cone voltage dissociation profiles were used to quantify the relative fragility of a particular 
complex in electrospray by calculating the cone voltage required to give 50 % dissociation of 
the complex. This value was defined as the VC50. Studies have suggested there might be a 
correlation between VC50 and affinity in solution (Daniel et al., 2002). In this study VC50 
was a poor indicator of affinity in solution. Comparison of VC50 and ITC data showed that 
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there was good correlation between VC50 and the enthalpic contribution to the free energy 
of binding (ΔHITC). There was also correlation with the number of hydrogen bonds between 
protein and ligand predicted by x-ray crystallography or modelling studies. 
 
The lack of correlation between VC50 and affinity in solution for FKBP12 has consequences 
for the use of ESI-MS as a screening technique. The results of this study suggest that 
complexes with a high component of a favourable free energy change on binding due to the 
hydrophobic effect are likely to be fragile in electrospray. Some complexes of low affinity 
ligands might appear as false negatives in a screen. However, this phenomenon could be 
used to advantage during lead optimisation. Drugs with nanomolar or better affinity for a 
target generally have favourable contributions from both enthalpic and entropic terms 
(Carbonell and Freire, 2005). Medicinal chemists often aim to improve the affinity of a drug 
for its target by the addition of non-polar groups during lead optimisation. The hydrophobic 
effect leads to an entropic gain on formation of the complex. However, drugs unduly 
dependent on the hydrophobic effect often have poor solubility. The optimisation of a drug 
by improving the number of electrostatic interactions between drug and protein is 
challenging. The aim is to improve affinity by including functionality that increases the 
number of electrostatic interactions. Polar groups consisting of hydrogen bond donors or 
acceptors can be added to the compound to make additional electrostatic interactions. Strong 
electrostatic interactions are dependent on the geometry of residues in the active site and can 
aid specificity for the target. It is self-evident that a small addition of –ΔH has a significant 
influence on the affinity. For example reducing ΔH by around 1.5 kcal∙mol
-1
 improves 
affinity ~10 fold at 25
o
C due to the logarithmic nature of the relationship described by 
equation 2. ESI-MS might provide a fast route to structure-activity relationships for a similar 
chemical series. Small changes in structure can often lead to large changes in affinity and it 
is useful to know what role electrostatic interactions might play (Eckert and Bajorath, 2007). 
A thermodynamic profile can inform the selection of lead compounds from primary hits. 
 
As a generalisation, biological ligands show a greater dependence on a favourable enthalpic 
term than most inhibitory drugs (Li et al., 2008). The binding of sugars and DNA to a 
protein often have an unfavourable entropic term that is counterbalanced by the ligand 
making numerous enthalpically favourable hydrogen bonds to the protein. Carbohydrate 
ligands, because of their modular nature, allow for great stereo chemical diversity and hence 
selectivity. Enzymatically catalysed synthetic routes in vivo are evolutionally optimised to 
deliver the preferred stereoisomer and conformation from very simple building blocks. 
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Stereo specific synthetic routes in the laboratory can be difficult and time consuming, as it is 
costly to perform separation. Macrocyclic drugs, such as FK506 and rapamycin, derived 
from natural products (often fungal metabolites) could be said to form a class of compounds 
with characteristics of both biological ligands (sugars, DNA and peptides) and small 
molecule drugs. It has been suggested that macrocycles offer a good compromise between a 
conformationally pre-organised structure and flexibility. Key fuctional groups are correctly 
arranged to hit “hot” residues some distance apart on the protein surface with just enough 
ring flexibility to allow binding without a large entropic loss (Driggers et al., 2008). 
  
The correlation between VC50 and ΔHITC is interesting as ΔHITC is not equivalent to the 
interaction energy between ligand and protein in the gas-phase. The magnitude of ΔHITC also 
reflects the enthalpy associated with desolvating the ligand from the aqueous media. Bonds 
are broken with water when the hydrogen bonding network of the bulk solvent is altered as 
the ligand is removed from the solvent. The magnitude of the enthalpy of desolvation is 
ligand dependent.  However, the “solvent past” of the complex can’t be overlooked. After a 
macromolecular complex is desolvated in ESI-MS there is no equilibrium between the 
complex and the binding partners. There are likely to be extremely few binding events 
compared to the number of ligands dissociating from a complex. The equilibrium in solution 
is important. The on-rate of the ligand is influenced by the presence of water and 
hydrophobic effects. After desolvation in ESI-MS, the off-rate is likely to be largely 
dependent on the enthalpic contribution to binding from electrostatic interactions between 
protein and ligand.  
9.1.3 Future work 
It would be interesting to extend this study to a larger collection of ligands. In the final series 
of screening experiments described in Chapter 7 over 28 new ligands appeared as hits in 
preliminary screens. It would be very interesting to include these in an ESI-MS study. Kd 
estimated by ESI-MS and VC50 could be compared with ITC and x-ray crystallographic 
data. Carbonic anhydrase might be an interesting protein to extend this study as many small 
soluble inhibitors are available over a range of Kd (Krishnamurthy et al., 2008). Carbonic 
anhydrase has been widely used as a model protein for biophysical studies. 
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9.2 Extending the sensitivity of ESI-MS – the charge-state ghost  
9.2.1 Aim 
This part of the study stemmed from the serendipitous observation that charge-state shifts 
accompanied dissociation of a protein-ligand complex. 
9.2.2 Major results and conclusions 
Mass spectrometry is regularly used in drug discovery to screen for non-covalent interactions 
between proteins and ligands. An interaction is defined by the presence of a peak in the 
electrospray spectrum indicative of protein in complex with a ligand (the complex ion). 
However, for weakly bound complexes (with Kd in the micromole range) this complex ion is 
not always observed because of collision induced dissociation of the protein-ligand complex. 
This technique (of monitoring the complex ion) is limited to relatively tightly bound 
complexes; as a result promising ligands can be undetectable or incorrectly ranked in a 
screen. In this study, the results described in Chapter 4 suggested that compounds with a 
significant entropic component to a favourable free energy change on ligand binding to be 
particularly fragile in electrospray. 
 
It was that found charge-state shift to be a significantly more sensitive screening technique 
than the current methodology of identifying protein-ligand complex ions in the electrospray 
spectrum. Charge-state shifts were observed for three protein-ligand systems on dissociation 
of a non-covalently bound complex. 
 
9.2.3 The charge-state method for the identification of low affinity 
interactions 
The charge-state method may have particular application when screening small fragment-
like molecules which have affinity in the micromolar range but become potential lead 
compounds after fragment linking or chemical modification. The identification of low 
affinity ligands by biophysical methods is currently challenging.  
 
To measure a weak interaction the ratio of ligand to protein must be selected to give a 
sufficient physical response to measure in the assay, this is often limited by ligand solubility 
if a high concentration of protein is required. ITC has the potential to detect weak 
interactions but is a protein hungry technique that requires the ligand to be soluble to 
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relatively high concentrations (mM). It is not routinely used for screening experiments. SPR 
has been successfully used for small molecule screening for some protein systems but it 
dependent on the immobilisation chemistry retaining high levels of protein activity 
(Neumann et al., 2007). It also involves considerable capital outlay for instruments and high 
running costs for consumables. Immobilising ligands onto beads by means of a chemical 
linker that allows the ligand to behave in a similar manner to a free ligand in solution 
facilitates the desirable protein ligand ratios. Combining this with very sensitive fluorescence 
based methods enables the technique to detect a very wide affinity range. (Hintersteiner and 
Auer, 2008). However, this method does require a high level of robotic assistance with its 
associated costs. NMR has been successfully used to detect weak interactions at attainable 
protein to ligand screening ratios as demonstrated by the work of Stebbins et al. It is an 
attractive alternative methodology albeit with a high capital outlay for instrumentation. 
 
In a university setting ESI-MS uses relatively simple and inexpensive equipment that is often 
already in place. The technique is not sensitive to coloured or fluorescent compounds that 
can be a problem in some systems where detection is based on optical absorbance or 
fluorescence.  On a more industrial scale the technology for the automation sample delivery 
is available (Nanomate
TM
, Advion Biosciences, Inc.).  
 
9.2.4 Future work  
It is important to test the charge-state shift hypothesis with a larger test set of diverse ligands. 
The ligand identified in the screening experiments described in Chapter 7 would provide 
such a set of compounds for FKBP12. Carbonic anhydrase would also be a useful model 
system to investigate. Only after a large compound set and a diverse range of targets have 
been investigated can the rates of false positives and false negatives be compared to other 
methodologies. 
 
Proof of principle in a nanospray instrument is a vital next step. This would reduce reagent 
consumption and enable the use of automated sample delivery systems that would be 




9.3 A comparison of biophysical methods to characterise protein-
ligand complexes 
9.3.1 Aims 
It was important to compare results from estimation of ligand affinity by ESI-MS with 
experimental approaches that rely on different physical phenomenon. Compounds from the 
ligand test set were used to compare different biochemical and biophysical methods. The aim 
was to choose the best assay for preliminary screening experiments at a single ligand 
concentration to provide the most active subset for re-testing. 
9.3.2 Major results and conclusions 
A comparison was made of the advantages of each screening method in terms of sensitivity, 
richness of thermodynamic data, throughput, reagent consumption and cost. Each method 
delivered an apparent Kd that must be considered with the inherent assumptions made in the 
model and the possibility of false positives. Only ITC provides a direct measurement of the 
enthalpy of a binding interaction. However, it was clear that ITC could not provide all the 
information required within a short timescale or with the reagents and funding available. It 
was necessary to design a strategy consisting of a preliminary screen at a single ligand 
concentration to cut down the number of compounds to be tested by more rigorous methods. 
A TDF assay was selected to perform the initial screen. The top 20 % were then retested by 
ESI-MS. This step was dependent on the ligand being soluble in methanol; DMSO was 
incompatible with this assay. The top hits were tested by ITC. 
 
For ligand with affinity less than 10 μM there was remarkable consistency between different 
assays (Table 6-6 and Figure 7-20). Perhaps contrary to expectations, estimating Kd by ESI-
MS using the established procedure of measuring the relative intensities of the protein and 
complex ions performed at least as well as other biophysical techniques. The charge-state 
ghost method described in Chapter 5 proved to be the most sensitive technique at the 
screening concentrations used in this study. However, this technique is most suited to an 
initial screen rather than the detailed characterisation of binding. 
 
The ligand test set proved a useful set of compounds to test the different assays. SD1 proved 
to a particularly useful positive control, as it was more than 100 x more soluble than the 
nanomolar affinity ligands FK506 and rapamycin. It was also closer in affinity to ligands that 
might be expected to be discovered in screening (Kd = 6.8 ± 1.2 μM). The enthalpy of 
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binding of SD1 was measured by ITC (ΔH = -6.1± 0.6 kcal∙mol
-1
). This is a more useful 
generic ΔH for a small molecule inhibitor of FKBP12 than the potent immunosuppressants 
FK506 or rapamycin. This makes it particularly useful as a positive control in the TDF assay. 
The ligand KB2_61D, discovered during the course of these experiments, proved to be a 
good positive control in the final screening experiments.
 
 
9.4 Screening for FKBP12 inhibitors  
9.4.1 Aims 
The aim was to discover novel non-immunosuppressant ligands for FKBP12. The primary 
aim was to test hits from virtual screening programs. Hits were tested from LIDAEUS, 
FlexX, UFSRAT and a Bayesian machine learning method. A fragment library was also 
tested and a series of compounds designed to target both FKBP12 and hcypA (KB series). 
9.4.2 Major results and conclusions 
The TDF assay has proved very successful in estimating affinity for low micromolar ligands 
of FKBP12 and a nanomolar inhibitor of hcypA, the immunosuppressant CsA. It has been a 
useful assay to test 100s of compounds in a few days. However, it is limited in its ability to 
discriminate between ligands with a Kd > 100 μM. This is largely due to the need to 
transform data from 55 
o
C to 25 
o
C using thermodynamic information (see Figure 6-9). At 
the present time it is challenging to detect ligands with an affinity > 150 μM by any of the 
methods used in this thesis. This is a limiting factor in fragment screening. Nonetheless, a 
fragment with micromolar affinity was discovered with chemical similarity to small 
molecules known to bind to FKBP12 (F65).  
 
A sub-structure was seen in the Specs green collection that is commonly seen in ligands of 
nanomolar affinity reported in the literature (present in 7 compounds). This consists of a 
heteroaromatic ring linked by a sulfonyl group to a heterocycle. This moiety occupies the 
most buried region of the active site in known inhibitors with crystallographic data (section 
1.11.6 and Appendix 3 for references).The testing of the Specs green collection is still a 
work in progress. Of the 162 compounds tested 28 showed some evidence of activity in the 




The KB series of compounds confirmed the observation from the literature that a substitution 
of –CO-R in the ortho position on a heterocyclic ring, taking the place of proline of the 
natural substrate, is important to affinity. This group is present in the majority of nanomolar 
inhibitors of FKBP12 (Figure 1-10). The active site of FKBP12 is a broad, shallow pocket 
and a hydrogen bond between a carbonyl group and the main chain N of Ile56 is a common 
feature of inhibitors. The most active compound in the KB series against was compound 
KB2_61D with a Kd of 6.6 μM for FKBP12. This compound is in a diastereotopic mixture 
and a single (S),(R) diastereomer is likely to have affinity in the high nanomolar range. 
 
9.4.3 Future Work 
It would be extremely interesting to test the 28 hits from the Specs green collection by ESI-
MS, ITC and SPR. If hits were confirmed by these alternative methods; the similarity search 
function of EDULISS 2 (UFSRAT and the descriptor and graph-based methods of Hsin) 
would make the selection of similar compounds straightforward (Hsin, 2009). At this stage it 
would be possible to make firmer comment on the relative enrichment rates of the different 
virtual screening programs. However to date the evidence suggests that all methods show 








10 Appendix 1 – Exploring competition for the active site 
 
Solving the law of mass action to calculate the proportion of a ligand in complex with a 
single-site binding model and one ligand in solution is mathematically straightforward. 
Equation 1 describes the law of mass action and equation 12 the solution to the quadratic 
equation. The situation becomes more complex when two ligands, A and B, are in solution 
are competing for the same site on the protein (P). The ligand B will displace A from the 
active site of the protein to a degree that is dependent on the affinity and concentration of A 













P B PB     Equation 32 
 
We make the assumption that A does not form a complex with B and that the enzyme does 
not chemically modify either ligand. 
 





k P A k PA
dt




k P B k PB
dt
    Equation 34 
 
 
Where: [P] is the free concentration of the protein; [A] the concentration of free ligand A; [B] the 
concentration of free ligand B; [PA] the concentration of the complex of A with P; [PB] the 
concentration of the complex of B with P; K1 the on-rate for ligand A; K2 the off-rate for ligand A;  K3 
the on-rate for ligand B and K4 the off-rate for ligand B. 
 
Equations of this form can be solved using the differential equation solving program 
Berkeley Madonna (V.8.3.11, Macy and Oster). The program enables the user to model the 
time course of the reaction if the initial concentrations of the protein (Ptotal) and ligands are 
entered (Atotal and Btotal) and the forward (on-rates, k1 and k3) and reverse (off-rates, k2 and 
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k4) rate constants are known. These parameters are entered with the equations describing the 
equilibria between the species (equations 31 and 32 in the above example) and the time 
course for the simulation. This study used the chemical reactions module of program; this 
module automatically generates the rate equations. The on and off-rates have been published 









) (Wear and Walkinshaw, 2007). Rapamycin is a large (MW = 914 Da), high 
affinity ligand (Kd = 0.2 nM). These results were for the same construct of 6H-FKBP12 used 
in this study by surface plasmon resonance. A similar experiment was carried out for the 
much smaller, lower affinity ligand SD1 (6.4.5, Figure 6-10 SPR FKBP12-SD1). This 













 and off-rates 10
-1




for protein ligand 
interactions. Unless the on and off-rates are accurately defined in the program it is 
impossible to accurately calculate the concentration of a given species before equilibrium is 
attained. This information was not known for the simulations carried out for the majority of 
the ligands and as ligands were not part of a chemically similar series of known kinetics. The 
decision was made to use the simulation to calculate the relative proportions of the species in 
solution at equilibrium, when the ratio of the off-rate/on-rate (Kd) is important rather than the 






, close to the diffusion rate 
limit (Scaronolc k. and Stockmayer W.H., 1973). The off-rate calculated from equation 35 









    Equation 35 
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11 Appendix 2 – The fragment library 
 
 
Figure 11-1 Fragment library (F1-F50) 




Figure 11-2 Fragment library (F51-F96) 
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12 Appendix 3 – Inhibitors crystallised in complex with FKBP12 




2DG3 Figure 1-7 rapamycin (Fulton 
et al., 2003) 
0.0002 
1fkf Figure 1-7 FK506 (Van 





SBX (Holt et al., 
1993) 
0.3 – 0.6 
1fkg 
 
SB3 (Holt et al., 
1993) 
0.3 ± 0.04 
1fki 
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